WO2016063990A1 - Kcnq2~5チャネル活性化剤 - Google Patents
Kcnq2~5チャネル活性化剤 Download PDFInfo
- Publication number
- WO2016063990A1 WO2016063990A1 PCT/JP2015/080034 JP2015080034W WO2016063990A1 WO 2016063990 A1 WO2016063990 A1 WO 2016063990A1 JP 2015080034 W JP2015080034 W JP 2015080034W WO 2016063990 A1 WO2016063990 A1 WO 2016063990A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- methyl
- group
- trifluoro
- phenyl
- dichloro
- Prior art date
Links
- 0 CC(C(F)(F)F)(c(cc1*)c(*)c(*)c1NC(NC(*)*)=O)O Chemical compound CC(C(F)(F)F)(c(cc1*)c(*)c(*)c1NC(NC(*)*)=O)O 0.000 description 8
- ZUEJNXDTUKXAPQ-UHFFFAOYSA-N CC(C(C)NC1)C1=C Chemical compound CC(C(C)NC1)C1=C ZUEJNXDTUKXAPQ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
- C07C233/24—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
- C07C233/26—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to an acyclic carbon atom of a saturated carbon skeleton containing rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
- C07C233/24—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
- C07C233/29—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to an acyclic carbon atom of a carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C275/32—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by singly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C275/40—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by nitrogen atoms not being part of nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/40—Acylated substituent nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/61—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/12—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/28—Radicals substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/04—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
- C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/28—Halogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Definitions
- the present invention relates to general formula (I) (Wherein all symbols have the same meaning as described below), a salt thereof, a solvate thereof or a co-crystal thereof (hereinafter sometimes abbreviated as the compound of the present invention).
- KCNQ2-5 other than KCNQ1 are expressed in nociceptive sensory nervous systems such as dorsal root ganglia and spinal cord, and activation of KCNQ2-5 channels is a nociceptive signal. causes hyperpolarization of neurons in the pathway.
- KCNQ2-5 channel activators have been reported to be useful in the treatment of numerous disorders characterized by neuronal excitability abnormalities including epilepsy, pain, migraine and anxiety (see Non-Patent Document 1), In fact, retigabine, a KCNQ2-5 channel activator, has already been marketed as an antiepileptic drug.
- a muscarinic receptor antagonist mainly having a bladder contraction inhibitory action has been widely used for its treatment.
- muscarinic receptors are also present in salivary glands, intestinal tracts and ciliary muscles in addition to the bladder, and also have functional roles, and may have side effects such as dry mouth, constipation and fog vision, Side effects such as difficulty in urination due to the bladder contraction inhibitory action of muscarinic receptor antagonists, increase in residual urine volume and urinary retention are feared, and it cannot be said that the therapeutic effect is always satisfactory.
- a selective ⁇ 3 adrenergic receptor agonist was launched in Japan in 2011 as a drug to overcome the problems of muscarinic receptor antagonists.
- a selective ⁇ 3 adrenergic receptor agonist enhances the urinary accumulation function by bladder relaxation action, but it is suggested that it has little effect on urination function, and exerts bladder relaxation action that does not depend on contraction stimulation. The effect is expected.
- the QT prolongation risk increases with an increase in dose and acts on the heart ⁇ -receptor, it shows an effect of increasing the heart rate, so they are dose limiting factors.
- KCNQ2-5 channel activator is expected as a drug that meets the unmet medical needs.
- KCNQ activator having a monocyclic amide skeleton for example, the general formula (a) (Wherein Za is O or S; qa is 0 or 1; R a1 and R a2 are each selected from the group consisting of halogen, cyano, amino, C 1-6 -alk (en / yn) yl, etc.
- R a3 is C 1-8 -alkyl (alkenyl / alkynyl), C 3-8 -cycloalkyl (cycloalkenyl), C 3-8 -cycloalkyl (cycloalkenyl) -C 1-6- Selected from the group consisting of alkyl (alkenyl / alkynyl), aryl-C 1-6 -alkyl (alkenyl / alkynyl), aryl-C 3-8 -cycloalkyl (cycloalkenyl) and the like;
- R a4 is halogen, cyano, C 1-6 -alkyl (alkenyl / alkynyl), C 3-8 -cycloalkyl (cycloalkenyl), C 3-8 -cycloalkyl (cycloalkenyl) -C 1-6 -alkyl (a A compound (see Patent Document 1) represented by a group selected from the group consisting of (rukenyl l
- Patent Document 1 neither describes nor suggests a technique from the compound described in Patent Document 1 to the compound of the present invention.
- Patent Document 2 discloses the following compound: (N-ethyl-N ′-[2-bromo-4- (hexafluoro-2-hydroxy-2-propyl) phenyl] urea) is described. However, Patent Document 2 is an application relating to a compound having anti-pressor activity, and there is no description or suggestion about KCNQ activity.
- An object of the present invention is to provide a compound having a strong opening action on KCNQ 2-5 channels.
- the compound of the present invention is a compound having a strong opening action on KCNQ 2-5 channels. Furthermore, the present inventors have found that the compound of the present invention is excellent in solubility, stability and / or safety, and completed the present invention.
- X 1 is (1) a nitrogen atom or (2) C—R 6
- X 2 is (1) a nitrogen atom or (2) C—R 7
- R 11 is (1 ) OR 1 or (2) NH 2 and R 1 is (1) a hydrogen atom or (2) a C1-4 alkyl group
- R 2 and R 3 are each independently (1) a hydrogen atom or (2) a C1-4 alkyl group which may be substituted with halogen, provided that both R 2 and R 3 are not simultaneously hydrogen atoms
- R 4 , R 5 , R 6 and R 7 are Each independently (1) a hydrogen atom, (2) a halogen, (3) a C1-4 alkyl group optionally substituted with halogen, or (4) a C1-4 alkoxy group optionally substituted with halogen.
- R 4 and R 5 are hydrogen atoms at the same time;
- Y is, (1) -NH -, ( 2) O- or (3) be a bond;
- R 8 is (1) a hydrogen atom or (2) a halogen or hydroxy group optionally substituted C1 ⁇ 4 alkyl group;
- R 9 is (1) Ring A, (2) C1-6 alkyl group, (3) C2-6 alkenyl group, (4) C2-6 alkynyl group, (5) -C1-4 alkylene group-Ring A, (6) -C2-4 Alkenylene group-ring A, (7) -C2-4 alkynylene group-ring A, (8) -ring B-ring C, (9) -ring B-C1-4 alkylene group-ring C, (10) -ring B—C2-4 alkenylene group—ring C, (11) -ring B—C2-4 alkynylene group—ring C or (12) —ring B—O—ring C, wherein each alkyl group, alkenyl group, An alkyn
- R 10 is When there are a plurality of R 10 s, they may be the same or different; R 10 is substituted with (1) halogen, (2) hydroxy group, (3) cyano group, (4) halogen or hydroxy group C1-6 alkyl group which may be substituted, (5) C1-6 alkoxy group which may be substituted with halogen or hydroxy group, or (6) C1-4 alkyl group or C2-5 acyl group which may be substituted It is an amino group.
- R 4 and R 5 are each independently (1) a hydrogen atom or (2) a halogen atom.
- R 4 and R 5 are each independently (1) a hydrogen atom or (2) a halogen atom.
- R 6 and R 7 are each independently a hydrogen atom or halogen; Y is (1) —NH—, (2) —CH 2 —, (3) —O— or (4 ) it is a bond; R 8 is (1) hydrogen atom or (2) a halogen Other is an unsubstituted or may C1 ⁇ have 4 alkyl group with a hydroxy group; R 9 is (1) ring A, (2) C1 ⁇ 6 alkyl group, (3) C2 ⁇ 6 alkenyl group, (4) C2-6 alkynyl group, (5) -C1-4 alkylene group-ring A, (6) -C2-4 alkenylene group-ring A, (7) -C2-4 alkynylene group-ring A, (8) -ring B-ring C, (9) -ring B-C1-4 alkylene group-ring C, (10) -ring B-C2-4 alkenylene group-ring C or (11) -ring B-C2-4 alkynylene group- Ring C, wherein each alkyl group, alken
- the compound of the present invention is useful as a preventive and / or therapeutic agent for KCNQ 2-5 channel-related diseases.
- the C1-4 alkyl group means a linear or branched C1-4 alkyl group.
- C1-4 alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl.
- the C2-4 alkyl group means a linear or branched C2-4 alkyl group.
- C2-4 alkyl includes ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl.
- the C1-6 alkyl group means a linear or branched C1-6 alkyl group.
- C1-6 alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl, isopentyl, tert-pentyl, neopentyl, hexyl, isohexyl, 3-methylpentyl and the like.
- the C2-5 acyl group means a linear or branched C2-5 acyl group.
- Examples of C2-5 acyl groups include acetyl, propionyl, butanoyl, pentanoyl and the like.
- the C2-6 alkenyl group means a linear or branched C2-6 alkenyl group having at least one carbon-carbon double bond.
- Examples of C2-6 alkenyl groups include ethenyl, 1-propen-1-yl, 1-propen-2-yl, 2-propen-1-yl, 1-buten-1-yl, 1-buten-2-yl 3-buten-1-yl, 3-buten-2-yl, 2-buten-1-yl, 2-buten-2-yl, 2-methyl-1-propen-1-yl, 2-methyl-2 -Propen-1-yl, 1,3-butadiene-1-yl, 1,3-butadiene-2-yl and the like.
- the C2-6 alkynyl group means a linear or branched C2-6 alkynyl group having at least one carbon-carbon triple bond.
- Examples of C2-6 alkynyl groups include ethynyl, 1-propyn-1-yl, 2-propyn-1-yl, 1-butyn-1-yl, 3-butyn-1-yl, 3-butyn-2-yl 2-butyn-1-yl and the like.
- the C1-4 alkylene group means a linear or branched C1-4 alkylene group.
- Examples of C1-4 alkylene groups include methylene, ethylene, methylmethylene, ethylmethylene, propylene, butylene, isopropylene, isobutylene, sec-butylene, tert-butylene and the like.
- the C2-4 alkenylene group means a linear or branched C2-4 alkenylene group.
- Examples of C2-4 alkenylene groups include ethenylene, 1-propenylene, 2-propenylene, 1-butenylene, 2-butenylene, 3-butenylene and the like.
- the C2-4 alkynylene group means a linear or branched C2-4 alkynylene group.
- Examples of C2-4 alkynylene groups include ethynylene, 1-propynylene, 2-propynylene, 1-butynylene, 2-butynylene, 3-butynylene and the like.
- the C1-4 alkoxy group means a linear or branched C1-4 alkoxy group.
- Examples of C1-4 alkoxy groups include methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutyloxy, tert-butoxy and the like.
- the C1-6 alkoxy group means a linear or branched C1-6 alkoxy group.
- Examples of C1-6 alkoxy groups include methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutyloxy, tert-butoxy, pentyloxy, isopentyloxy, tert-pentyloxy, neopentyloxy, hexyloxy and the like.
- halogen means fluorine, chlorine, bromine, iodine or the like.
- the C3-8 cycloalkane is a C3-8 saturated hydrocarbon ring, which may have a spiro bond or a bridge.
- Examples of C3-8 cycloalkanes include cyclopropane, cyclobutane, cyclopentane, cyclohexane, bicyclo [2.2.1] heptane, bicyclo [3.1.1] heptane, bicyclo [2.2.2] octane, Examples include cycloheptane, cyclooctane, perhydropentalene, and cubane.
- C3-8 monocyclic cycloalkane examples include cyclopropane, cyclobutane, cyclopentane, cyclohexane, cycloheptane, and cyclooctane.
- C3-6 monocyclic cycloalkane examples include cyclopropane, cyclobutane, cyclopentane, and cyclohexane.
- the 3- to 8-membered heterocycloalkane is a 3- to 8-membered saturated heterocyclic ring containing 1 to 3 heteroatoms selected from an oxygen atom, a nitrogen atom and a sulfur atom, You may have bridge
- Specific examples of the 3- to 8-membered heterocycloalkane include aziridine, oxirane, thiirane, azetidine, oxetane, thietane, pyrrolidine, tetrahydrofuran, tetrahydrothiophene, piperidine, tetrahydropyran, tetrahydrothiopyran, azabicyclo [2.2.1].
- 3- to 7-membered monocyclic heterocycloalkane containing one oxygen atom as a hetero atom include oxirane, oxetane, tetrahydrofuran, tetrahydropyran, perhydrooxepin and the like.
- 3- to 7-membered monocyclic heterocycloalkane containing one oxygen atom or nitrogen atom as a hetero atom include aziridines, oxiranes, azetidines, oxetanes, pyrrolidines, tetrahydrofuran, piperidine, tetrahydropyran, Examples include perhydroazepine and perhydrooxepin.
- 3- to 7-membered monocyclic heterocycloalkane containing one nitrogen atom as a hetero atom include aziridine, azetidine, pyrrolidine, piperidine, perhydroazepine and the like.
- C3-12 monocyclic or bicyclic unsaturated carbocyclic ring, or a carbocyclic ring which may be partially saturated include cyclopropene, cyclobutene, cyclopentene, cyclopentadiene, Examples include cyclohexene, cyclohexadiene, benzene, cycloheptene, cycloheptadiene, cyclooctene, cyclooctadiene, pentalene, indene, indane, dihydronaphthalene, tetrahydronaphthalene, azulene, naphthalene, and heptalene.
- C5-12 monocyclic or bicyclic unsaturated carbocyclic ring, or a carbocyclic ring that may be partially saturated include cyclopentene, cyclopentadiene, cyclohexene, cyclohexadiene, Examples include benzene, cycloheptene, cycloheptadiene, cyclooctene, cyclooctadiene, pentalene, indene, indane, dihydronaphthalene, tetrahydronaphthalene, azulene, naphthalene, heptalene and the like.
- C3-7 monocyclic unsaturated carbocycle or a carbocycle in which a part thereof may be saturated include cyclopropene, cyclobutene, cyclopentene, cyclopentadiene, cyclohexene, cyclohexadiene. , Benzene, cycloheptene, cycloheptadiene and the like.
- C5-7 monocyclic unsaturated carbocyclic ring or a carbocyclic ring that may be partially saturated include cyclopentene, cyclopentadiene, cyclohexene, cyclohexadiene, benzene, cycloheptene, And cycloheptadiene.
- C5-6 monocyclic unsaturated carbocyclic ring or a carbocyclic ring which may be partially saturated include cyclopentene, cyclopentadiene, cyclohexene, cyclohexadiene, benzene and the like. It is done.
- C8-10 bicyclic unsaturated carbocyclic ring or carbocyclic ring which may be partially saturated include pentalene, indene, indane, dihydronaphthalene, tetrahydronaphthalene, azulene, And naphthalene.
- a 3 to 12-membered monocyclic or bicyclic unsaturated heterocyclic ring containing 1 to 4 heteroatoms selected from an oxygen atom, a nitrogen atom and a sulfur atom, or a part thereof is saturated.
- optional heterocycle include azirine, oxylene, thiylene, azeto, pyrroline, imidazoline, triazoline, tetrazoline, pyrazoline, dihydrofuran, dihydrothiophene, dihydrooxazole, dihydroisoxazole, dihydrothiazole, dihydroisothiazole, Dihydrofurazan, dihydrooxadiazole, dihydrothiadiazole, pyrrole, imidazole, triazole, tetrazole, pyrazole, furan, thiophene, oxazole, isoxazole, thiazole, isothiazole, furazane, oxadiazole
- a 5- to 12-membered monocyclic or bicyclic unsaturated heterocyclic ring containing 1 to 4 heteroatoms selected from oxygen, nitrogen and sulfur atoms, or a part thereof is saturated.
- optional heterocycle include pyrroline, imidazoline, triazoline, tetrazoline, pyrazoline, dihydrofuran, dihydrothiophene, dihydrooxazole, dihydroisoxazole, dihydrothiazole, dihydroisothiazole, dihydrofurazan, dihydrooxadiazole , Dihydrothiadiazole, pyrrole, imidazole, triazole, tetrazole, pyrazole, furan, thiophene, oxazole, isoxazole, thiazole, isothiazole, furazane, oxadiazole, thiadiazole, pyran, thiopyran, o Sazine,
- a 3 to 7-membered monocyclic unsaturated heterocyclic ring containing 1 to 3 heteroatoms selected from an oxygen atom, a nitrogen atom and a sulfur atom, or a part thereof may be saturated.
- heterocycle include azirine, oxylene, thylene, azeto, pyrroline, dihydrofuran, dihydrothiophene, pyrrole, furan, thiophene, pyran, thiopyran, dihydropyridine, tetrahydropyridine, dihydropyran, dihydrothiopyran, pyridine, azepine , Oxepin, thiepine, dihydroazepine, tetrahydroazepine, dihydrooxepin, tetrahydrooxepin, dihydrothiepine, tetrahydrothiepine, imidazoline, pyrazoline, dihydrooxazole
- a 5- to 7-membered monocyclic unsaturated heterocyclic ring containing 1 to 3 heteroatoms selected from an oxygen atom, a nitrogen atom and a sulfur atom, or a part thereof may be saturated.
- ⁇ heterocycle '' include pyrroline, dihydrofuran, dihydrothiophene, pyrrole, furan, thiophene, pyran, thiopyran, dihydropyridine, tetrahydropyridine, dihydropyran, dihydrothiopyran, pyridine, azepine, oxepin, thiepine, dihydroazepine, Tetrahydroazepine, dihydrooxepin, tetrahydrooxepin, dihydrothiepine, tetrahydrothiepine, imidazoline, pyrazoline, dihydrooxazole, dihydroisoxazole, dihydrothiazole,
- ring include pyrroline, dihydrofuran, dihydrothiophene, imidazoline, pyrazoline, dihydrooxazole, dihydroisoxazole, dihydrothiazole, dihydroisothiazole, triazoline, dihydrofurazan, dihydrooxadiazole, dihydrothiadiazole, pyran, Thiopyran, dihydropyridine, tetrahydropyridine, dihydropyran, dihydrothiopyran, oxazine, thiazine, dihydropyrazine, tetrahydropyrazine, dihydropyrimidine, tetrahydropyrimidine, dihydropyridazine,
- specific examples of “5- to 6-membered monocyclic unsaturated heterocycle containing 1 to 3 heteroatoms selected from oxygen, nitrogen and sulfur atoms” include pyrrole, furan, thiophene. Imidazole, pyrazole, oxazole, isoxazole, thiazole, isothiazole, triazole, furazane, oxadiazole, thiadiazole, pyridine, pyrazine, pyrimidine, pyridazine and the like.
- Examples include pyrrole, oxazole, isoxazole, thiazole, isothiazole, pyridine, imidazole, pyrazole, furazane, oxadiazole, thiadiazole, pyrazine, pyrimidine, pyridazine, triazole and the like.
- heterocycle include indolizine, indoline, isoindoline, dihydrobenzofuran, dihydroisobenzofuran, dihydrobenzothiophene, dihydroisobenzothiophene, dihydroindazole, dihydrobenzoxazole, dihydrobenzothiazole, dihydrobenzimidazole, dioxaindane, Benzodithiolane, quinolidine, chromene, dihydroquinoline, tetrahydroquinoline, dihydroisoquinoline, tetrahydroisoquinoline, chroman, dithiaphthalene, dihydrophthalazine, tetrahydrophthalazine, dihydron
- heterocycle or a heterocycle which may be partially saturated include indole, isoindole, benzofuran, isobenzofuran, benzothiophene, isobenzothiophene, quinoline, isoquinoline, indazole, benzoxazole, benzothiazole , Benzimidazole, phthalazine, quinoxaline, quinazoline, cinnoline, benzofurazan, benzothiadiazole, benzotriazole, indoline, isoindoline, dihydrobenzofuran, dihydroisobenzofuran, dihydrobenzothiophene, dihydroisobenzothiophen
- the number of substituents when a substituent is present is intended to be one or more.
- each substituent is independently defined for each occurrence in the definition of the general formula. For example, if there are more than one substituent R 10 each on “Ring A” or on “Ring B” and / or “Ring C”, each substituent is independently selected at each occurrence,
- the groups may be the same or different from one another.
- the KCNQ2-5 channel means a KCNQ channel in which four subtypes of the KCNQ2 to KCNQ5 are collected to form a homotetramer or a heterotetramer.
- KCNQ2, KCNQ3, KCNQ4, and KCNQ5 that are homotetramers
- KCNQ2 / 3, KCNQ3 / 4, and KCNQ3 / 5 channels that are heterotetramers.
- KCNQ2 / 3, KCNQ4 and / or KCNQ5 channels are preferred.
- the KCNQ2-5 channel activator means a compound having an opening action on the KCNQ2-5 channel (preferably KCNQ2 / 3, KCNQ4 and / or KCNQ5 channel).
- the KCNQ channel activating action and the KCNQ channel opening action are synonymous.
- X 1 is preferably C—R 6 .
- X 2 is preferably C—R 7 .
- R 11 is preferably OR 1 . OH and NH 2 are also preferable.
- Y is preferably —NH— or a bond, more preferably —NH—.
- R 1 is preferably a hydrogen atom or a methyl group, more preferably a hydrogen atom.
- R 2 is preferably a C1-2 alkyl group which may be substituted with a hydrogen atom or halogen, more preferably a methyl group optionally substituted with a hydrogen atom or halogen, and further preferably A methyl group or a trifluoromethyl group;
- R 3 is preferably a C1-2 alkyl group optionally substituted with a hydrogen atom or halogen, more preferably a methyl group optionally substituted with a hydrogen atom or halogen, and further preferably A hydrogen atom, a methyl group or a trifluoromethyl group;
- R 2 and R 3 are a methyl group which may be substituted by halogen, methyl optionally other is substituted with a hydrogen atom or a halogen More preferably, at least one of R 2 and R 3 is a trifluoromethyl group, and the other is a hydrogen atom or a methyl group.
- R 4 is preferably a hydrogen atom, a halogen, a C1-4 alkyl group or a C1-4 alkoxy group, more preferably a hydrogen atom, a halogen or a C1-4 alkyl group, still more preferably a halogen or methyl Group, particularly preferably halogen.
- R 5 is preferably a hydrogen atom, halogen, C1-4 alkyl group or C1-4 alkoxy group, more preferably a hydrogen atom, halogen or C1-4 alkyl group, still more preferably halogen or methyl. Group, particularly preferably halogen.
- R 6 is preferably a hydrogen atom or a halogen, and more preferably a hydrogen atom.
- R 7 is preferably a hydrogen atom or a halogen, and more preferably a hydrogen atom.
- At least one of R 6 and R 7 is preferably a hydrogen atom, more preferably both are hydrogen atoms.
- R 8 is preferably a hydrogen atom or a methyl group, more preferably a hydrogen atom.
- R 9 is preferably (1) ring A, (2) a C2-4 alkyl group optionally substituted with a halogen or a hydroxy group, (3) -ring B-ring C, (4) -ring B-methylene ring C or (5) -ring B—O—ring C, wherein each ring may be independently substituted with 1 to 5 R 10 groups.
- R 9 is more preferably ring A optionally substituted by 1 to 5 R 10 , and more preferably (1) halogen, (2) C1-4 alkyl group optionally substituted by halogen.
- each selected from the group consisting of C1-4 alkoxy groups optionally substituted with halogen (preferably selected from the group consisting of C1-4 alkyl groups optionally substituted with halogen and halogen, respectively) 5 to 6 members containing 1 to 3 heteroatoms selected from oxygen, nitrogen and sulfur atoms optionally substituted by 1 to 3 (preferably 1) substituents
- a 5- to 6-membered monocyclic unsaturated nitrogen-containing heterocycle containing 1 to 3 heteroatoms selected from oxygen, nitrogen and sulfur atoms substituted with at least one nitrogen atom .
- ring A is preferably (1) a C3-8 monocyclic cycloalkane, (2) a 3- to 7-membered monocyclic heterocycloalkane containing one oxygen atom as a heteroatom, and (3) C5 7 to 7 monocyclic unsaturated carbocycles or carbocycles that may be partially saturated, (4) C8 to 10 bicyclic unsaturated carbocycles or carbons that may be partially saturated A ring, (5) a 5- to 7-membered monocyclic unsaturated heterocyclic ring containing 1 to 3 heteroatoms selected from an oxygen atom, a nitrogen atom and a sulfur atom, or a part of which may be saturated A ring or (6) a 9 to 10-membered bicyclic unsaturated heterocycle containing 1 to 4 heteroatoms selected from oxygen, nitrogen and sulfur atoms, or a heterocycle in which a part thereof may be saturated A ring (where each ring is independently 1 to 5 R It may be substituted by 10), more preferably (1) a
- ring B is preferably (1) a C3-8 monocyclic cycloalkane, (2) a 3- to 7-membered monocyclic heterocycloalkane containing one oxygen atom as a heteroatom, (3) C5 7 to 7 monocyclic unsaturated carbocycles or carbocycles in which a part thereof may be saturated or (4) 5 to 1 containing 1 to 3 heteroatoms selected from oxygen, nitrogen and sulfur atoms A 7-membered monocyclic unsaturated heterocyclic ring or a heterocyclic ring that may be partially saturated (wherein each ring may be independently substituted with 1 to 5 R 10 ).
- halogen preferably an oxygen atom, nitrogen, optionally substituted by 1 to 3 (preferably 1) substituents (each selected from the group consisting of C1-4 alkyl groups optionally substituted with halogen)
- ring C is preferably (1) a C3-8 monocyclic cycloalkane, (2) a 3- to 7-membered monocyclic heterocycloalkane containing one oxygen atom or nitrogen atom as a hetero atom, ( 3) a C5-7 monocyclic unsaturated carbocycle or a carbocycle in which a part thereof may be saturated or (4) 1 to 3 heteroatoms selected from an oxygen atom, a nitrogen atom and a sulfur atom A 5- to 7-membered monocyclic unsaturated heterocycle or a heterocycle in which a part thereof may be saturated (wherein each ring is independently substituted with 1 to 5 R 10) More preferably (1) a C3-8 monocyclic cycloalkane, (2) a 3- to 7-membered monocyclic heterocycloalkane containing one nitrogen atom as a heteroatom, or (3) C5- 7 monocyclic unsaturated carbocycle or part thereof is saturated A carbocyclic ring which may optionally be (optionally substituted
- R 10 is preferably (1) halogen, (2) hydroxy group, (3) cyano group, (4) C1-4 alkyl group optionally substituted with halogen or hydroxy group, or (5) halogen.
- a C1-4 alkoxy group optionally substituted with a hydroxy group more preferably (1) halogen, (2) a C1-4 alkyl group optionally substituted with halogen, or (3) substituted with halogen.
- An optionally substituted C1-4 alkoxy group more preferably (1) a halogen or (2) a C1-4 alkyl group optionally substituted by a halogen, particularly preferably a halogen or a trifluoromethyl group. .
- the compound of the general formula (I) containing the combination of the preferred groups listed above is preferable.
- the preferred compound is represented by the general formula (III) (Wherein the symbols have the same meanings as described above), salts thereof, solvates thereof or co-crystals thereof.
- the more preferred compound is represented by the general formula (II-1) (Wherein R 6 represents a hydrogen atom or a halogen, and other symbols have the same meaning as described above), salts thereof, solvates thereof or cocrystals thereof.
- more preferred compounds are those represented by the general formula (II-2) (Wherein R 6 represents a hydrogen atom or a halogen, and other symbols have the same meaning as described above), salts thereof, solvates thereof or cocrystals thereof.
- the compound of the general formula (II-1) or the general formula (II-2) containing a combination of the preferable groups listed above is preferable.
- the more preferred compound is represented by the general formula (II-1-1) Wherein R 4 and R 5 are each independently (1) a hydrogen atom, (2) a halogen, (3) a C1-4 alkyl group or (4) a C1-4 alkoxy group (R 4 and R 5 is preferably each independently a hydrogen atom, halogen or a C1-4 alkyl group), provided that both R 4 and R 5 are not simultaneously hydrogen atoms; R 6 is a hydrogen atom or halogen.
- R 8 is (1) a hydrogen atom or (2) a C1-4 alkyl group optionally substituted with a halogen or a hydroxy group (preferably a hydrogen atom or a methyl group);
- R 9 is (1) Ring A, (2) a C2-4 alkyl group optionally substituted with a halogen or hydroxy group, (3) -ring B-ring C, (4) -ring B-methylene-ring C or (5 ) - a ring B-O-ring C and
- R 9 Ring A is preferably (1) a C3-8 monocyclic cycloalkane, (2) a 3-7 membered monocyclic heterocycloalkane containing one oxygen atom as a heteroatom, (3) a C5-7 monocyclic unsaturated carbocyclic ring or a carbocyclic ring that may be partially saturated; and (4) a C8-10 bicyclic unsaturated carbocyclic ring or a portion thereof that is saturated.
- An optionally substituted carbocycle (5) a 5- to 7-membered monocyclic unsaturated heterocycle containing 1 to 3 heteroatoms selected from oxygen, nitrogen and sulfur atoms, or a part thereof is saturated
- Ring B is (1) a C3-8 monocyclic cycloalkane, (2) a 3-7 membered monocyclic heterocycloalkane containing one oxygen atom as a heteroatom, (3) a C5-7 monocyclic unsaturated carbocyclic ring or a part of which may be saturated
- the more preferred compound is represented by the general formula (II-2-1) Wherein R 4 and R 5 are each independently (1) a hydrogen atom, (2) a halogen, (3) a C1-4 alkyl group or (4) a C1-4 alkoxy group (R 4 and R 5 is preferably each independently a hydrogen atom, halogen or a C1-4 alkyl group), provided that both R 4 and R 5 are not simultaneously hydrogen atoms; R 6 is a hydrogen atom or halogen.
- R 8 is (1) a hydrogen atom or (2) a C1-4 alkyl group optionally substituted with a halogen or a hydroxy group (preferably a hydrogen atom or a methyl group);
- R 9 is (1) Ring A, (2) a C2-4 alkyl group optionally substituted with a halogen or hydroxy group, (3) -ring B-ring C, (4) -ring B-methylene-ring C or (5 ) - a ring B-O-ring C and
- R 9 Ring A is preferably (1) a C3-8 monocyclic cycloalkane, (2) a 3-7 membered monocyclic heterocycloalkane containing one oxygen atom as a heteroatom, (3) a C5-7 monocyclic unsaturated carbocyclic ring or a carbocyclic ring that may be partially saturated; and (4) a C8-10 bicyclic unsaturated carbocyclic ring or a portion thereof that is saturated.
- An optionally substituted carbocycle (5) a 5- to 7-membered monocyclic unsaturated heterocycle containing 1 to 3 heteroatoms selected from oxygen, nitrogen and sulfur atoms, or a part thereof is saturated
- Ring B is (1) a C3-8 monocyclic cycloalkane, (2) a 3-7 membered monocyclic heterocycloalkane containing one oxygen atom as a heteroatom, (3) a C5-7 monocyclic unsaturated carbocyclic ring or a part of which may be saturated
- R 4 and R 5 are each independently a halogen or a methyl group (preferably R 4 and R 5 are each independently a halogen);
- R 6 is a hydrogen atom or a halogen (Preferably a hydrogen atom);
- R 8 is a hydrogen atom or a methyl group (preferably a hydrogen atom);
- R 9 is (1) halogen, (2) C1 optionally substituted by halogen -4 alkyl groups and (3) each selected from the group consisting of C1-4 alkoxy groups optionally substituted with halogen (preferably consisting of C1-4 alkyl groups optionally substituted with halogen and halogen) 1 to 3 selected from an oxygen atom, a nitrogen atom and a sulfur atom, each optionally substituted by 1 to 3 (preferably 1) substituents (each selected from the group) Is a monocyclic unsaturated heterocyclic ring of 5 to 6-membered containing pieces of heteroatoms (preferably as R 9,
- R 4 and R 5 are each independently a halogen or a methyl group (preferably R 4 and R 5 are each independently a halogen);
- R 6 is a hydrogen atom or a halogen (Preferably a hydrogen atom);
- R 8 is a hydrogen atom or a methyl group (preferably a hydrogen atom);
- R 9 is (1) halogen, (2) C1 optionally substituted by halogen -4 alkyl groups and (3) each selected from the group consisting of C1-4 alkoxy groups optionally substituted with halogen (preferably consisting of C1-4 alkyl groups optionally substituted with halogen and halogen) 1 to 3 selected from an oxygen atom, a nitrogen atom and a sulfur atom, each optionally substituted by 1 to 3 (preferably 1) substituents (each selected from the group) Is a monocyclic unsaturated heterocyclic ring of 5 to 6-membered containing pieces of heteroatoms (preferably as R
- preferred compounds are (1) 1- ⁇ 2,6-dichloro-4-[(2R) -1,1,1-trifluoro-2-hydroxy-2-propanyl] phenyl ⁇ -3- ⁇ [5- (trifluoromethyl) -2-pyridinyl] methyl ⁇ urea, (2) 1- ⁇ 2,6-dichloro-4-[(2R) -1,1,1-trifluoro-2-hydroxy-2-propanyl] phenyl ⁇ -3- ⁇ [5- (trifluoromethyl) -2-pyrimidinyl] methyl ⁇ urea, (3) 1- ⁇ 2,6-dichloro-4-[(2R) -1,1,1-trifluoro-2-hydroxy-2-propanyl] phenyl ⁇ -3- ⁇ [6- (trifluoromethyl) -3-pyridinyl] methyl ⁇ urea, (4) 1-[(5-Chloro-2-pyridinyl) methyl] -3- ⁇ 2,6-dichloro-4-
- the compound of the present invention has an opening effect on KCNQ2 / 3 of EC 50 value (or EC rtg 50 (see (1) Biological Example 1 described later)) of 100 ⁇ M or less, more preferably 10 ⁇ M or less, more preferably The compound is 1 ⁇ M or less, particularly preferably 0.1 ⁇ M or less. More preferably, the KCNQ2 / 3, KCNQ4, and KCNQ5 channels all have an opening action (EC 50 value (or ECrtg50) of 100 ⁇ M or less, more preferably 10 ⁇ M or less, and even more preferably 1 ⁇ M or less for all channels). It is a compound that has.
- the compound of the present invention is preferably a compound having excellent solubility.
- the compound has a solubility of 20 ⁇ M or more, more preferably 40 ⁇ M or more, still more preferably 60 ⁇ M or more, and particularly preferably 80 ⁇ M or more.
- the compound of the present invention is preferably a compound having excellent metabolic stability. Metabolic stability can be confirmed using a general measurement method, for example, liver microsomes (preferably human) of human or other animal species. The stability of the compound in human liver microsomes is determined by, for example, reacting commercially available human liver microsomes with the compound of the present invention for a certain period of time (for example, 5 to 30 minutes), and comparing the reaction sample with the unreacted sample. It can be evaluated by calculating (see (4) Stability evaluation in human liver microsome described later).
- the compound of the present invention is preferably a compound having excellent safety.
- the compound of the present invention is a compound that does not have an action on a hERG (human ether-a-go-go related gene) channel or has a weak hERG channel inhibitory action.
- the hERG channel inhibitory action can be evaluated by a known method such as the rubidium method for measuring the outflow of rubidium ion (Rb +) in hERG-expressing cells, the patch clamp test for measuring the HERG current by the patch clamp method, etc. (Refer to (5) Evaluation of action on hERG IKr current described later).
- stereoisomers are included unless otherwise specified.
- geometric isomers in double bonds, rings and condensed rings E-form, Z-form, cis-form, trans-form
- optical isomers due to the presence of asymmetric carbon R, S-form, ⁇ , ⁇ configuration, enantiomers, dia Stereomer
- optically active substance having optical activity D, L, d, l form
- polar form high polar form, low polar form
- optically active compound in the present invention may include not only 100% pure compounds but also other enantiomers or diastereomers of less than 50%.
- Example 22 (1) 1- ⁇ 2,6-dichloro-4-[(2R) -1,1,1-trifluoro-2-hydroxy-2-propanyl] phenyl ⁇ - 3- ⁇ [5- (trifluoromethyl) -2-pyridinyl] methyl ⁇ urea and
- Example 25 (4): 1- ⁇ 2,6-dichloro-4-[(2S) -1,1,1-tri Fluoro-2-hydroxy-2-propanyl] phenyl ⁇ -3- ⁇ [5- (trifluoromethyl) -2-pyridinyl] methyl ⁇ urea
- Example 5 1- [2,6-dichloro- 4- (1,1,1-trifluoro-2-hydroxy-2-propanyl) phenyl] -3- ⁇ [5- (trifluoromethyl) -2-pyr
- references to the compound of the present invention are solvation of the compound represented by the general formula (I), or a salt, solvate or co-crystal thereof, or a salt of the compound represented by the general formula (I). Or a co-crystal thereof.
- the compound represented by the general formula (I) is converted into a corresponding salt by a known method.
- the salt is preferably a pharmaceutically acceptable salt.
- the salt is preferably water-soluble. Suitable salts include acid adduct salts (inorganic acid salts (hydrochloride, hydrobromide, hydroiodide, sulfate, phosphate, nitrate, etc.), organic acid salts (formate, acetate) , Propionate, trifluoroacetate, lactate, tartrate, oxalate, malonate, succinate, fumarate, malate, maleate, benzoate, citrate, methanesulfone Acid salts, ethane sulfonates, benzene sulfonates, toluene sulfonates, isethionates, glucuronates, gluconates, aspartates, glutamates, etc.).
- acid adduct salts inorganic acid salts (
- the compound represented by the general formula (I) and a salt thereof may exist in an unsolvated form or may exist in a solvated form with a pharmaceutically acceptable solvent such as water and ethanol. .
- the solvate is preferably a hydrate.
- the compound represented by the general formula (I) and a salt thereof can be converted into a solvate by a known method.
- the compound represented by the general formula (I) can form a cocrystal with an appropriate cocrystal forming agent.
- the co-crystal is preferably a pharmaceutically acceptable one formed with a pharmaceutically acceptable co-crystal former.
- a co-crystal is typically defined as a crystal in which two or more different molecules are formed by intermolecular interactions different from ionic bonds.
- the co-crystal may be a complex of a neutral molecule and a salt.
- Co-crystals can be prepared by known methods, such as by melt crystallization, by recrystallization from a solvent, or by physically grinding the components together. Suitable co-crystal formers include those described in WO 2006/007448.
- the compound of the present invention can be administered as a prodrug.
- a prodrug of a compound represented by the general formula (I) is converted into a compound represented by the general formula (I) by a reaction with an enzyme, gastric acid or the like in a living body.
- a prodrug of the compound represented by the general formula (I) when the compound represented by the general formula (I) has a hydroxyl group, a compound in which the hydroxyl group is acylated, alkylated, phosphorylated or borated (for example, And the like in which the hydroxyl group of the compound of the present invention is acetylated, palmitoylated, propanoylated, pivaloylated, succinylated, fumarylated, alanylated, dimethylaminomethylcarbonylated, and the like. These compounds can be produced by known methods.
- the prodrug of the compound represented by the general formula (I) may be either a hydrate or a non-hydrate.
- prodrugs of the compounds represented by the general formula (I) are represented by the general formula under physiological conditions as described in Yodogawa Shoten 1990, “Drug Development”, Vol. 7, “Molecular Design”, pages 163-198. It may be changed to the compound represented by (I).
- the compounds of general formula (I) also have at least one atom replaced by an atom having the same atomic number, but whose atomic mass or mass number is different from the atomic mass or mass number prevailing in nature, Includes all isotopes.
- Suitable isotopes contained in the compound represented by the general formula (I) include, for example, 2 H, 3 H, 11 C, 13 C, 14 C, 13 N, 15 N, 15 O, 17 O, 18 O, 35 S, 18 F, 36 Cl, 123 I, 125 I, etc.
- the compound represented by the general formula (I) can be prepared by a known method, for example, the method shown below, the method according to these, the method described in the Examples, or “Comprehensive Organic Transformations: A Guided to Functional Group Preparations, Second Edition ( The method described in “Richard C. Larock, John Wiley & Sons Inc, 1999)” can be appropriately modified and used in combination.
- each raw material compound may be used as a salt.
- salts those described as the pharmaceutically acceptable salts of the aforementioned general formula (I) are used.
- the compound represented by the general formula (I-1) in which R 11 is OR 1 is represented by the general formula (SM1) (Wherein T represents a protecting group for R 1 or a hydroxyl group, and other symbols have the same meanings as described above) Can be manufactured.
- Examples of the hydroxyl-protecting group for T include a methyl group, ethyl group, propyl group, butyl group, trityl group, methoxymethyl (MOM) group, 1-ethoxyethyl (EE) group, methoxyethoxymethyl (MEM) group, 2 -Tetrahydropyranyl (THP) group, trimethylsilyl (TMS) group, triethylsilyl (TES) group, tert-butyldimethylsilyl (TBDMS) group, tert-butyldiphenylsilyl (TBDPS) group, acetyl (Ac) group, pivaloyl group Benzoyl group, benzyl (Bn) group, p-methoxybenzyl group, allyloxycarbonyl (Alloc) group, 2,2,2-trichloroethoxycarbonyl (Troc) group and the like.
- MOM methoxymethyl
- EE
- the urea or urethanation reaction represented by reaction 1 is carried out by, for example, converting a compound represented by the general formula (SM1) into an organic solvent (tetrahydrofuran, N-methyl-2-pyrrolidinone, N, N-dimethyl).
- an organic solvent tetrahydrofuran, N-methyl-2-pyrrolidinone, N, N-dimethyl.
- a base triethylamine, diisopropylethylamine, etc.
- base triethylamine, diisopropylethylamine, etc.
- the reaction is carried out by reacting the compound represented by the general formula (1-b) in an organic solvent (tetrahydrofuran, N-methyl-2-pyrrolidinone, dichloromethane, etc.) at a temperature of room temperature to 60 ° C.
- an organic solvent tetrahydrofuran, N-methyl-2-pyrrolidinone, dichloromethane, etc.
- the order in which the isocyanate generated from the compound represented by the general formula (SM1) and the compound represented by the general formula (1-b) are reacted may be reversed.
- reaction for example, in an organic solvent (dichloromethane, N, N-dimethylformamide), in the presence of 1,1′-carbonylbis-1H-imidazole (CDI), in the presence or absence of a base (triethylamine, N-methylmorpholine, etc.)
- a base triethylamine, N-methylmorpholine, etc.
- the deprotection of the hydroxyl group represented by the reaction 2 is performed as necessary.
- T is R 1 in the compound represented by the general formula (1-a)
- the deprotection reaction is performed.
- the compound represented by the general formula (1-a) can be produced without intervention.
- the deprotection reaction of the hydroxyl-protecting group is known and can be carried out by the following method. For example, (1) Deprotection reaction by alkali hydrolysis, (2) Deprotection reaction under acidic conditions, (3) Deprotection reaction by hydrogenolysis, (4) Deprotection reaction of silyl group, (5) Deprotection reaction using metal, (6) Deprotection reaction using a metal complex and the like can be mentioned.
- the deprotection reaction by alkali hydrolysis is carried out, for example, in an organic solvent (methanol, tetrahydrofuran, dioxane, etc.), alkali metal hydroxide (sodium hydroxide, potassium hydroxide, lithium hydroxide, etc.), alkaline earth It is carried out at a temperature of about 0 to 40 ° C. using a metal hydroxide (barium hydroxide, calcium hydroxide etc.) or carbonate (sodium carbonate, potassium carbonate etc.) or an aqueous solution thereof or a mixture thereof.
- organic solvent methanol, tetrahydrofuran, dioxane, etc.
- alkali metal hydroxide sodium hydroxide, potassium hydroxide, lithium hydroxide, etc.
- alkaline earth It is carried out at a temperature of about 0 to 40 ° C. using a metal hydroxide (barium hydroxide, calcium hydroxide etc.) or carbonate (sodium carbonate, potassium carbon
- the deprotection reaction under acid conditions is carried out, for example, by using an organic acid (acetic acid, trifluoroacetic acid, methanesulfonic acid, p-toluenesulfonic acid) in an organic solvent (dichloromethane, chloroform, dioxane, ethyl acetate, anisole, etc.). Etc.), or an inorganic acid (hydrochloric acid, sulfuric acid, etc.) or a mixture thereof (hydrogen bromide / acetic acid, etc.) at a temperature of about 0 to 100 ° C.
- organic acid acetic acid, trifluoroacetic acid, methanesulfonic acid, p-toluenesulfonic acid
- organic solvent diichloromethane, chloroform, dioxane, ethyl acetate, anisole, etc.
- Etc. an organic acid
- an inorganic acid hydroochloric acid, sulfuric acid, etc.
- Deprotection reaction by hydrogenolysis includes, for example, solvent (ether (tetrahydrofuran, dioxane, dimethoxyethane, diethyl ether, etc.), alcohol (methanol, ethanol, etc.), benzene (benzene, toluene, etc.), ketone System (acetone, methyl ethyl ketone, etc.), nitrile (acetonitrile, etc.), amide system (dimethylformamide, etc.), water, ethyl acetate, acetic acid or a mixed solvent of two or more thereof, catalyst (palladium-carbon, palladium black, In the presence of palladium hydroxide, platinum oxide, Raney nickel, etc.), in a hydrogen atmosphere under normal pressure or under pressure, or in the presence of ammonium formate, at a temperature of about 0 to 200 ° C.
- solvent ether (tetrahydrofuran, dioxane, dimethoxyethane, die
- the deprotection reaction of the silyl group is performed at a temperature of about 0 to 40 ° C. using tetrabutylammonium fluoride in an organic solvent miscible with water (tetrahydrofuran, acetonitrile, etc.).
- the deprotection reaction using a metal is carried out, for example, in an acidic solvent (acetic acid, a buffer solution of pH 4.2 to 7.2 or a mixture thereof with an organic solvent such as tetrahydrofuran) in the presence of powdered zinc. If necessary, it is performed at a temperature of about 0 to 40 ° C. while applying ultrasonic waves.
- the deprotection reaction using a metal complex is carried out, for example, in an organic solvent (dichloromethane, dimethylformamide, tetrahydrofuran, ethyl acetate, acetonitrile, dioxane, ethanol, etc.), water or a mixed solvent thereof with a trap reagent (tributyltin hydride, Triethylsilane, dimedone, morpholine, diethylamine, pyrrolidine, etc.), organic acids (acetic acid, formic acid, 2-ethylhexanoic acid, etc.) and / or organic acid salts (sodium 2-ethylhexanoate, potassium 2-ethylhexanoate, etc.)
- a phosphine-based reagent such as triphenylphosphine
- metal complexes tetrakistriphenylphosphine palladium (0), bis
- the deprotection reaction can be performed, for example, by the method described in “Protective Groups in Organic Synthesis (by TW Greene, John Wiley & Sons Inc, 1999)”.
- the intended compound of the present invention can be easily produced by properly using these deprotection reactions.
- the compound represented by the general formula (SM1) and the compound represented by the general formula (2-b) are subjected to a reaction 3: amidation reaction, and further subjected to a reaction 4: a deprotection reaction of a protecting group as necessary. Can be manufactured.
- Amidation reactions are known, for example (1) a method using an acid halide, (2) a method using a mixed acid anhydride, (3) A method using a condensing agent is exemplified.
- the method using an acid halide is, for example, using a carboxylic acid in an organic solvent (chloroform, dichloromethane, diethyl ether, tetrahydrofuran, etc.) or without a solvent and an acid halide agent (oxalyl chloride, thionyl chloride, etc.) and ⁇ 20 C.
- an organic solvent chloroform, dichloromethane, diethyl ether, tetrahydrofuran, etc.
- an acid halide agent oxalyl chloride, thionyl chloride, etc.
- the resulting acid halide in the presence of a base (pyridine, triethylamine, dimethylaniline, dimethylaminopyridine, diisopropylethylamine, etc.) and an organic solvent (chloroform, dichloromethane, diethyl ether, tetrahydrofuran, etc.)
- a base pyridine, triethylamine, dimethylaniline, dimethylaminopyridine, diisopropylethylamine, etc.
- an organic solvent chloroform, dichloromethane, diethyl ether, tetrahydrofuran, etc.
- the obtained acid halide can be reacted with an amine at 0 to 40 ° C. in an organic solvent (dioxane, tetrahydrofuran, etc.) using an aqueous alkali solution (aqueous sodium bicarbonate or sodium hydroxide solution).
- a method using a mixed acid anhydride is, for example, a method in which a carboxylic acid is used in an organic solvent (chloroform, dichloromethane, diethyl ether, tetrahydrofuran, etc.) or without a solvent, and a base (pyridine, triethylamine, dimethylaniline, dimethylaminopyridine, diisopropyl).
- an organic solvent chloroform, dichloromethane, diethyl ether, tetrahydrofuran, etc.
- a base pyridine, triethylamine, dimethylaniline, dimethylaminopyridine, diisopropyl
- ethylamine In the presence of ethylamine, etc., it is reacted with an acid halide (pivaloyl chloride, tosyl chloride, mesyl chloride, etc.) or an acid derivative (ethyl chloroformate, isobutyl chloroformate, etc.) at 0 to 40 ° C., and the resulting mixture
- an acid halide pivaloyl chloride, tosyl chloride, mesyl chloride, etc.
- an acid derivative ethyl chloroformate, isobutyl chloroformate, etc.
- the reaction is carried out by reacting the acid anhydride with an amine at 0 to 40 ° C. in an organic solvent (chloroform, dichloromethane, diethyl ether, tetrahydrofuran, etc.).
- a method using a condensing agent includes, for example, a carboxylic acid and an amine in an organic solvent (chloroform, dichloromethane, dimethylformamide, diethyl ether, tetrahydrofuran, etc.) or without a solvent, with a base (pyridine, triethylamine, dimethylaniline, In the presence or absence of dimethylaminopyridine and the like), a condensing agent (1,3-dicyclohexylcarbodiimide (DCC), 1-ethyl-3- [3- (dimethylamino) propyl] carbodiimide (EDC), 1,1 ′ 1-hydroxybenzil using 1-hydroxyphosphonic acid cyclic anhydride (PPA), etc., using 2-carbonylbis-1H-imidazole (CDI), 2-chloro-1-methylpyridinium iodine, 1-propylphosphonic acid cyclic anhydride The reaction is carried out at 0 to 40 ° C.
- the hydroxyl group deprotection reaction can be carried out in the same manner as the hydroxyl group deprotection reaction described in Reaction Scheme 1.
- the compound represented by the general formula (SM1) is represented by the general formula (3-a) Wherein W represents halogen (Cl, Br, I) or Tf (trifluoromethanesulfonyl) O group, Ts (toluenesulfonyl) O group, and R 41 and R 51 have the same meanings as R 4 and R 5 , respectively.
- W in the compound represented by the general formula (3-a) is a TfO group or a TsO group
- they are known from a hydroxyl group, for example, “Comprehensive Organic Transformations: A Guide to Functional Group Preparations, Second Edition (Rich) C. Larock, John Wiley & Sons Inc, 1999) ”.
- it can be produced by the method described in Example 37.
- Examples of the amino-protecting group for R 100 and R 110 include benzyloxycarbonyl group, tert-butoxycarbonyl (Boc) group, allyloxycarbonyl (Alloc) group, 1-methyl-1- (4-biphenyl) ethoxycarbonyl (Bpoc) group, trifluoroacetyl group, 9-fluorenylmethoxycarbonyl group (Fmoc), benzyl (Bn) group, p-methoxybenzyl group, benzyloxymethyl (BOM) group, 2- (trimethylsilyl) ethoxymethyl ( SEM) group and the like.
- benzyloxycarbonyl group tert-butoxycarbonyl (Boc) group
- allyloxycarbonyl (Alloc) group 1-methyl-1- (4-biphenyl) ethoxycarbonyl (Bpoc) group
- trifluoroacetyl group 9-fluorenylmethoxycarbonyl
- the nucleophilic reaction represented by reaction 5 or reaction 6 is carried out by subjecting the compound represented by general formula (3-a) or general formula (3-b) to an organic solvent (tetrahydrofuran, diethyl ether, etc.)
- the reaction is carried out by reacting an organometallic reagent corresponding to R 3 such as alkyl (R 3 ) magnesium bromide, alkyl (R 3 ) lithium and the like in the presence or absence of cerium chloride at ⁇ 78 ° C. to room temperature.
- Rupert reagent trifluoromethyltrimethylsilane
- organic solvent tetrahydrofuran, diethyl ether, etc.
- the reduction reaction represented by the reaction 5 and the reaction 6 is carried out by reacting the compound represented by the general formula (3-a) (wherein R 2 represents other than hydrogen) in an organic solvent (methanol, ethanol , Tetrahydrofuran, hexane, etc.) by reacting a reducing agent (sodium borohydride, lithium borohydride, lithium aluminum hydride, diisobutylaluminum hydride, etc.) at a temperature of ⁇ 78 to 80 ° C.
- a reducing agent sodium borohydride, lithium borohydride, lithium aluminum hydride, diisobutylaluminum hydride, etc.
- the amination reaction represented by reaction 7 is carried out using an organic solvent (ethyl acetate, isopropyl acetate, benzene, toluene, xylene, heptane, cyclohexane, tetrahydrofuran, dioxane, dimethoxyethane, ethanol, isopropanol, polyethylene glycol, dimethyl A base (diethylamine, triethylamine, propyl) in sulfoxide, N, N-dimethylformamide, N, N-dimethylacetamide, N-methyl-2-pyrrolidinone, methylene chloride, chloroform, acetone, acetonitrile, water, or a mixture thereof.
- organic solvent ethyl acetate, isopropyl acetate, benzene, toluene, xylene, heptane, cyclohexane, tetrahydrofuran, di
- the halogen / metal exchange reaction of the aryl halide represented by the reaction 8, followed by the nucleophilic reaction is carried out by subjecting the compound represented by the general formula (3-g) to an organic solvent (tetrahydrofuran, diethyl ether, etc.) After reacting an organometallic reagent (n-butyllithium, tert-butyllithium, isopropylmagnesium bromide, isopropylmagnesium chloride) at a temperature of ⁇ 78 to 60 ° C., a compound represented by the general formula (3-h); The reaction is carried out at ⁇ 78 to 60 ° C. in an organic solvent (tetrahydrofuran, diethyl ether, etc.).
- an organometallic reagent n-butyllithium, tert-butyllithium, isopropylmagnesium bromide, isopropylmagnesium chloride
- the hydroxyl group protection reaction represented by reaction 9, reaction 12, and reaction 14 is performed as necessary.
- the protection reaction include general formula (3-e), general formula (3- f)
- a base imidazole, triethylamine, etc.
- an organic solvent tetrahydrofuran, dichloromethane, etc.
- a silylating agent chlorotrimethylsilane, chlorotriethylsilane, chlorotert -Butyldimethylsilane, chloro tert-butyldiphenylsilane, etc.
- reaction process formula 3 the reduction reaction of the nitro group represented by reaction 10 or reaction 13 is carried out by reacting the compound represented by general formula (3-e) or general formula (3-i) with a solvent (ether system (tetrahydrofuran, dioxane).
- a solvent ether system (tetrahydrofuran, dioxane).
- a solvent miscible with water ethanol, methanol, tetrahydrofuran, etc.
- an acid hydrobromic acid, ammonium chloride, acetic acid, ammonium formate, etc.
- a metal reagent zinc, iron, Tin, tin chloride, iron chloride, samarium, indium, sodium borohydride-nickel chloride, or the like
- a temperature 0 to 150 ° C.
- reaction process formula 3 the deprotection reaction of the amino group represented by reaction 11 or reaction 15 can be carried out by the following method.
- Deprotection reactions of amino protecting groups are well known, for example, (1) Deprotection reaction by alkali hydrolysis, (2) Deprotection reaction under acidic conditions, (3) Deprotection reaction by hydrogenolysis, (4) Deprotection reaction of silyl group, (5) Deprotection reaction using metal, (6) Deprotection reaction using a metal complex and the like can be mentioned.
- the halogenation reaction represented by the reaction 16 is carried out by subjecting the compound represented by the general formula (3-n) to a halogenating reagent (N--) in an organic solvent (acetonitrile, N, N-dimethylformamide, etc.). Chlorosuccinimide, 1,3-dichloro-5,5-dimethylhydantoin, N-bromosuccinimide, N-iodosuccinimide, and the like) at 0 to 80 ° C.
- urea or urethanization represented by the reaction 17 can be carried out in the same manner as the reaction 1 described in the reaction process formula 1.
- the reduction reaction of the azide group represented by reaction 18 is performed by reacting triphenylphosphine at room temperature in a mixed solvent of an organic solvent (tetrahydrofuran, dimethylethyl ether, etc.) and water. It can also be carried out by reacting lithium aluminum hydride in an organic solvent (such as tetrahydrofuran) at 0 ° C. to heating under reflux.
- an organic solvent such as tetrahydrofuran
- a compound in which R 11 is NH 2 and Y is a bond that is, a compound represented by the general formula (5-a) (wherein all symbols are as defined above) Can be produced by the method shown in Reaction Step 5 (wherein all symbols have the same meaning as described above) using the compound represented by the general formula (SM2). .
- the amidation reaction represented by the reaction 19 can be carried out in the same manner as the reaction 3 described in the reaction process formula 2.
- the reduction reaction represented by the reaction 20 can be performed in the same manner as the reaction 18 described in the reaction process formula 4.
- the compound represented by the general formula (SM2) can be produced by the method represented by the reaction process formula 6 (wherein all symbols have the same meanings as described above) using the general formula (SM1) as a starting material. it can.
- the hydroxyl group deprotection reaction represented by the reaction 21 can be carried out in the same manner as the hydroxyl group deprotection reaction described in the reaction process formula 1.
- the conversion reaction of the hydroxyl group represented by the reaction 22 to the azide group is carried out by converting the compound represented by the general formula (6-a) in an organic solvent (chloroform, dichloromethane, etc.) in the presence of trifluoroacetic acid. It is carried out by reacting sodium or potassium azide at room temperature.
- the optically active form of the compound represented by the general formula (I) can be produced by subjecting to an ordinary method (for example, an optical resolution method using a chiral column). Further, general formula (3-c), general formula (3-e), general formula (3-f), general formula (3-i), general formula (3-k), general formula (3-m), A compound represented by the general formula (3-n), the general formula (SM1), the general formula (4-b), the general formula (5-b), the general formula (6-a), or the general formula (SM2) is prepared in advance. Using the conventional method (for example, optical resolution method using a chiral column) or optical isomers separated by optical resolution according to the method described in the examples of the present specification, the above reaction scheme is shown. It can be manufactured by a method.
- reaction involving heating can be performed using a water bath, an oil bath, a sand bath, or a microwave, as will be apparent to those skilled in the art.
- a solid-phase-supported reagent supported on a polymer eg, polystyrene, polyacrylamide, polypropylene, polyethylene glycol, etc.
- a polymer eg, polystyrene, polyacrylamide, polypropylene, polyethylene glycol, etc.
- the reaction product is obtained by a conventional purification means such as distillation under normal pressure or reduced pressure, high performance liquid chromatography using silica gel or magnesium silicate, thin layer chromatography, ion exchange resin, It can be purified by scavenger resin, column chromatography, washing or recrystallization. Purification may be performed for each reaction or after completion of several reactions.
- a conventional purification means such as distillation under normal pressure or reduced pressure, high performance liquid chromatography using silica gel or magnesium silicate, thin layer chromatography, ion exchange resin, It can be purified by scavenger resin, column chromatography, washing or recrystallization. Purification may be performed for each reaction or after completion of several reactions.
- the toxicity of the compound of the present invention is sufficiently low and can be used safely as a pharmaceutical product.
- the compounds of the present invention are suitable for the prevention and / or treatment of KCNQ2-5 channel-related diseases.
- the compound of the present invention can be used for preventing and / or treating KCNQ2-5 channel-related diseases.
- diseases include, for example, epilepsy, painful disorders (eg, neuropathic pain, migraine), diabetic peripheral neuropathy, anxiety disorder, mood adjustment disorder, schizophrenia, drug dependence, attention adjustment disorder, sleep disorder , Stroke, tinnitus, memory impairment (eg, Alzheimer's disease, dementia), amyotrophic lateral sclerosis, movement disorder (eg, Parkinson's disease, dystonia related movement disorder), dysuria (eg, overactive bladder, Frequent urination, nocturia, urgency, urge incontinence, stress urinary incontinence, interstitial cystitis, chronic prostatitis, prostatic hypertrophy), hearing loss, asthma, chronic obstructive pulmonary disease, cough, pulmonary hypertension Diseases, neurodegenerative diseases of the visual organs (eg glaucoma, progressive diabetic retinopathy, age-related macular disease, retinitis pigmento
- the compound of the present invention is preferably suitable for prevention and / or treatment of dysuria.
- the compound of the present invention is more preferably suitable for the prevention and / or treatment of overactive bladder.
- Overactive bladder is a symptom syndrome that requires urinary urgency and usually accompanies frequent urination and nocturia and sometimes urge urinary incontinence.
- the compound of the present invention is preferably a compound having reduced brain migration.
- a test substance is orally or intravenously administered to a mammal (eg, rat, mouse), and the plasma concentration and / or brain content after administration (eg, 1 hour after administration) is measured. It can be evaluated by the brain content or the calculated brain transfer rate (brain content / plasma concentration).
- the compound of the present invention 1) complementation and / or enhancement of preventive and / or therapeutic effects, It may be administered as a concomitant drug in combination with other drugs in order to 2) improve kinetics / absorption, reduce dosage, and / or 3) reduce side effects.
- the concomitant drug of the compound of the present invention and one or more other drugs may be administered in the form of a combination preparation in which all ingredients are mixed in one preparation, or may be in the form of separate preparations.
- simultaneous administration and administration by time difference are included.
- administration with a time difference may be such that the compound of the present invention is administered first and the other drug may be administered later, or the other drug may be administered first and the compound of the present invention may be administered later.
- Each administration method may be the same or different.
- the disease that exerts a preventive and / or therapeutic effect by the above concomitant drug is not particularly limited as long as it is a disease that complements and / or enhances the preventive and / or therapeutic effect of the compound of the present invention.
- drugs for supplementing and / or enhancing the preventive and / or therapeutic effect of the compound of the present invention on overactive bladder include, for example, (1) muscarinic receptor antagonists (for example, tolterodine, oxybutynin, hyoscyamine, propane) Terin, propiverine, trospium, solifenacin, darifenacin, imidafenacin, fesoterodine, temiverine, flavoxate, tarafenacin, afacifenacin, THVD-101, THVD-201 agonist), (2) beta receptor Drugs (mirabegron, KRP-114V, solabegron, TRK-380, etc.), (3) NK-1 or -2 antagonists (eg, aprepita (4) gene recombinant botulinum toxin (senrebotase, etc.), (5) opioid ⁇ receptor agonist (TRK-130, etc.), (6) ⁇ 4 ⁇
- the dose of the other drug can be appropriately selected based on the clinically used dose.
- the compounding ratio of the compound of the present invention and other drugs can be appropriately selected depending on the age and weight of the administration subject, administration method, administration time, target disease, symptom, combination and the like. For example, 0.01 to 100 parts by mass of another drug may be used with respect to 1 part by mass of the compound of the present invention. Two or more other drugs may be administered in combination at an appropriate ratio.
- the other drugs include not only those found so far but also those found in the future.
- the compound of the present invention or a concomitant drug of the present compound and another drug for the above-mentioned purpose it is usually formulated as an appropriate pharmaceutical composition together with a pharmaceutically acceptable carrier and then systemically or locally. Orally or parenterally.
- the compound of the present invention is administered to a mammal (preferably a human, more preferably a patient) in a pharmaceutically effective amount.
- the dose of the compound of the present invention depends on age, body weight, symptoms, desired therapeutic effect, administration route, treatment period, etc., inevitably varies. In general, it is administered orally once to several times a day in the range of 0.1 mg to 1000 mg per patient, or in the range of 0.01 mg to 100 mg once per patient. It is administered parenterally once to several times a day, or continuously administered intravenously in the range of 1 to 24 hours per day.
- a solid preparation for internal use or a liquid for internal use for oral administration a sustained-release preparation for oral administration, a controlled-release preparation, or a parenteral Used as injections, external preparations, inhalants or suppositories for administration.
- solid preparations for internal use for oral administration include tablets, pills, capsules, powders and granules.
- Capsules include hard capsules and soft capsules.
- one or more active substances are left as they are, or excipients (eg, lactose, mannitol, glucose, microcrystalline cellulose, starch, etc.), binders (eg, hydroxypropylcellulose) , Polyvinyl pyrrolidone, magnesium aluminate metasilicate, etc.), disintegrant (eg, calcium calcium glycolate), lubricant (eg, magnesium stearate), stabilizer, solubilizer (eg, glutamic acid, aspartic acid) Etc.) and the like, and formulated into a conventional method.
- excipients eg, lactose, mannitol, glucose, microcrystalline cellulose, starch, etc.
- binders eg, hydroxypropylcellulose
- Polyvinyl pyrrolidone e.g, magnesium aluminate metasilicate, etc.
- disintegrant eg, calcium calcium glycolate
- lubricant eg, magnesium stea
- cover may coat
- a coating agent for example, sucrose, gelatin, hydroxypropyl cellulose, hydroxypropyl methylcellulose phthalate etc.
- cover may be coated with two or more layers.
- capsules of absorbable materials such as gelatin.
- Oral liquids for oral administration include pharmaceutically acceptable solutions, suspensions, emulsions, syrups and elixirs.
- a solution one or more active substances are dissolved, suspended or emulsified in a commonly used diluent (for example, purified water, ethanol, or a mixture thereof).
- this liquid agent may contain a wetting agent, a suspending agent, an emulsifier, a sweetening agent, a flavoring agent, a fragrance, a preservative or a buffering agent.
- sustained-release preparations for oral administration are also effective.
- the gel-forming substance used in these sustained-release preparations is a substance that swells with a solvent, the colloidal particles are connected to each other, take a three-dimensional network structure, and can form a jelly-like object that loses fluidity It is. On the formulation, it is mainly used as a binder, thickener and sustained release base.
- gum arabic for example, gum arabic, agar, polyvinylpyrrolidone, sodium alginate, propylene glycol alginate, carboxyvinyl polymer, carboxymethylcellulose, sodium carboxymethylcellulose, guar gum, gelatin, hydroxypropylmethylcellulose, hydroxypropylcellulose, polyvinyl alcohol, methylcellulose or hydroxyethylmethylcellulose Can be used.
- injections for parenteral administration are solutions, suspensions, emulsions and solid injections used by dissolving or suspending in a solvent at the time of use.
- An injection is used by dissolving, suspending or emulsifying one or more active substances in a solvent.
- the solvent for example, distilled water for injection, physiological saline, vegetable oil, propylene glycol, polyethylene glycol, alcohols such as ethanol, and combinations thereof are used.
- this injection contains a stabilizer, a solubilizing agent (for example, glutamic acid, aspartic acid, polysorbate 80 (registered trademark), etc.), a suspending agent, an emulsifying agent, a soothing agent, a buffering agent or a preservative. May be.
- a solubilizing agent for example, glutamic acid, aspartic acid, polysorbate 80 (registered trademark), etc.
- a suspending agent for example, glutamic acid, aspartic acid, polysorbate 80 (registere
- Examples of external dosage forms for parenteral administration include sprays, inhalants, sprays, aerosols, ointments, gels, creams, poultices, patches, liniments and nasal drops. Is included. These contain one or more active substances and are prepared by known methods or commonly used formulations.
- Sprays, inhalants, and sprays include buffers that provide isotonicity with stabilizers such as sodium bisulfite in addition to commonly used diluents, such as sodium chloride, sodium citrate or citric acid.
- stabilizers such as sodium bisulfite
- diluents such as sodium chloride, sodium citrate or citric acid.
- An isotonic agent such as A method for producing a spray is described in detail in, for example, US Pat. Nos. 2,868,691 and 30,955,355.
- Inhalants for parenteral administration include aerosols, inhalable powders or inhalable solutions, which are used by dissolving or suspending them in water or other suitable media at the time of use. It may be.
- preservatives eg, benzalkonium chloride, parabens, etc.
- colorants e.g., sodium phosphate, sodium acetate, etc.
- buffering agents e.g, sodium phosphate, sodium acetate, etc.
- isotonic agents e.g, chloride
- thickeners for example, carboxyvinyl polymer, etc.
- absorption accelerators and the like, as appropriate.
- lubricants eg, stearic acid and its salts
- binders eg, starch, dextrin, etc.
- excipients eg, lactose, cellulose, etc.
- colorants eg, antiseptics
- an agent for example, benzalkonium chloride, paraben, etc. or an absorption accelerator is appropriately selected as necessary.
- a nebulizer for example, an atomizer, a nebulizer, etc.
- an inhalation administration device for a powder drug is usually used.
- the ointment is manufactured by a known or commonly used formulation. For example, it is prepared by mixing or melting one or more active substances in a base.
- the ointment base is selected from known or commonly used ones.
- higher fatty acid or higher fatty acid ester for example, adipic acid, myristic acid, palmitic acid, stearic acid, oleic acid, adipic acid ester, myristic acid ester, palmitic acid ester, stearic acid ester, oleic acid ester, etc.
- waxes E.g., beeswax, whale wax, ceresin, etc.
- surfactants e.g., polyoxyethylene alkyl ether phosphates, etc.
- higher alcohols e.g., cetanol, stearyl alcohol, cetostearyl alcohol, etc.
- silicone oils e.g., Dimethylpolysiloxane, etc.
- hydrocarbons eg, hydro
- Gel is manufactured by a known or commonly used formulation. For example, it is prepared by melting one or more active substances in a base.
- the gel base is selected from known or commonly used ones.
- lower alcohol eg, ethanol, isopropyl alcohol, etc.
- gelling agent eg, carboxymethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, ethylcellulose, etc.
- neutralizing agent eg, triethanolamine, diisopropanolamine, etc.
- surfactants for example, polyethylene glycol monostearate
- gums water
- absorption promoters and anti-rash agents are used alone or in admixture of two or more.
- a preservative, an antioxidant or a flavoring agent may be included.
- Creams are produced by known or commonly used formulations. For example, it is produced by melting or emulsifying one or more active substances in a base.
- the cream base is selected from known or commonly used ones. For example, higher fatty acid esters, lower alcohols, hydrocarbons, polyhydric alcohols (eg, propylene glycol, 1,3-butylene glycol, etc.), higher alcohols (eg, 2-hexyldecanol, cetanol, etc.), emulsifiers (eg, polyoxy (Ethylene alkyl ethers, fatty acid esters, etc.), water, absorption accelerators and anti-rash agents are used alone or in admixture of two or more. Furthermore, a preservative, an antioxidant or a flavoring agent may be included.
- the poultice is manufactured by a known or commonly used formulation. For example, it is produced by melting one or more active substances in a base material, and applying it as a kneaded product on a support.
- the poultice base is selected from known or commonly used ones.
- thickeners eg, polyacrylic acid, polyvinyl pyrrolidone, gum arabic, starch, gelatin, methyl cellulose, etc.
- wetting agents eg, urea, glycerin, propylene glycol, etc.
- fillers eg, kaolin, zinc oxide, Those selected from talc, calcium, magnesium, etc.
- solubilizers, tackifiers and anti-rash agents are used alone or in admixture of two or more.
- a preservative, an antioxidant or a flavoring agent may be included.
- the patch is manufactured by a known or commonly used formulation. For example, it is produced by melting one or more active substances in a base and spreading and coating them on a support.
- the base for patch is selected from known or commonly used ones. For example, those selected from polymer bases, fats and oils, higher fatty acids, tackifiers and anti-rash agents may be used alone or in admixture of two or more. Furthermore, a preservative, an antioxidant or a flavoring agent may be included.
- the liniment is produced by a known or commonly used formulation.
- one or more active substances may be selected from water, alcohol (eg, ethanol, polyethylene glycol, etc.), higher fatty acids, glycerin, soap, emulsifier, suspending agent, etc. alone or in two or more types It is prepared by suspending or emulsifying.
- a preservative, an antioxidant or a flavoring agent may be included.
- compositions for parenteral administration include suppositories for rectal administration and pessaries for intravaginal administration, which contain one or more active substances and are formulated by conventional methods.
- the solvent in the parenthesis shown in the chromatographic separation site and TLC indicates the elution solvent or developing solvent used, and the ratio indicates the volume ratio.
- chromatolex registered trademark
- Yamazen Hi-Flash column trade name
- Chromatograph W-prep 2XY trade name
- the NMR data is 1 H-NMR data unless otherwise specified.
- the parentheses shown in the NMR part indicate the solvent used for the measurement.
- the compound name used in this specification is generally a computer program for naming according to the IUPAC rules, Advanced Chemistry Development ACD / Name (registered trademark), or according to the IUPAC nomenclature. It is named.
- Example 1 1,1,1-trifluoro-2- (4-nitrophenyl) -2-propanol 1- (4-nitrophenyl) ethanone (1.65 g) (CAS registration number: 100-19-6) and (trifluoro Tetrabutylammonium fluoride (1M tetrahydrofuran solution, 1 mL) was added to a tetrahydrofuran (16 mL) solution of methyl) trimethylsilane (4.26 g) under ice cooling, and the mixture was stirred at room temperature for 2 hours. A saturated aqueous ammonium chloride solution was added to the reaction mixture, and the mixture was extracted with ethyl acetate.
- Example 2 2- (4-Aminophenyl) -1,1,1-trifluoro-2-propanol
- the compound (2.28 g) prepared in Example 1 was suspended in ethanol (50 mL) and water (10 mL), and powdered zinc (3.17 g) and acetic acid (2.82 mL) were added.
- the reaction mixture was stirred at 50 ° C. overnight.
- the reaction mixture was cooled to room temperature, saturated aqueous sodium hydrogen carbonate solution was added, and the mixture was stirred for 30 min.
- Ethyl acetate was added to the reaction mixture, filtered through Celite (trade name), and the filtrate was extracted with ethyl acetate.
- Example 3 2- (4-Amino-3,5-dichlorophenyl) -1,1,1-trifluoro-2-propanol
- N, N-dimethylformamide (12 mL) N-chlorosuccinimide (1.56 g) was added, and the mixture was stirred at room temperature for 15 hours.
- Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate and concentrated under reduced pressure.
- Example 4 2,6-dichloro-4- ⁇ 1,1,1-trifluoro-2-[(trimethylsilyl) oxy] -2-propanyl ⁇ aniline Imidazole was added to a solution of the compound prepared in Example 3 (860 mg) in tetrahydrofuran (17 mL). (1.07 g) and chlorotrimethylsilane (2 mL) were added. The reaction mixture was stirred at room temperature for 2.5 hours, water was added, and the mixture was extracted with ethyl acetate. The organic layer was washed with water, dried over anhydrous sodium sulfate, and concentrated under reduced pressure.
- Example 5 1- [2,6-dichloro-4- (1,1,1-trifluoro-2-hydroxy-2-propanyl) phenyl] -3- ⁇ [5- (trifluoromethyl) -2-pyridinyl] methyl ⁇
- Urea N, N-diisopropylethylamine (261 ⁇ L) and triphosgene (447 mg) were added to a solution of the compound prepared in Example 4 (475 mg) in tetrahydrofuran (9.5 mL). The reaction mixture was stirred at room temperature for 2.5 hours and then concentrated under reduced pressure.
- the reaction mixture was stirred at room temperature overnight and then at 50 ° C. for 2 hours.
- the reaction mixture was concentrated under reduced pressure, saturated aqueous sodium hydrogen carbonate solution was added, and the mixture was extracted with ethyl acetate.
- the organic layer was dried over anhydrous magnesium sulfate and concentrated under reduced pressure.
- Example 5 (1) to (35) The title compound having the following physical data was obtained by conducting the same operations as in Example 5, using the corresponding amine instead of 1- [5- (trifluoromethyl) -2-pyridinyl] methanamine hydrochloride. .
- Example 5 (4) 1- [2,6-Dichloro-4- (1,1,1-trifluoro-2-hydroxy-2-propanyl) phenyl] -3- (3,3-dimethyl-2-butanyl) urea
- Example 5 1- [2,6-Dichloro-4- (1,1,1-trifluoro-2-hydroxy-2-propanyl) phenyl] -3-[(2,2-dimethyltetrahydro-2H-pyran-4-yl ) Methyl] urea
- Example 5 1- [2,6-Dichloro-4- (1,1,1-trifluoro-2-hydroxy-2-propanyl) phenyl] -3-[(4,4-difluoro-1-hydroxycyclohexyl) methyl] urea
- Example 5 1- [2,6-Dichloro-4- (1,1,1-trifluoro-2-hydroxy-2-propanyl) phenyl] -3-[(3-methyl-2-pyridinyl) methyl] urea
- Example 5 (14) 1- [2,6-dichloro-4- (1,1,1-trifluoro-2-hydroxy-2-propanyl) phenyl] -3-[(2R) -tetrahydro-2-furanylmethyl] urea
- Example 5 (15) 1- [2,6-dichloro-4- (1,1,1-trifluoro-2-hydroxy-2-propanyl) phenyl] -3-[(2S) -tetrahydro-2-furanylmethyl] urea
- Example 5 (22) 1-[(3-Cyclopropyl-1,2,4-oxadiazol-5-yl) methyl] -3- [2,6-dichloro-4- (1,1,1-trifluoro-2-hydroxy) -2-propanyl) phenyl] urea
- Example 5 (27) 1- [2,6-dichloro-4- (1,1,1-trifluoro-2-hydroxy-2-propanyl) phenyl] -3- ⁇ [3- (2-methyl-2-propanyl) -1, 2,4-oxadiazol-5-yl] methyl ⁇ urea
- Example 5 (28) 1- [2,6-dichloro-4- (1,1,1-trifluoro-2-hydroxy-2-propanyl) phenyl] -3- ⁇ [5- (2-methyl-2-propanyl) -1, 2,4-oxadiazol-3-yl] methyl ⁇ urea
- Example 5 (29) 1- [2,6-Dichloro-4- (1,1,1-trifluoro-2-hydroxy-2-propanyl) phenyl] -3- [4- (trifluoromethyl) benzyl] urea LC retention time (min), LC condition 2: 0.96; 1 H-NMR (DMSO-d 6 ): ⁇ 1.68, 4.36, 6.91, 7.00, 7.49-7.51, 7.63, 7.68-7.71, 8.24.
- Example 5 1- [2,6-Dichloro-4- (1,1,1-trifluoro-2-hydroxy-2-propanyl) phenyl] -3-[(2,2-difluorocyclopropyl) methyl] urea
- Example 5 (32) 1- [2,6-Dichloro-4- (1,1,1-trifluoro-2-hydroxy-2-propanyl) phenyl] -3- (1,2-oxazol-3-ylmethyl) urea
- Example 5 (33) 1- [2,6-Dichloro-4- (1,1,1-trifluoro-2-hydroxy-2-propanyl) phenyl] -3- (1,3-thiazol-2-ylmethyl) urea
- Example 5 1- [2,6-Dichloro-4- (1,1,1-trifluoro-2-hydroxy-2-propanyl) phenyl] -3-[(3,3-difluorocyclobutyl) methyl] urea
- Example 5 (35) 1- [2,6-Dichloro-4- (1,1,1-trifluoro-2-hydroxy-2-propanyl) phenyl] -3- [4- (trifluoromethoxy) benzyl] urea
- Example 7 2- ⁇ [2- (2-Methyl-2-propanyl) -1,3-oxazol-5-yl] methyl ⁇ -1H-isoindole-1,3 (2H) -dione
- Triphenylphosphine (135 mg) and phthalimide (75 mg) were added to a solution of the prepared compound (40 mg) in tetrahydrofuran (1 mL).
- Diethyl azodicarboxylate (230 ⁇ L) was added to the reaction mixture under ice cooling, and the mixture was stirred at room temperature for 1 hour.
- Example 8 1- [2- (2-Methyl-2-propanyl) -1,3-oxazol-5-yl] methanamine
- ethanol 1.7 mL
- Hydrazine monohydrate 129 mg
- the reaction mixture was stirred at 80 ° C. for 30 minutes and then cooled to room temperature.
- a mixed solvent of ethyl acetate and ethanol was added to the reaction mixture, followed by filtration.
- the filtrate was concentrated under reduced pressure to give the title compound (40 mg) having the following physical properties.
- Example 9 1- [2,6-dichloro-4- (1,1,1-trifluoro-2-hydroxy-2-propanyl) phenyl] -3- ⁇ [2- (2-methyl-2-propanyl) -1, 3-Oxazol-5-yl] methyl ⁇ urea
- the title compound having the following physical property values was obtained by performing the same operation as in Example 5. A compound was obtained.
- Example 10 1- [2- (Trifluoromethyl) -1,3-thiazol-5-yl] methanamine Instead of the compound prepared in Example 6, (2- (trifluoromethyl) thiazol-5-yl) methanol (CAS The title compound having the following physical data was obtained by conducting the same operations as in Example 7 ⁇ Example 8 using registration number: 131748-97-5).
- Example 11 1- [2,6-dichloro-4- (1,1,1-trifluoro-2-hydroxy-2-propanyl) phenyl] -3- ⁇ [2- (trifluoromethyl) -1,3-thiazole- 5-yl] methyl ⁇ urea
- the same procedure as in Example 5 was performed, and the following physical property values were obtained.
- a compound was obtained.
- TLC: Rf 0.26 (hexane: ethyl acetate 1: 1); 1 H-NMR (DMSO-d 6 ): ⁇ 1.70, 4.53, 6.94, 7.19, 7.65, 7.96, 8.40.
- Example 12 1- [5- (2-Methyl-2-propanyl) -1,2-oxazol-3-yl] methanamine Instead of the compound prepared in Example 6, (5-tert-butyl-1,2-oxazole- The title compound having the following physical data was obtained by conducting the same operation as in Example 7, then Example 8 using 3-yl) methanol (CAS Registry Number: 202817-06-9). 1 H-NMR (DMSO-d 6 ): ⁇ 1.27, 3.63, 6.20.
- Example 13 1- [2,6-dichloro-4- (1,1,1-trifluoro-2-hydroxy-2-propanyl) phenyl] -3- ⁇ [5- (2-methyl-2-propanyl) -1, 2-Oxazol-3-yl] methyl ⁇ urea
- the same procedure as in Example 5 was performed, and the following physical property values were obtained. A compound was obtained.
- Example 14 2- (4-Bromophenyl) -1,1,1-trifluoro-2-propanol Cerium chloride (51 g) that has been heated and dried under reduced pressure in an argon atmosphere is suspended in tetrahydrofuran (316 mL) and allowed to stand at room temperature for 1 hour. After stirring, it was cooled to -70 ° C. Methyl lithium (3.0 M diethyl ether solution, 185 mL) was added dropwise, and the mixture was stirred at ⁇ 70 ° C. for 30 minutes, and then 1- (4-bromophenyl) -2,2,2-trifluoroethanone (40 g) (CAS registration) (No.
- Examples 15a and 15b (2R) -2- (4-Bromophenyl) -1,1,1-trifluoro-2-propanyl [(1S) -1- (1-naphthyl) ethyl] carbamate
- Examples 15a and 15b (2R) -2- (4-Bromophenyl) -1,1,1-trifluoro-2-propanyl [(1S) -1- (1-naphthyl) ethyl] carbamate
- Examples 15a and 15b (2R) -2- (4-Bromophenyl) -1,1,1-trifluoro-2-propanyl [(1S) -1- (1-naphthyl) ethyl] carbamate
- Dimethylaminopyridine (23.2 g) and 4-nitrophenyl chloroformate (35.1 g) were added to a solution of the compound prepared in Example 14 (43 g) in dichloromethane (237 mL) under
- Example 17 2-Methyl-2-propanyl ⁇ 4-[(2R) -1,1,1-trifluoro-2-hydroxy-2-propanyl] phenyl ⁇ carbamate
- Compound prepared in Example 16 (27 g), tert-butyl carbamate (15 g), palladium (II) acetate (2.2 g), 4,5-bis (diphenylphosphino) -9,9-dimethylxanthene (8.6 g), cesium carbonate (49 g), 1,4-dioxane ( (200 mL) was stirred at 100 ° C. for 2 hours under an argon atmosphere.
- Example 18 (2R) -2- (4-Aminophenyl) -1,1,1-trifluoro-2-propanol
- trifluoroacetic acid 85 mL
- Toluene was added to the reaction mixture, and the mixture was concentrated under reduced pressure.
- a saturated aqueous sodium hydrogen carbonate solution 300 mL was added to the resulting residue, and the mixture was extracted with ethyl acetate. The organic layer was washed successively with aqueous ammonium chloride solution and saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure.
- Example 19 (2R) -2- (4-Aminophenyl) -1,1,1-trifluoro-2-propanol hydrochloride
- tert-butyl methyl ether 96 mL
- 4N hydrogen chloride / 1,4-dioxane solution 15 mL
- the resulting precipitate was collected by filtration and washed with tert-butyl methyl ether.
- Acetonitrile (200 mL) was added to the obtained solid and stirred at 80 ° C. After dissolution, the mixture was cooled to room temperature and stirred overnight.
- Example 20 4- ⁇ (2R) -1,1,1-trifluoro-2-[(trimethylsilyl) oxy] -2-propanyl ⁇ aniline
- the compound (7.8 g) prepared in Example 19 was mixed with methanol (10 mL) and ethyl acetate. (50 mL), a saturated aqueous sodium hydrogen carbonate solution (150 mL) was added in several portions with stirring, and the reaction mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure.
- Tetrahydrofuran (130 mL) solution was added to the obtained residue and cooled in an ice-water bath, imidazole (11 g) and chlorotrimethylsilane (20 mL) were added, and the mixture was stirred at 30 ° C. for 1 hr.
- the reaction mixture was poured into water (300 mL), the aqueous layer was separated, saturated aqueous sodium hydrogen carbonate solution was added to adjust the pH to 7 or higher, and the mixture was extracted with ethyl acetate.
- the organic layer was washed successively with water and saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure to give the title compound having the following physical data (9.4 g).
- Example 21 2,6-Dichloro-4- ⁇ (2R) -1,1,1-trifluoro-2-[(trimethylsilyl) oxy] -2-propanyl ⁇ aniline N of the compound (9.4 g) prepared in Example 20 N-chlorosuccinimide (9.1 g) was added to N, N-dimethylformamide (100 mL) solution, and the mixture was stirred at room temperature for 15 hours, and further stirred at 40 ° C. for 2 hours. The reaction mixture was poured into water (300 mL) and extracted with hexane-ethyl acetate (1: 1, 100 mL ⁇ 3).
- Example 22 1- ⁇ 2,6-dichloro-4-[(2R) -1,1,1-trifluoro-2-hydroxy-2-propanyl] phenyl ⁇ -3-[(5-methyl-1,2-oxazole- 3-yl) methyl] urea
- N, N-diisopropylethylamine (160 ⁇ L) and triphosgene (283 mg) were added to a solution of the compound prepared in Example 21 (300 mg) in tetrahydrofuran (5 mL). The reaction mixture was stirred at room temperature for 30 minutes and then concentrated under reduced pressure.
- Example 22 (1) to (17) The same procedure as in Example 22 was carried out using the amine prepared in Example 10 or the corresponding amine instead of 1- (5-methyl-1,2-oxazol-3-yl) methanamine hydrochloride. The title compound having the following physical property values was obtained.
- Example 22 (1) 1- ⁇ 2,6-dichloro-4-[(2R) -1,1,1-trifluoro-2-hydroxy-2-propanyl] phenyl ⁇ -3- ⁇ [5- (trifluoromethyl) -2- Pyridinyl] methyl ⁇ urea
- Example 22 (2) 1- ⁇ 2,6-dichloro-4-[(2R) -1,1,1-trifluoro-2-hydroxy-2-propanyl] phenyl ⁇ -3- ⁇ [5- (trifluoromethyl) -2- Pyrimidinyl] methyl ⁇ urea
- Example 22 (3) 1- ⁇ 2,6-dichloro-4-[(2R) -1,1,1-trifluoro-2-hydroxy-2-propanyl] phenyl ⁇ -3- ⁇ [6- (trifluoromethyl) -3- Pyridinyl] methyl ⁇ urea
- Example 22 (4) 1- ⁇ 2,6-dichloro-4-[(2R) -1,1,1-trifluoro-2-hydroxy-2-propanyl] phenyl ⁇ -3- ⁇ [2- (trifluoromethyl) -5 Pyrimidinyl] methyl ⁇ urea
- Example 22 1- ⁇ 2,6-dichloro-4-[(2R) -1,1,1-trifluoro-2-hydroxy-2-propanyl] phenyl ⁇ -3- ⁇ [6- (2,2,2-tri Fluoroethoxy) -3-pyridinyl] methyl ⁇ urea
- Example 22 1- ⁇ 2,6-dichloro-4-[(2R) -1,1,1-trifluoro-2-hydroxy-2-propanyl] phenyl ⁇ -3- [4- (trifluoromethyl) benzyl] urea
- Example 22 (8) 1-Benzyl-3- ⁇ 2,6-dichloro-4-[(2R) -1,1,1-trifluoro-2-hydroxy-2-propanyl] phenyl ⁇ urea LC retention time (min), LC condition 3: 0.90; 1 H-NMR (DMSO-d 6 ): ⁇ 1.70, 4.29, 6.89, 6.95, 7.20-7.35, 7.64, 8.14.
- Example 22 1- ⁇ 2,6-dichloro-4-[(2R) -1,1,1-trifluoro-2-hydroxy-2-propanyl] phenyl ⁇ -3- (4-methoxybenzyl) urea LC retention time (min), LC condition 3: 0.90; 1 H-NMR (DMSO-d 6 ): ⁇ 1.69, 3.72, 4.21, 6.79, 6.87-6.92, 7.20-7.23, 7.63, 8.07.
- Example 22 10- ⁇ 2,6-dichloro-4-[(2R) -1,1,1-trifluoro-2-hydroxy-2-propanyl] phenyl ⁇ -3- (4-methylbenzyl) urea LC retention time (min), LC condition 3: 0.95; 1 H-NMR (DMSO-d 6 ): ⁇ 1.70, 2.27, 4.24, 6.82, 6.94, 7.14-7.20, 7.64, 8.10.
- Example 22 (11) 1- ⁇ 2,6-dichloro-4-[(2R) -1,1,1-trifluoro-2-hydroxy-2-propanyl] phenyl ⁇ -3- [4- (2-methyl-2-propanyl) Benzyl] urea LC retention time (min), LC condition 3: 1.05; 1 H-NMR (DMSO-d 6 ): ⁇ 1.27, 1.70, 4.25, 6.84, 6.92, 7.21-7.24, 7.34-7.36, 7.64, 8.09.
- Example 22 (12) 1- ⁇ 2,6-dichloro-4-[(2R) -1,1,1-trifluoro-2-hydroxy-2-propanyl] phenyl ⁇ -3- (4-phenoxybenzyl) urea LC retention time (min), LC condition 3: 1.03; 1 H-NMR (DMSO-d 6 ): ⁇ 1.70, 4.28, 6.87-6.91, 6.96-7.00, 7.09-7.15, 7.31-7.41, 7.64, 8.14.
- Example 22 (13) 1- ⁇ 2,6-dichloro-4-[(2R) -1,1,1-trifluoro-2-hydroxy-2-propanyl] phenyl ⁇ -3- [4- (difluoromethoxy) benzyl] urea LC retention time (min), LC condition 3: 0.94; 1 H-NMR (DMSO-d 6 ): ⁇ 1.70, 4.28, 6.88-6.94, 7.13-7.16, 7.20, 7.33-7.36, 7.64, 8.16.
- Example 22 (14) 1- ⁇ 2,6-dichloro-4-[(2R) -1,1,1-trifluoro-2-hydroxy-2-propanyl] phenyl ⁇ -3- [4- (4-morpholinyl) benzyl] urea LC retention time (min), LC condition 3: 0.73; 1 H-NMR (DMSO-d 6 ): ⁇ 1.70, 3.07-3.11, 3.72-3.75, 4.19, 6.77, 6.92-6.95, 7.17-7.20, 7.64, 8.07.
- Example 22 (15) 1- (4-Cyanobenzyl) -3- ⁇ 2,6-dichloro-4-[(2R) -1,1,1-trifluoro-2-hydroxy-2-propanyl] phenyl ⁇ urea LC retention time (min), LC condition 3: 0.87; 1 H-NMR (DMSO-d 6 ): ⁇ 1.70, 4.37, 6.93, 7.02, 7.47-7.50, 7.65, 7.80-7.82, 8.28.
- Example 22 (16) 1- ⁇ 2,6-dichloro-4-[(2R) -1,1,1-trifluoro-2-hydroxy-2-propanyl] phenyl ⁇ -3- [4- (4-fluorophenoxy) benzyl] urea LC retention time (min), LC condition 3: 1.03; 1 H-NMR (DMSO-d 6 ): ⁇ 1.70, 4.27, 6.86-7.05, 7.19-7.23, 7.30-7.33, 7.64, 8.13.
- Example 22 1- ⁇ 2,6-dichloro-4-[(2R) -1,1,1-trifluoro-2-hydroxy-2-propanyl] phenyl ⁇ -3- ⁇ [2- (trifluoromethyl) -1, 3-thiazol-5-yl] methyl ⁇ urea
- Example 23 1- ⁇ 2,6-dichloro-4-[(2R) -1,1,1-trifluoro-2-hydroxy-2-propanyl] phenyl ⁇ -3- ⁇ [3- (trifluoromethyl) -1, 2,4-oxadiazol-5-yl] methyl ⁇ urea
- N, N-diisopropylethylamine (165 ⁇ L) and triphosgene (283 mg) were added to a solution of the compound prepared in Example 21 (300 mg) in tetrahydrofuran (6 mL). The reaction mixture was stirred at room temperature for 1 hour and then concentrated under reduced pressure.
- Example 24 2,6-Dichloro-4- ⁇ (2S) -1,1,1-trifluoro-2-[(trimethylsilyl) oxy] -2-propanyl ⁇ aniline
- Example 15b instead of the compound prepared in Example 15a Using the prepared compound, the title compound having the following physical property values was obtained in the same manner as in Example 16 ⁇ Example 17 ⁇ Example 18 ⁇ Example 19 ⁇ Example 20 ⁇ Example 21.
- TLC: Rf 0.56 (hexane: ethyl acetate 4: 1); 1 H-NMR (CDCl 3 ): ⁇ 0.15, 1.75, 4.51, 7.33.
- Example 25 1- ⁇ 2,6-dichloro-4-[(2S) -1,1,1-trifluoro-2-hydroxy-2-propanyl] phenyl ⁇ -3-[(5-methyl-1,2-oxazole- 3-yl) methyl] urea
- Example 25 (1) to (8) The compound prepared in Example 24 was used in place of the compound prepared in Example 21, and the compound prepared in Example 10 was used instead of 1- (5-methyl-1,2-oxazol-3-yl) methanamine hydrochloride.
- the title compound having the following physical data was obtained by conducting the same procedures as in Example 22 using the prepared amine or a corresponding amine.
- Example 25 (1) 1- ⁇ 2,6-dichloro-4-[(2S) -1,1,1-trifluoro-2-hydroxy-2-propanyl] phenyl ⁇ -3- ⁇ [5- (trifluoromethyl) -2- Pyrimidinyl] methyl ⁇ urea
- Example 25 (2) 1- ⁇ 2,6-dichloro-4-[(2S) -1,1,1-trifluoro-2-hydroxy-2-propanyl] phenyl ⁇ -3- ⁇ [6- (trifluoromethyl) -3- Pyridinyl] methyl ⁇ urea
- Example 25 (3) 1- ⁇ 2,6-dichloro-4-[(2S) -1,1,1-trifluoro-2-hydroxy-2-propanyl] phenyl ⁇ -3- ⁇ [2- (trifluoromethyl) -5- Pyrimidinyl] methyl ⁇ urea
- Example 25 (4) 1- ⁇ 2,6-dichloro-4-[(2S) -1,1,1-trifluoro-2-hydroxy-2-propanyl] phenyl ⁇ -3- ⁇ [5- (trifluoromethyl) -2- Pyridinyl] methyl ⁇ urea
- Example 25 1-[(5-Chloro-2-pyridinyl) methyl] -3- ⁇ 2,6-dichloro-4-[(2S) -1,1,1-trifluoro-2-hydroxy-2-propanyl] phenyl ⁇
- Example 25 (6) 1- ⁇ 2,6-dichloro-4-[(2S) -1,1,1-trifluoro-2-hydroxy-2-propanyl] phenyl ⁇ -3- ⁇ [6- (2,2,2-tri Fluoroethoxy) -3-pyridinyl] methyl ⁇ urea
- 1 H-NMR (DMSO-d 6 ) ⁇ 1.70, 4.25, 4.93-5.02, 6.93-6.98, 7.64, 7.74, 8.11, 8.19.
- Example 25 1- ⁇ 2,6-dichloro-4-[(2S) -1,1,1-trifluoro-2-hydroxy-2-propanyl] phenyl ⁇ -3- [4- (trifluoromethyl) benzyl] urea
- Example 25 (8) 1- ⁇ 2,6-dichloro-4-[(2S) -1,1,1-trifluoro-2-hydroxy-2-propanyl] phenyl ⁇ -3- ⁇ [2- (trifluoromethyl) -1, 3-thiazol-5-yl] methyl ⁇ urea
- Example 26 1- ⁇ 2,6-dichloro-4-[(2S) -1,1,1-trifluoro-2-hydroxy-2-propanyl] phenyl ⁇ -3- ⁇ [3- (trifluoromethyl) -1, 2,4-oxadiazol-5-yl] methyl ⁇ urea
- reaction solution was cooled again in an ice bath, (1S) -1- (1-naphthyl) ethanamine (4 mL) (CAS registration number: 10420-89-0) was added, and the mixture was stirred at room temperature for 30 minutes.
- the reaction solution was filtered, and the filtrate was washed successively with 1N aqueous sodium hydroxide solution twice, 1N hydrochloric acid once, and saturated brine once.
- the organic layer was dried over anhydrous magnesium sulfate and concentrated under reduced pressure.
- Example 28 (1R) -1- (4-Bromophenyl) -2,2,2-trifluoroethanol Mixing of the compound prepared in Example 27a (2.37 g) with 1,4-dioxane (40 mL) and water (20 mL) Lithium hydroxide monohydrate (2.20 g) was added to the solution, and the mixture was stirred at 50 ° C. for 1 hr. To the reaction mixture was added 2N hydrochloric acid (40 mL) in an ice bath, and the mixture was extracted with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate and concentrated under reduced pressure.
- Example 29 2-Methyl-2-propanyl ⁇ 4-[(1R) -2,2,2-trifluoro-1-hydroxyethyl] phenyl ⁇ carbamate 1,4-dioxane of the compound prepared in Example 28 (1.34 g) (30 mL), tert-butyl carbamate (800 mg), palladium (II) acetate (118 mg), 4,5-bis (diphenylphosphino) -9,9-dimethylxanthene (456 mg), cesium carbonate (2.57 g) ) And heated to reflux for 3 hours. The reaction mixture was filtered through Celite (trade name), and the filtrate was concentrated under reduced pressure.
- Example 30 (1R) -1- (4-Amino-3,5-dichlorophenyl) -2,2,2-trifluoroethanol To a solution of the compound prepared in Example 29 (1.32 g) in dichloromethane (20 mL) in an ice bath , Trifluoroacetic acid (10 mL) was added and stirred at room temperature for 1 hour. Toluene (10 mL) was added to the reaction mixture, and the mixture was concentrated under reduced pressure. A saturated aqueous sodium hydrogen carbonate solution was added to the obtained residue, and the mixture was extracted with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate and concentrated under reduced pressure.
- Example 31 2,6-Dichloro-4- ⁇ (1R) -2,2,2-trifluoro-1-[(trimethylsilyl) oxy] ethyl ⁇ aniline
- tetrahydrofuran 10 mL
- Chlorotrimethylsilane 583 ⁇ L
- imidazole 405 mg
- a saturated aqueous ammonium chloride solution was added to the reaction mixture, and the mixture was extracted with ethyl acetate.
- the organic layer was dried over anhydrous magnesium sulfate and concentrated under reduced pressure.
- Example 32 1- ⁇ 2,6-dichloro-4-[(1R) -2,2,2-trifluoro-1-hydroxyethyl] phenyl ⁇ -3- ⁇ [5- (trifluoromethyl) -2-pyridinyl] methyl ⁇
- Urea N, N-diisopropylamine (49 ⁇ L) and triphosgene (78 mg) were added to a solution of the compound prepared in Example 31 (80 mg) in tetrahydrofuran (4 mL). The reaction mixture was stirred at room temperature for 2 hours and then concentrated under reduced pressure.
- Example 32 (1) to (7) The title compound having the following physical data was obtained by conducting the same operation as in Example 32 using the corresponding amine instead of 1- [5- (trifluoromethyl) -2-pyridinyl] methanamine hydrochloride. .
- Example 32 (1) 1- ⁇ 2,6-dichloro-4-[(1R) -2,2,2-trifluoro-1-hydroxyethyl] phenyl ⁇ -3- ⁇ [3- (trifluoromethyl) -1,2,4 -Oxadiazol-5-yl] methyl ⁇ urea
- Example 32 (2) 1- ⁇ 2,6-dichloro-4-[(1R) -2,2,2-trifluoro-1-hydroxyethyl] phenyl ⁇ -3-[(5-methyl-1,2-oxazol-3-yl ) Methyl] urea
- Example 32 (6) 1- ⁇ 2,6-dichloro-4-[(1R) -2,2,2-trifluoro-1-hydroxyethyl] phenyl ⁇ -3- ⁇ [6- (2,2,2-trifluoroethoxy) -3-pyridinyl] methyl ⁇ urea
- Example 32 (7) 1- ⁇ 2,6-dichloro-4-[(1R) -2,2,2-trifluoro-1-hydroxyethyl] phenyl ⁇ -3- [4- (trifluoromethyl) benzyl] urea
- Example 33 1- ⁇ 2,6-dichloro-4-[(1R) -2,2,2-trifluoro-1-hydroxyethyl] phenyl ⁇ -3- ⁇ [2- (trifluoromethyl) -1,3-thiazole -5-yl] methyl ⁇ urea
- the same procedure as in Example 32 was performed, and the following physical property values were obtained.
- a compound was obtained.
- TLC: Rf 0.33 (hexane: ethyl acetate 1: 1); 1 H-NMR (DMSO-d 6 ): ⁇ 4.53, 5.27, 7.12, 7.18, 7.58, 7.95, 8.40.
- Example 34 2,6-Dichloro-4- ⁇ (1S) -2,2,2-trifluoro-1-[(trimethylsilyl) oxy] ethyl ⁇ aniline Prepared in Example 27b instead of the compound prepared in Example 27a
- the title compound having the following physical data was obtained by conducting the same operations as in Example 28 ⁇ Example 29 ⁇ Example 30 ⁇ Example 31 using the compound.
- TLC: Rf 0.75 (hexane: ethyl acetate 5: 1); 1 H-NMR (CDCl 3 ): ⁇ 0.13, 4.56, 4.75, 7.26.
- Example 35 1- ⁇ 2,6-dichloro-4-[(1S) -2,2,2-trifluoro-1-hydroxyethyl] phenyl ⁇ -3- ⁇ [5- (trifluoromethyl) -2-pyridinyl] methyl ⁇ Urea
- Example 35 (1) to (7) The compound prepared in Example 34 was used in place of the compound prepared in Example 31, and the corresponding amine was used in place of 1- [5- (trifluoromethyl) -2-pyridinyl] methanamine hydrochloride. The same operation as in Example 32 was performed to give the title compound having the following physical data.
- Example 35 (1) 1- ⁇ 2,6-dichloro-4-[(1S) -2,2,2-trifluoro-1-hydroxyethyl] phenyl ⁇ -3- ⁇ [3- (trifluoromethyl) -1,2,4 -Oxadiazol-5-yl] methyl ⁇ urea
- Example 35 (2) 1- ⁇ 2,6-dichloro-4-[(1S) -2,2,2-trifluoro-1-hydroxyethyl] phenyl ⁇ -3-[(5-methyl-1,2-oxazol-3-yl ) Methyl] urea
- Example 35 (6) 1- ⁇ 2,6-dichloro-4-[(1S) -2,2,2-trifluoro-1-hydroxyethyl] phenyl ⁇ -3- ⁇ [6- (2,2,2-trifluoroethoxy) -3-pyridinyl] methyl ⁇ urea
- Example 35 1- ⁇ 2,6-dichloro-4-[(1S) -2,2,2-trifluoro-1-hydroxyethyl] phenyl ⁇ -3- [4- (trifluoromethyl) benzyl] urea
- Example 36 1- ⁇ 2,6-dichloro-4-[(1S) -2,2,2-trifluoro-1-hydroxyethyl] phenyl ⁇ -3- ⁇ [2- (trifluoromethyl) -1,3-thiazole -5-yl] methyl ⁇ urea
- the same procedure as in Example 32 was performed, and the following physical property values were obtained.
- a compound was obtained.
- TLC: Rf 0.33 (hexane: ethyl acetate 1: 1); 1 H-NMR (DMSO-d 6 ): ⁇ 4.53, 5.27, 7.12, 7.18, 7.58, 7.96, 8.39.
- Example 37 4-acetyl-3-fluorophenyl trifluoromethanesulfonate 1- (2-fluoro-4-hydroxyphenyl) ethanone (2.05 g) (CAS registration number: 68301-59-7) was suspended in dichloromethane (20 mL). Under ice-cooling, triethylamine (2.04 mL) and trifluoromethanesulfonic anhydride (2.46 mL) were added. The reaction mixture was stirred at room temperature for 30 minutes and then concentrated under reduced pressure.
- Example 38 3-Fluoro-4- (1,1,1-trifluoro-2-hydroxy-2-propanyl) phenyl trifluoromethanesulfonate
- tetrahydrofuran 13.6 mL
- Trifluoromethyl trimethylsilane
- tetrabutylammonium fluoride 1M tetrahydrofuran solution, 40 ⁇ L
- the reaction mixture was stirred at room temperature for 14 hours, (trifluoromethyl) trimethylsilane (2.9 g) was added, and the mixture was stirred at room temperature for 6 hours.
- Example 39 2-Methyl-2-propanyl [3-fluoro-4- (1,1,1-trifluoro-2-hydroxy-2-propanyl) phenyl] carbamate 1,4- (1) To a solution of 4-dioxane (22.4 mL), tert-butyl carbamate (735 mg), palladium (II) acetate (93 mg), 4,5-bis (diphenylphosphino) -9,9-dimethylxanthene (363 mg), cesium carbonate (2.04 g) was added, followed by stirring at 110 ° C. for 1.5 hours under an argon atmosphere. Insoluble matters in the reaction mixture were filtered off, and the filtrate was concentrated.
- Example 40 2- (4-Amino-2-fluorophenyl) -1,1,1-trifluoro-2-propanol
- dichloromethane 22 mL
- Fluoroacetic acid 5 mL
- Example 41 2- (4-Amino-3,5-dichloro-2-fluorophenyl) -1,1,1-trifluoro-2-propanol
- N, N-dimethylformamide (5 mL) N-chlorosuccinimide (347 mg) was added to the solution and stirred at 80 ° C. for 17 hours.
- Example 42 2,6-Dichloro-3-fluoro-4- ⁇ 1,1,1-trifluoro-2-[(trimethylsilyl) oxy] -2-propanyl ⁇ aniline
- Chlorotrimethylsilane (419 ⁇ L) and imidazole (291 mg) were added to the solution and stirred at 55 ° C. for 3 hours.
- a saturated aqueous ammonium chloride solution was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate and concentrated under reduced pressure.
- Example 43 1- [2,6-dichloro-3-fluoro-4- (1,1,1-trifluoro-2-hydroxy-2-propanyl) phenyl] -3- ⁇ [5- (trifluoromethyl) -2- Pyridinyl] methyl ⁇ urea
- Example 43 (1) to (3) The compound prepared in Example 42 was used in place of the compound prepared in Example 4, and the corresponding amine was used in place of 1- [5- (trifluoromethyl) -2-pyridinyl] methanamine hydrochloride.
- the title compound having the following physical data was obtained by the same procedure as in 5.
- Example 43 (1) 1- [2,6-dichloro-3-fluoro-4- (1,1,1-trifluoro-2-hydroxy-2-propanyl) phenyl] -3- ⁇ [5- (trifluoromethyl) -2- Pyrimidinyl] methyl ⁇ urea
- Example 44 4-acetyl-2-fluorophenyltrifluoromethanesulfonate 1- (3-Fluoro-4-hydroxyphenyl) ethanone (1.0 g) (CAS registration number: 403-14-5) in dichloromethane (20 mL) was added to ice. Under cooling, triethylamine (995 ⁇ L) and trifluoromethanesulfonic anhydride (1.2 mL) were added, and the mixture was stirred at room temperature for 1 hour. A saturated aqueous sodium hydrogen carbonate solution was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate and concentrated under reduced pressure.
- Example 45 2-Fluoro-4- (1,1,1-trifluoro-2-hydroxy-2-propanyl) phenyltrifluoromethanesulfonate
- Compound (1.8 g) prepared in Example 44 and (trifluoromethyl) trimethylsilane ( 2.8 mL) in tetrahydrofuran (54 mL) was added tetrabutylammonium fluoride (1M tetrahydrofuran solution, 310 ⁇ L) in an ice bath and stirred at room temperature for 2 hours.
- Tetrabutylammonium fluoride (1M tetrahydrofuran solution, 7.5 mL) was added to the reaction mixture under ice cooling, and the mixture was stirred for 10 minutes.
- Example 46 2-Methyl-2-propanyl [2-fluoro-4- (1,1,1-trifluoro-2-hydroxy-2-propanyl) phenyl] carbamate
- the compound prepared in Example 45 (855 mg) of 1,4- To a dioxane (12 mL) solution, tert-butyl carbamate (421 mg), palladium (II) acetate (54 mg), 4,5-bis (diphenylphosphino) -9,9-dimethylxanthene (208 mg), cesium carbonate (1. 17 g) was added, and the mixture was reacted at 110 ° C. for 1 hour under microwave irradiation (manufactured by Biotage, Initiator 60).
- Example 47 2- (4-Amino-3-fluorophenyl) -1,1,1-trifluoro-2-propanol
- dichloromethane 4 mL
- Toluene (2 mL) was added to the reaction mixture, and the mixture was concentrated under reduced pressure.
- Example 48 2-Chloro-6-fluoro-4- ⁇ 1,1,1-trifluoro-2-[(trimethylsilyl) oxy] -2-propanyl ⁇ aniline
- N, N-dimethyl N-chlorosuccinimide 32 mg was added to a formamide (2 mL) solution, and the mixture was stirred at room temperature for 18 hours.
- Water was added to the reaction mixture, and the mixture was extracted with a mixed solvent of ethyl acetate and hexane. The organic layer was dried over anhydrous magnesium sulfate and concentrated under reduced pressure.
- Example 49 1- [2-Chloro-6-fluoro-4- (1,1,1-trifluoro-2-hydroxy-2-propanyl) phenyl] -3- ⁇ [5- (trifluoromethyl) -2-pyridinyl] Methyl ⁇ urea
- Example 50 2-Cyclohexyl-N- [2,6-dichloro-4- (1,1,1-trifluoro-2-hydroxy-2-propanyl) phenyl] acetamide Cyclohexylacetyl chloride (27 mg) was added to a toluene (2 mL) solution of the compound prepared in Example 4 (50 mg), and the mixture was stirred at 100 ° C. for 1 hour under microwave irradiation (Biotage, Initiator 60). Tetrabutylammonium fluoride (1M tetrahydrofuran solution, 288 ⁇ L) was added to the reaction mixture, and the mixture was stirred at room temperature for 20 hours.
- Example 50 (1) to (7) The title compound having the following physical data was obtained by conducting the same operation as in Example 50 using the corresponding acid chloride instead of cyclohexylacetyl chloride.
- Example 50 N- [2,6-dichloro-4- (1,1,1-trifluoro-2-hydroxy-2-propanyl) phenyl] -3- (4-fluorophenyl) propanamide LC retention time (min), LC condition 1: 0.97; 1 H-NMR (DMSO-d 6 ) ⁇ 1.70, 2.62-2.67, 2.89-2.94, 6.96, 7.07-7.12, 7.27-7.32, 7.66, 9.87.
- Example 50 N- [2,6-dichloro-4- (1,1,1-trifluoro-2-hydroxy-2-propanyl) phenyl] -3- [3- (trifluoromethyl) phenyl] propanamide LC retention time (min), LC condition 2: 1.03; 1 H-NMR (DMSO-d 6 ): ⁇ 1.69, 2.72, 3.02, 6.94, 7.50-7.65, 9.87.
- Example 50 N- [2,6-dichloro-4- (1,1,1-trifluoro-2-hydroxy-2-propanyl) phenyl] -3- [2- (trifluoromethyl) phenyl] propanamide LC retention time (min), LC condition 2: 1.03; 1 H-NMR (DMSO-d 6 ): ⁇ 1.70, 2.67-2.71, 3.06-3.11, 6.95, 7.42, 7.54-7.70, 9.94.
- Example 51 2- (4-Bromo-3-methylphenyl) -1,1,1-trifluoro-2-propanol 1- (4-Bromo-3-methylphenyl) ethanone (4.0 g) (CAS registration number: 37074-) To a solution of 40-1) in tetrahydrofuran (40 mL), (trifluoromethyl) trimethylsilane (8.3 mL) and tetrabutylammonium fluoride (1M tetrahydrofuran solution, 0.9 mL) were added under ice-cooling. Stir.
- Example 52 2-Methyl-2-propanyl [2-methyl-4- (1,1,1-trifluoro-2-hydroxy-2-propanyl) phenyl] carbamate 1 of the compound prepared in Example 51 (4.5 g) To a solution of 4-dioxane (80 mL), 4,5-bis (diphenylphosphino) -9,9-dimethylxanthene (1.4 g), palladium (II) acetate (360 mg), tert-butyl carbamate (2.4 g) Then, cesium carbonate (7.8 g) was added, and the mixture was heated to reflux for 1.5 hours.
- Example 53 2- (4-Amino-3-methylphenyl) -1,1,1-trifluoro-2-propanol
- Fluoroacetic acid (12 mL) was added, and the mixture was stirred at room temperature for 1 hour.
- Toluene was added to the reaction mixture, and the mixture was concentrated under reduced pressure.
- a saturated aqueous sodium hydrogen carbonate solution was added to the obtained residue, and the mixture was extracted with ethyl acetate.
- the organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure to give the title compound (743 mg) having the following physical data.
- Example 55 2-Chloro-6-methyl-4- ⁇ 1,1,1-trifluoro-2-[(trimethylsilyl) oxy] -2-propanyl ⁇ aniline
- N-chlorosuccinimide (439 mg) was added to a formamide (8 mL) solution, and the mixture was stirred at room temperature for 6 hours.
- a saturated aqueous sodium hydrogen carbonate solution was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure.
- Example 56 [2-Chloro-6-methyl-4- (1,1,1-trifluoro-2-hydroxy-2-propanyl) phenyl] -3- ⁇ [5- (trifluoromethyl) -2-pyrimidinyl] Methyl ⁇ urea
- Triphosgene (20 mg) and diisopropylethylamine (11 ⁇ L) were added to a solution of the compound prepared in Example 55 (20 mg) in tetrahydrofuran (0.4 mL), and the mixture was stirred at room temperature for 1 hour.
- reaction mixture was concentrated under reduced pressure, and the resulting residue was dissolved in tetrahydrofuran (0.4 mL), and 1- [5- (trifluoromethyl) -2-pyridinyl] methanamine hydrochloride (19 mg) and diisopropylethylamine (53 ⁇ L) were added. The mixture was further stirred at 45 ° C. for 17 hours. Tetrabutylammonium fluoride (1M tetrahydrofuran solution, 73 ⁇ L) was added to the reaction mixture, and the mixture was stirred at room temperature for 1 hour. A saturated aqueous ammonium chloride solution was added to the reaction mixture, and the mixture was extracted with ethyl acetate.
- Example 56 (1) to (3) The title compound having the following physical data was obtained by conducting the same operation as that of Example 56 using the corresponding amine instead of 1- [5- (trifluoromethyl) -2-pyridinyl] methanamine hydrochloride. .
- Example 56 1- [2-Chloro-6-methyl-4- (1,1,1-trifluoro-2-hydroxy-2-propanyl) phenyl] -3- ⁇ [6- (trifluoromethyl) -3-pyridinyl] Methyl ⁇ urea
- Example 57 2,2,2-trifluoro-1- (3-methyl-4-nitrophenyl) ethanol 3-methyl-4-nitrobenzaldehyde (2.5 g) (CAS registration number: 18515-67-8) in tetrahydrofuran (40 mL) ) (Trifluoromethyl) trimethylsilane (6.7 mL) and tetrabutylammonium fluoride (1M tetrahydrofuran solution, 0.76 mL) were added to the solution under ice-cooling, and the mixture was stirred at room temperature for 30 minutes. Tetrabutylammonium fluoride (1M tetrahydrofuran solution, 18 mL) was added under ice cooling, and the mixture was stirred at room temperature for 30 minutes.
- Example 59 4- (1- ⁇ [Dimethyl (2-methyl-2-propanyl) silyl] oxy ⁇ -2,2,2-trifluoroethyl) -2-methylaniline of the compound prepared in Example 58 (1.50 g) Imidazole (2.50 g) and chloro (dimethyl) (2-methyl-2-propanyl) silane (4.94 g) were added to a N, N-dimethylformamide (30 mL) solution, and the mixture was stirred at room temperature for 2.5 hours. And stirred at 50 ° C. for 1 hour. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate.
- Example 60 [2-Methyl-4- (2,2,2-trifluoro-1-hydroxyethyl) phenyl] -3- ⁇ [5- (trifluoromethyl) -2-pyridinyl] methyl ⁇ urea
- Triphosgene (31 mg) and diisopropylethylamine (17 ⁇ L) were added to a solution of the compound prepared in Example 59 (30 mg) in tetrahydrofuran (0.6 mL), and the mixture was stirred at room temperature for 1 hour.
- reaction mixture was concentrated under reduced pressure, and the resulting residue was dissolved in tetrahydrofuran (0.6 mL), and 1- [5- (trifluoromethyl) -2-pyridinyl] methanamine hydrochloride (30 mg) and diisopropylethylamine (81 ⁇ L) were added. The mixture was further stirred at room temperature for 1 hour. Tetrabutylammonium fluoride (1M tetrahydrofuran solution, 112 ⁇ L) was added to the reaction mixture. The reaction mixture was stirred at room temperature for 1 hour, tetrabutylammonium fluoride (1M tetrahydrofuran solution, 940 ⁇ L) was added, and the mixture was stirred at room temperature for 30 minutes.
- Example 61 2-chloro-4- (1- ⁇ [dimethyl (2-methyl-2-propanyl) silyl] oxy ⁇ -2,2,2-trifluoroethyl) -6-methylaniline Compound prepared in Example 59 (470 mg ) In acetonitrile (20 mL) was added 1,3-dichloro-5,5-dimethylhydantoin (290 mg), and the mixture was stirred at room temperature for 40 minutes. A saturated aqueous ammonium chloride solution was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure.
- Example 62 1- [2-Chloro-6-methyl-4- (2,2,2-trifluoro-1-hydroxyethyl) phenyl] -3- ⁇ [5- (trifluoromethyl) -2-pyridinyl] methyl ⁇ urea
- Example 62 (1) to (3) The compound prepared in Example 61 was used in place of the compound prepared in Example 59, and the corresponding amine was used in place of 1- [5- (trifluoromethyl) -2-pyridinyl] methanamine hydrochloride. By performing the same operations as in Example 60, the title compound having the following physical property values was obtained.
- Example 62 (1) 1- [2-Chloro-6-methyl-4- (2,2,2-trifluoro-1-hydroxyethyl) phenyl] -3- ⁇ [5- (trifluoromethyl) -2-pyrimidinyl] methyl ⁇ urea
- Example 62 (2) 1- [2-Chloro-6-methyl-4- (2,2,2-trifluoro-1-hydroxyethyl) phenyl] -3- ⁇ [6- (trifluoromethyl) -3-pyridinyl] methyl ⁇ urea
- Example 63 2- [4- (Dibenzylamino) phenyl] -4,4,4-trifluoro-2-butanol N, N-dibenzyl-4-bromoaniline (300 mg) (CAS Registry Number: 65145-14-4) N-Butyllithium (1.64 M hexane solution, 0.78 mL) was added dropwise to a tetrahydrofuran (4 mL) solution at ⁇ 78 ° C. The reaction mixture was stirred at ⁇ 78 ° C. for 10 minutes, 4,4,4-trifluoro-2-butanone (214 mg) was added, and the mixture was stirred at room temperature for 1 hour.
- Example 64 2- (4-aminophenyl) -4,4,4-trifluoro-2-butanol
- the compound prepared in Example 63 (100 mg) in a mixed solvent of methanol (2 mL) and ethyl acetate (2 mL) was mixed with 5% palladium / Carbon (50% water-containing product, 10 mg) was added.
- the reaction mixture was stirred for 2 hours at room temperature under hydrogen atmosphere.
- the reaction mixture was filtered through Celite (trade name), and the filtrate was concentrated to give the title compound.
- Example 65 4- ⁇ 4,4,4-trifluoro-2-[(trimethylsilyl) oxy] -2-butanyl ⁇ aniline
- chlorotrimethylsilane 120 ⁇ L
- imidazole 83 mg
- a saturated aqueous ammonium chloride solution was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate and concentrated under reduced pressure.
- Example 66 2,6-dichloro-4- ⁇ 4,4,4-trifluoro-2-[(trimethylsilyl) oxy] -2-butanyl ⁇ aniline N, N-dimethylformamide (31 mg) of the compound prepared in Example 65 ( 2 mL) solution was added N-chlorosuccinimide (31 mg) and stirred at 40 ° C. for 20 hours. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate and concentrated under reduced pressure.
- Example 67 1- [2,6-dichloro-4- (4,4,4-trifluoro-2-hydroxy-2-butanyl) phenyl] -3- ⁇ [5- (trifluoromethyl) -2-pyridinyl] methyl ⁇
- Urea N, N-diisopropylethylamine (11 ⁇ L) and triphosgene (19 mg) were added to a solution of the compound prepared in Example 66 (21 mg) in dichloromethane (2 mL), and the mixture was stirred at 40 ° C. for 1 hour.
- Example 68 1-nitro-4- (1,1,1-trifluoro-2-methoxy-2-propanyl) benzene
- Methyl iodide (987 mg) was added to the reaction mixture under ice cooling, and the mixture was stirred at room temperature for 1 hr.
- a saturated aqueous ammonium chloride solution and water were added to the reaction mixture under ice cooling, and the mixture was extracted with ethyl acetate.
- Example 70 2,6-Dichloro-4- (1,1,1-trifluoro-2-methoxy-2-propanyl) aniline
- acetonitrile 25 mL
- 1,3-dichloro-5,5-dimethylhydantoin (1.21 g) was added, and the mixture was stirred at room temperature for 1 hour and then at 45 ° C. for 3 hours.
- a sodium sulfite aqueous solution was added to the reaction mixture under ice cooling.
- the reaction mixture was stirred at room temperature for 30 minutes and extracted with ethyl acetate.
- Example 71 1- [2,6-dichloro-4- (1,1,1-trifluoro-2-methoxy-2-propanyl) phenyl] -3- ⁇ [5- (trifluoromethyl) -2-pyridinyl] methyl ⁇ Urea
- diisopropylethylamine (20 ⁇ L) and triphosgene (34 mg) were added to a solution of the compound prepared in Example 70 (30 mg) in tetrahydrofuran (1 mL) and triphosgene (34 mg), and the mixture was stirred at room temperature for 30 minutes and then concentrated under reduced pressure.
- Example 72 ⁇ [1,1-Difluoro-2- (4-nitrophenyl) -2-propanyl] oxy ⁇ (trimethyl) silane 1- (4-nitrophenyl) ethanone (CAS registration number: 100-19-6) (1. 00 g) in N, N-dimethylformamide (15 mL), cesium fluoride (183 mg) was added, and (difluoromethyl) (trimethyl) silane (CAS registration number: 65864-64-4) (2 .26 g) was added. The reaction mixture was stirred under ice-cooling for 1 hour, then stirred at room temperature for 2 hours and then stirred at 45 ° C. for 2 hours.
- Example 73 4- ⁇ 1,1-difluoro-2-[(trimethylsilyl) oxy] -2-propanyl ⁇ aniline
- methanol 4.1 mL
- 5% palladium / carbon NE (Chemcat, water-containing product, KER type) (20 mg
- the reaction mixture was filtered through Celite (trade name), and the filtrate was concentrated under reduced pressure to give the title compound (203 mg) having the following physical data.
- Example 74 2,6-Dichloro-4- ⁇ 1,1-difluoro-2-[(trimethylsilyl) oxy] -2-propanyl ⁇ aniline N, N-dimethylformamide (5. 5) of the compound obtained in Example 73 (203 mg) 2 mL) solution was added N-chlorosuccinimide (209 mg), stirred at 35 ° C. for 1 hour, and then stirred at 45 ° C. overnight. The reaction mixture was diluted with a mixed solvent of ethyl acetate and hexane, washed successively with water and saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure.
- Example 75 1- [2,6-dichloro-4- (1,1-difluoro-2-hydroxy-2-propanyl) phenyl] -3- ⁇ [5- (trifluoromethyl) -2-pyridinyl] methyl ⁇ urea
- Example 76 1- (4-amino-3,5-dichlorophenyl) -2,2,2-trifluoroethanone 1- (4-aminophenyl) -2,2,2-trifluoroethanone (CAS registration number: 23516-79- 2) To a solution of (2.60 g) in N, N-dimethylformamide (30 mL) was added N-chlorosuccinimide (3.70 g), and the mixture was stirred at 40 ° C. for 18 hours. A saturated aqueous sodium hydrogen carbonate solution was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure.
- Example 77 4-Amino-3,5-dichlorophenyl) -2,2,2-trifluoroethanol To a solution of the compound prepared in Example 76 (1.00 g) in methanol (10 mL) was added borohydride under ice-cooling. Sodium (146 mg) was added and stirred at room temperature for 1 hour. A saturated aqueous ammonium chloride solution was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure to give the title compound (975 mg) having the following physical data. 1 H-NMR (CDCl 3 ): ⁇ 4.58, 4.83-4.91, 7.31.
- Example 78 4- (1-azido-2,2,2-trifluoroethyl) -2,6-dichloroaniline To a solution of the compound prepared in Example 77 (314 mg) in toluene (10 mL) was added 2,3,4,6, 7,8,9,10-Octahydropyrimido [1,2-a] azepine (CAS registry number: 41015-70-7) (0.22 mL) and diphenylphosphoradidate (CAS registry number 26386-88-9) ) (0.33 mL) was added and stirred at 45 ° C. for 3 hours. A saturated aqueous sodium hydrogen carbonate solution was added to the reaction mixture, and the mixture was extracted with ethyl acetate.
- Example 79 1- [4- (1-Amino-2,2,2-trifluoroethyl) -2,6-dichlorophenyl] -3- ⁇ [6- (trifluoromethyl) -3-pyridinyl] methyl ⁇ urea
- Triphosgene (355 mg) and N, N-diisopropylethylamine (207 ⁇ L) were added to a solution of the compound prepared in Example 78 (310 mg) in tetrahydrofuran (5 mL), and the mixture was stirred at room temperature for 1 hour and concentrated under reduced pressure.
- Example 79 (1) to (4) Using the amine prepared in Example 10 or a corresponding amine instead of 1- [6- (trifluoromethyl) -3-pyridinyl] methanamine, the same physical properties as in Example 79 were performed, and the following physical property values were obtained. The product of the invention shown was obtained.
- Example 79 (1) 1- [4- (1-Amino-2,2,2-trifluoroethyl) -2,6-dichlorophenyl] -3- ⁇ [5- (trifluoromethyl) -2-pyridinyl] methyl ⁇ urea
- Example 79 (2) 1- [4- (1-Amino-2,2,2-trifluoroethyl) -2,6-dichlorophenyl] -3-[(5-chloro-2-pyridinyl) methyl] urea LC retention time (min), LC condition 3: 0.66; 1 H-NMR (DMSO-d 6 ): ⁇ 4.38, 5.42-5.50, 7.14, 7.39, 7.75, 7.94, 8.54-8.56.
- Example 79 (3) 1- [4- (1-Amino-2,2,2-trifluoroethyl) -2,6-dichlorophenyl] -3- (4-fluorobenzyl) urea LC retention time (min), LC condition 3: 0.74; 1 H-NMR (DMSO-d 6 ): ⁇ 4.26, 5.30-5.40, 6.98, 7.12-7.18, 7.30-7.35, 7.73, 8.29.
- Example 79 (4) 1- [4- (1-Amino-2,2,2-trifluoroethyl) -2,6-dichlorophenyl] -3- ⁇ [2- (trifluoromethyl) -1,3-thiazol-5-yl] Methyl ⁇ urea LC retention time (min), LC condition 3: 0.74; 1 H-NMR (DMSO-d 6 ): ⁇ 4.54, 5.28-5.40, 7.28, 7.74, 7.97, 8.55.
- Biological Example 1 Opening action on KCNQ2 / 3 channel by depolarization stimulation
- Human KCNQ2 / 3-expressing cells (CHO-DHFR-cells) 1 hole in 384-well plate (collagen coat, black, clear bottom) 0.5 ⁇ 10 4 cells / 50 ⁇ L per seed, and MEM ALPHA medium (containing 10 vol% inactivated (56 ° C., 30 min) Fetal Bovine Serum and 100 IU / mL Penicillin-100 ⁇ g / mL Streptomycin-2 mM L-Glutamine) Incubated at 37 ° C. under 5% CO 2 for 18-24 hours.
- the KCNQ2 / 3 channel opening action (intracellular thallium influx) by depolarization stimulation (5 mM potassium and 0.5 mM thallium) was measured with FLIPR TETRA (Molecular Devices).
- the compound of the present invention was treated 5 minutes before the depolarization stimulus, and the reaction induced by the depolarization stimulus was measured over time for 180 seconds.
- the channel opening action of the compound of the present invention is evaluated by the amount of change in fluorescence intensity from before depolarization stimulation to 180 seconds later, and satisfies 50% of the change in fluorescence intensity of the maximum reaction of retigabine (at the time of 10 ⁇ M treatment) under the experimental conditions. Concentration (ECrtg50) was calculated.
- the KCNQ2 / 3 channel opening action of the compound of the present invention was 100 ⁇ M or less in terms of ECrtg50 value.
- Table 1 shows the opening action (ECrtg50 value) of the following compounds on KCNQ2 / 3 channels as representative examples of the compounds of the present invention.
- the compound of the present invention exhibited a strong opening action on the KCNQ2 / 3 channel.
- the ECrtg50 value of Comparative Compound 1 was> 10 ⁇ M. From this, it was found that it is essential to improve the KCNQ opening activity of the compound of the present invention that at least one of R 4 and R 5 in the general formula (I) is a substituent such as halogen.
- human KCNQ4 or human KCNQ5 expressing cells are used instead of human KCNQ2 / 3 expressing cells, and the above conditions are appropriately changed based on the general knowledge of those skilled in the art, so that the human KCNQ4 channel or The opening effect on the human KCNQ5 channel can be measured.
- Specimens were prepared on ice so that the body part of the rat-extracted bladder became a vertically long strip (about 10 ⁇ 3 mm). Immediately after that, a 500 mg tension load was applied to a Magnus tube filled with Krebs buffer (37 ° C.) which was aerated with a mixed gas, and suspended. The specimen was prepared within 24 hours after the tissue was removed.
- the tension change of the specimen is transmitted through a Magnus system equipped with an isometric transducer (UFER UM-203, Iwashiya Kishimoto Medical Industry Co., Ltd.) and an amplifier (UFER AP-5, Iwashiya Kishimoto Medical Industry Co., Ltd.).
- the data was recorded on a data collection system (NR-1000, KEYENCE CORPORATION) and displayed on a computer by recorder analysis software WAVE THERMO 1000 (KEYENCE CORPORATION). After suspending the specimen for 1 hour or longer, 2.5 M KCl was added to a final concentration of 100 mM, and a specimen in which contraction reaction was confirmed was used.
- Carbachol (contraction-inducing substance) contraction was induced at a concentration of 1 ⁇ M.
- Each group was arbitrarily assigned so that there was no difference in the degree of contraction between the groups and samples collected from the same individual were not in the same group.
- physiological saline or the compound of the present invention was cumulatively added from a low concentration to final concentrations of 1, 10, 100 nM, 1 and 10 ⁇ M.
- the tension (mg) in the isolated bladder was used as an evaluation item.
- the tension was read using analysis software WAVE THERMO 1000.
- the tension change rate after addition of the compound of the present invention when the tension after addition of the shrinkage-inducing substance was 0% was defined as the tension change rate (%), which was used as an evaluation index.
- the tension change rate (%) is calculated from the following formula.
- Rate of change in tension ⁇ Tension after addition of compound of the present invention (mg) ⁇ Tension before addition of contraction-inducing substance (mg) ⁇ / ⁇ Tension after addition of contraction-inducing substance (mg) ⁇ Before addition of contraction-inducing substance Tension (mg) ⁇ ⁇ 100-100
- a value at which the rate of change in tension (%) was ⁇ 20% was calculated as IC 20 and used as an index of the effect of relaxing the isolated bladder.
- Table 2 shows IC 20 values in the rat Magnus test of the following compounds as representative examples of the compounds of the present invention.
- the compound of the present invention had a relaxing action on the isolated rat bladder. Therefore, the compound of the present invention is useful as a therapeutic agent for overactive bladder.
- Solubility test A calibration curve solution was prepared by diluting a test substance (10 mM DMSO solution) with acetonitrile and adding acetonitrile containing an internal standard substance (candesartan) to 0.1, 0.4 and 2 ⁇ M.
- the compound of the present invention 10 mM DMSO solution
- pH Japanese Pharmacopoeia Dissolution Test Second Solution
- a calibration curve and 5 ⁇ L of the sample solution were injected into LC-MS / MS (Discovery Max manufactured by Thermo Scientific) and quantified (quantification range: 5 to 100 ⁇ M).
- the solubility when the value below the quantitative range was obtained was ⁇ 5 ⁇ M, and the solubility when the value above the quantitative range was obtained was 100 ⁇ M.
- test compound (10 mmol / L DMSO solution, 5 ⁇ L) was diluted with 50% aqueous acetonitrile (195 ⁇ L) to prepare a 0.25 mmol / L solution.
- Formulation Example 1 The following components were mixed by a conventional method and then tableted to obtain 10,000 tablets each containing 10 mg of the active ingredient.
- Formulation Example 2 The following components were mixed by a conventional method, filtered through a dust removal filter, filled in 5 ml aliquots, and sterilized by heating in an autoclave to obtain 10,000 ampoules containing 20 mg of active ingredient per ampoule.
- 1- ⁇ 2,6-dichloro-4-[(2R) -1,1,1-trifluoro-2-hydroxy-2-propanyl] phenyl ⁇ -3- ⁇ [5- (trifluoromethyl) -2 -Pyridinyl] methyl ⁇ urea (200 g); ⁇ Mannitol (2 kg); -Distilled water (50 L).
- the toxicity of the compound of the present invention is sufficiently low, can be safely used as a pharmaceutical, and is useful as a therapeutic agent for KCNQ 2-5 channel-related diseases.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyridine Compounds (AREA)
- Indole Compounds (AREA)
- Furan Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Pyrane Compounds (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
(1) 一般式(I)
(2) Yが-NH-または結合手である、前記(1)に記載の化合物、その塩、その溶媒和物またはその共結晶、
(3) X1がC-R6であり、X2がC-R7である、前記(1)または前記(2)に記載の化合物、その塩、その溶媒和物またはその共結晶、
(4) 一般式(II)
(5) R1が水素原子である、前記(1)~(4)いずれか1つに記載の化合物、その塩、その溶媒和物またはその共結晶、
(6) R2およびR3の一方がハロゲンで置換されていてもよいメチル基であり、他方が水素原子またはハロゲンで置換されていてもよいメチル基である、前記(1)~(5)いずれか1つに記載の化合物、その塩、その溶媒和物またはその共結晶、
(7) R6が水素原子またはハロゲンであり、R7が水素原子である、前記(1)~(6)いずれか1つに記載の化合物、その塩、その溶媒和物またはその共結晶、
(8) 一般式(II-1)
(9) 一般式(II-2)
(10) R4およびR5がそれぞれ独立してハロゲンまたはメチル基である、前記(1)~(9)いずれか1つに記載の化合物、その塩、その溶媒和物またはその共結晶、
(11) R8が水素原子またはメチル基である、前記(1)~(10)いずれか1つに記載の化合物、その塩、その溶媒和物またはその共結晶、
(12) 化合物が、(1)1-{2,6-ジクロロ-4-[(2R)-1,1,1-トリフルオロ-2-ヒドロキシ-2-プロパニル]フェニル}-3-{[5-(トリフルオロメチル)-2-ピリジニル]メチル}ウレア、
(2)1-{2,6-ジクロロ-4-[(2R)-1,1,1-トリフルオロ-2-ヒドロキシ-2-プロパニル]フェニル}-3-{[5-(トリフルオロメチル)-2-ピリミジニル]メチル}ウレア、
(3)1-{2,6-ジクロロ-4-[(2R)-1,1,1-トリフルオロ-2-ヒドロキシ-2-プロパニル]フェニル}-3-{[6-(トリフルオロメチル)-3-ピリジニル]メチル}ウレア、
(4)1-[(5-クロロ-2-ピリジニル)メチル]-3-{2,6-ジクロロ-4-[(2R)-1,1,1-トリフルオロ-2-ヒドロキシ-2-プロパニル]フェニル}ウレア、
(5)1-{2,6-ジクロロ-4-[(2R)-1,1,1-トリフルオロ-2-ヒドロキシ-2-プロパニル]フェニル}-3-{[3-(トリフルオロメチル)-1,2,4-オキサジアゾール-5-イル]メチル}ウレア、
(6)1-{2,6-ジクロロ-4-[(2S)-1,1,1-トリフルオロ-2-ヒドロキシ-2-プロパニル]フェニル}-3-{[5-(トリフルオロメチル)-2-ピリミジニル]メチル}ウレア、
(7)1-{2,6-ジクロロ-4-[(2S)-1,1,1-トリフルオロ-2-ヒドロキシ-2-プロパニル]フェニル}-3-{[6-(トリフルオロメチル)-3-ピリジニル]メチル}ウレア、
(8)1-[(5-クロロ-2-ピリジニル)メチル]-3-{2,6-ジクロロ-4-[(2S)-1,1,1-トリフルオロ-2-ヒドロキシ-2-プロパニル]フェニル}ウレア、
(9)1-{2,6-ジクロロ-4-[(2S)-1,1,1-トリフルオロ-2-ヒドロキシ-2-プロパニル]フェニル}-3-{[3-(トリフルオロメチル)-1,2,4-オキサジアゾール-5-イル]メチル}ウレア、
(10)1-{2,6-ジクロロ-4-[(1R)-2,2,2-トリフルオロ-1-ヒドロキシエチル]フェニル}-3-{[3-(トリフルオロメチル)-1,2,4-オキサジアゾール-5-イル]メチル}ウレア、
(11)1-{2,6-ジクロロ-4-[(1R)-2,2,2-トリフルオロ-1-ヒドロキシエチル]フェニル}-3-{[2-(トリフルオロメチル)-5-ピリミジニル]メチル}ウレア、
(12)1-{2,6-ジクロロ-4-[(1R)-2,2,2-トリフルオロ-1-ヒドロキシエチル]フェニル}-3-{[5-(トリフルオロメチル)-2-ピリミジニル]メチル}ウレア、
(13)1-{2,6-ジクロロ-4-[(1R)-2,2,2-トリフルオロ-1-ヒドロキシエチル]フェニル}-3-{[2-(トリフルオロメチル)-1,3-チアゾール-5-イル]メチル}ウレア、
(14)1-{2,6-ジクロロ-4-[(1S)-2,2,2-トリフルオロ-1-ヒドロキシエチル]フェニル}-3-{[3-(トリフルオロメチル)-1,2,4-オキサジアゾール-5-イル]メチル}ウレア、
(15)1-{2,6-ジクロロ-4-[(1S)-2,2,2-トリフルオロ-1-ヒドロキシエチル]フェニル}-3-{[2-(トリフルオロメチル)-5-ピリミジニル]メチル}ウレア、
(16)1-{2,6-ジクロロ-4-[(1S)-2,2,2-トリフルオロ-1-ヒドロキシエチル]フェニル}-3-{[2-(トリフルオロメチル)-1,3-チアゾール-5-イル]メチル}ウレア、
(17)1-{2,6-ジクロロ-4-[(2S)-1,1,1-トリフルオロ-2-ヒドロキシ-2-プロパニル]フェニル}-3-{[5-(トリフルオロメチル)-2-ピリジニル]メチル}ウレア、または
(18)1-{2,6-ジクロロ-4-[(1S)-2,2,2-トリフルオロ-1-ヒドロキシエチル]フェニル}-3-{[5-(トリフルオロメチル)-2-ピリミジニル]メチル}ウレアである前記(1)記載の化合物、その塩、その溶媒和物またはその共結晶、
(13) 一般式(I)で示される化合物、その塩、その溶媒和物またはその共結晶と薬学的に許容される担体とを含有してなる医薬組成物、
(14) KCNQ2~5チャネル関連疾患の予防および/または治療剤である、前記(13)記載の医薬組成物、
(15) KCNQ2~5チャネル関連疾患が排尿障害である、前記(14)記載の医薬組成物、
(16) 排尿障害が過活動膀胱である、前記(15)記載の医薬組成物、
(17) 一般式(I)で示される化合物、その塩、その溶媒和物またはその共結晶の有効量を哺乳動物に投与することを特徴とするKCNQ2~5チャネル関連疾患の予防および/または治療方法、
(18) KCNQ2~5チャネル関連疾患の予防および/または治療のための一般式(I)で示される化合物、その塩、その溶媒和物またはその共結晶、
(19) KCNQ2~5チャネル関連疾患の予防および/または治療剤の製造のための一般式(I)で示される化合物、その塩、その溶媒和物またはその共結晶の使用、
(21) 一般式(I-1)
(22) Yが、-NH-、-CH2-または結合手である前記(21)に記載の化合物、その塩、その溶媒和物またはその共結晶、
(23) 一般式(II)
(24) R1が水素原子である、前記(21)~(23)いずれか1つに記載の化合物、その塩、その溶媒和物またはその共結晶、
(25) R2およびR3の一方がハロゲンで置換されていてもよいメチル基であり、他方が水素原子またはハロゲンで置換されていてもよいメチル基である、前記(21)~(24)いずれか1つに記載の化合物、その塩、その溶媒和物またはその共結晶、
(26) R7が水素原子である前記(21)~(25)いずれか1つに記載の化合物、その塩、その溶媒和物またはその共結晶、
(27) 一般式(II-1)
(28) 一般式(II-2)
(29) R4およびR5が、それぞれ独立してハロゲンまたはメチル基である前記(21)~(28)いずれか1つに記載の化合物、その塩、その溶媒和物またはその共結晶、
(30) R8が、水素原子またはメチル基である前記(21)~(29)いずれか1つに記載の化合物、その塩、その溶媒和物またはその共結晶等に関する。
(1)1-{2,6-ジクロロ-4-[(2R)-1,1,1-トリフルオロ-2-ヒドロキシ-2-プロパニル]フェニル}-3-{[5-(トリフルオロメチル)-2-ピリジニル]メチル}ウレア、
(2)1-{2,6-ジクロロ-4-[(2R)-1,1,1-トリフルオロ-2-ヒドロキシ-2-プロパニル]フェニル}-3-{[5-(トリフルオロメチル)-2-ピリミジニル]メチル}ウレア、
(3)1-{2,6-ジクロロ-4-[(2R)-1,1,1-トリフルオロ-2-ヒドロキシ-2-プロパニル]フェニル}-3-{[6-(トリフルオロメチル)-3-ピリジニル]メチル}ウレア、
(4)1-[(5-クロロ-2-ピリジニル)メチル]-3-{2,6-ジクロロ-4-[(2R)-1,1,1-トリフルオロ-2-ヒドロキシ-2-プロパニル]フェニル}ウレア、
(5)1-{2,6-ジクロロ-4-[(2R)-1,1,1-トリフルオロ-2-ヒドロキシ-2-プロパニル]フェニル}-3-{[3-(トリフルオロメチル)-1,2,4-オキサジアゾール-5-イル]メチル}ウレア、
(6)1-{2,6-ジクロロ-4-[(2S)-1,1,1-トリフルオロ-2-ヒドロキシ-2-プロパニル]フェニル}-3-{[5-(トリフルオロメチル)-2-ピリミジニル]メチル}ウレア、
(7)1-{2,6-ジクロロ-4-[(2S)-1,1,1-トリフルオロ-2-ヒドロキシ-2-プロパニル]フェニル}-3-{[6-(トリフルオロメチル)-3-ピリジニル]メチル}ウレア、
(8)1-[(5-クロロ-2-ピリジニル)メチル]-3-{2,6-ジクロロ-4-[(2S)-1,1,1-トリフルオロ-2-ヒドロキシ-2-プロパニル]フェニル}ウレア、
(9)1-{2,6-ジクロロ-4-[(2S)-1,1,1-トリフルオロ-2-ヒドロキシ-2-プロパニル]フェニル}-3-{[3-(トリフルオロメチル)-1,2,4-オキサジアゾール-5-イル]メチル}ウレア、
(10)1-{2,6-ジクロロ-4-[(1R)-2,2,2-トリフルオロ-1-ヒドロキシエチル]フェニル}-3-{[3-(トリフルオロメチル)-1,2,4-オキサジアゾール-5-イル]メチル}ウレア、
(11)1-{2,6-ジクロロ-4-[(1R)-2,2,2-トリフルオロ-1-ヒドロキシエチル]フェニル}-3-{[2-(トリフルオロメチル)-5-ピリミジニル]メチル}ウレア、
(12)1-{2,6-ジクロロ-4-[(1R)-2,2,2-トリフルオロ-1-ヒドロキシエチル]フェニル}-3-{[5-(トリフルオロメチル)-2-ピリミジニル]メチル}ウレア、
(13)1-{2,6-ジクロロ-4-[(1R)-2,2,2-トリフルオロ-1-ヒドロキシエチル]フェニル}-3-{[2-(トリフルオロメチル)-1,3-チアゾール-5-イル]メチル}ウレア、
(14)1-{2,6-ジクロロ-4-[(1S)-2,2,2-トリフルオロ-1-ヒドロキシエチル]フェニル}-3-{[3-(トリフルオロメチル)-1,2,4-オキサジアゾール-5-イル]メチル}ウレア、
(15)1-{2,6-ジクロロ-4-[(1S)-2,2,2-トリフルオロ-1-ヒドロキシエチル]フェニル}-3-{[2-(トリフルオロメチル)-5-ピリミジニル]メチル}ウレア、
(16)1-{2,6-ジクロロ-4-[(1S)-2,2,2-トリフルオロ-1-ヒドロキシエチル]フェニル}-3-{[2-(トリフルオロメチル)-1,3-チアゾール-5-イル]メチル}ウレア、
(17)1-{2,6-ジクロロ-4-[(2S)-1,1,1-トリフルオロ-2-ヒドロキシ-2-プロパニル]フェニル}-3-{[5-(トリフルオロメチル)-2-ピリジニル]メチル}ウレア、
(18)1-{2,6-ジクロロ-4-[(1S)-2,2,2-トリフルオロ-1-ヒドロキシエチル]フェニル}-3-{[5-(トリフルオロメチル)-2-ピリミジニル]メチル}ウレア、またはその立体異性体、もしくは、その塩、その溶媒和物またはその共結晶である。
一般式(I)で示される化合物は、公知の方法、例えば以下に示す方法、これらに準ずる方法、実施例に記載した方法、または「Comprehensive Organic Transformations:A Guide to Functional Group Preparations、第2版(Richard C.Larock著、John Wiley&Sons Inc、1999)」に記載された方法等を適宜改良し、組み合わせて用いることで製造することができる。なお、以下各製造方法において、各原料化合物は塩として用いてよい。このような塩としては、前述した一般式(I)の薬学的に許容される塩として記載されたもの等が用いられる。
(1)アルカリ加水分解による脱保護反応、
(2)酸性条件下における脱保護反応、
(3)加水素分解による脱保護反応、
(4)シリル基の脱保護反応、
(5)金属を用いる脱保護反応、
(6)金属錯体を用いる脱保護反応等が挙げられる。
(1)アルカリ加水分解による脱保護反応は、例えば、有機溶媒(メタノール、テトラヒドロフラン、ジオキサン等)中、アルカリ金属の水酸化物(水酸化ナトリウム、水酸化カリウム、水酸化リチウム等)、アルカリ土類金属の水酸化物(水酸化バリウム、水酸化カルシウム等)または炭酸塩(炭酸ナトリウム、炭酸カリウム等)あるいはその水溶液もしくはこれらの混合物を用いて、約0~40℃の温度で行なわれる。
(2)酸条件下での脱保護反応は、例えば、有機溶媒(ジクロロメタン、クロロホルム、ジオキサン、酢酸エチル、アニソール等)中、有機酸(酢酸、トリフルオロ酢酸、メタンスルホン酸、p-トルエンスルホン酸等)、または無機酸(塩酸、硫酸等)もしくはこれらの混合物(臭化水素/酢酸等)中、約0~100℃の温度で行なわれる。
(3)加水素分解による脱保護反応は、例えば、溶媒(エーテル系(テトラヒドロフラン、ジオキサン、ジメトキシエタン、ジエチルエーテル等)、アルコール系(メタノール、エタノール等)、ベンゼン系(ベンゼン、トルエン等)、ケトン系(アセトン、メチルエチルケトン等)、ニトリル系(アセトニトリル等)、アミド系(ジメチルホルムアミド等)、水、酢酸エチル、酢酸またはそれらの2以上の混合溶媒等)中、触媒(パラジウム-炭素、パラジウム黒、水酸化パラジウム、酸化白金、ラネーニッケル等)の存在下、常圧または加圧下の水素雰囲気下またはギ酸アンモニウム存在下、約0~200℃の温度で行なわれる。
(4)シリル基の脱保護反応は、例えば、水と混和しうる有機溶媒(テトラヒドロフラン、アセトニトリル等)中、テトラブチルアンモニウムフルオライドを用いて、約0~40℃の温度で行なわれる。
(5)金属を用いる脱保護反応は、例えば、酸性溶媒(酢酸、pH4.2~7.2の緩衝液またはそれらの溶液とテトラヒドロフラン等の有機溶媒との混合液)中、粉末亜鉛の存在下、必要であれば超音波をかけながら、約0~40℃の温度で行なわれる。
(6)金属錯体を用いる脱保護反応は、例えば、有機溶媒(ジクロロメタン、ジメチルホルムアミド、テトラヒドロフラン、酢酸エチル、アセトニトリル、ジオキサン、エタノール等)、水またはそれらの混合溶媒中、トラップ試薬(水素化トリブチルスズ、トリエチルシラン、ジメドン、モルホリン、ジエチルアミン、ピロリジン等)、有機酸(酢酸、ギ酸、2-エチルヘキサン酸等)および/または有機酸塩(2-エチルヘキサン酸ナトリウム、2-エチルヘキサン酸カリウム等)の存在下、ホスフィン系試薬(トリフェニルホスフィン等)の存在下または非存在下、金属錯体(テトラキストリフェニルホスフィンパラジウム(0)、二塩化ビス(トリフェニルホスフィン)パラジウム(II)、酢酸パラジウム(II)、塩化トリス(トリフェニルホスフィン)ロジウム(I)等)を用いて、約0~40℃の温度で行なわれる。
(1)酸ハライドを用いる方法、
(2)混合酸無水物を用いる方法、
(3)縮合剤を用いる方法等が挙げられる。
(1)酸ハライドを用いる方法は、例えば、カルボン酸を有機溶媒(クロロホルム、ジクロロメタン、ジエチルエーテル、テトラヒドロフラン等)中または無溶媒で、酸ハライド化剤(オキザリルクロライド、チオニルクロライド等)と-20℃~還流温度で反応させ、得られた酸ハライドを塩基(ピリジン、トリエチルアミン、ジメチルアニリン、ジメチルアミノピリジン、ジイソプロピルエチルアミン等)の存在下、アミンと有機溶媒(クロロホルム、ジクロロメタン、ジエチルエーテル、テトラヒドロフラン等)中、0~40℃の温度で反応させることにより行なわれる。また、得られた酸ハライドを有機溶媒(ジオキサン、テトラヒドロフラン等)中、アルカリ水溶液(重曹水または水酸化ナトリウム溶液等)を用いて、アミンと0~40℃で反応させることにより行なうこともできる。
(2)混合酸無水物を用いる方法は、例えば、カルボン酸を有機溶媒(クロロホルム、ジクロロメタン、ジエチルエーテル、テトラヒドロフラン等)中または無溶媒で、塩基(ピリジン、トリエチルアミン、ジメチルアニリン、ジメチルアミノピリジン、ジイソプロピルエチルアミン等)の存在下、酸ハライド(ピバロイルクロライド、トシルクロライド、メシルクロライド等)、または酸誘導体(クロロギ酸エチル、クロロギ酸イソブチル等)と、0~40℃で反応させ、得られた混合酸無水物を有機溶媒(クロロホルム、ジクロロメタン、ジエチルエーテル、テトラヒドロフラン等)中、アミンと0~40℃で反応させることにより行なわれる。
(3)縮合剤を用いる方法は、例えば、カルボン酸とアミンを、有機溶媒(クロロホルム、ジクロロメタン、ジメチルホルムアミド、ジエチルエーテル、テトラヒドロフラン等)中、または無溶媒で、塩基(ピリジン、トリエチルアミン、ジメチルアニリン、ジメチルアミノピリジン等)の存在下または非存在下、縮合剤(1,3-ジシクロヘキシルカルボジイミド(DCC)、1-エチル-3-[3-(ジメチルアミノ)プロピル]カルボジイミド(EDC)、1,1’-カルボニルビス-1H-イミダゾール(CDI)、2-クロロ-1-メチルピリジニウムヨウ素、1-プロピルホスホン酸環状無水物(1-propanephosphonic acid cyclic anhydride、PPA)等)を用い、1-ヒドロキシベンズトリアゾール(HOBt)存在下または非存在下、0~40℃で反応させることにより行なわれる。
(1)アルカリ加水分解による脱保護反応、
(2)酸性条件下における脱保護反応、
(3)加水素分解による脱保護反応、
(4)シリル基の脱保護反応、
(5)金属を用いる脱保護反応、
(6)金属錯体を用いる脱保護反応等が挙げられる。
本発明化合物の毒性は十分に低いものであり、医薬品として安全に使用することができる。
本発明化合物は、KCNQ2~5チャネル関連疾患の予防および/または治療に適している。
1)予防および/または治療効果の補完および/または増強、
2)動態・吸収改善、投与量の低減、および/または
3)副作用の軽減のために、他の薬物と組み合わせて、併用薬として投与してもよい。
分析装置:ACQUITY UPLC I-Classシステム(Waters社製)
検出器:UV(PDA)、ELSD、MS
条件1
カラム:ACQUITY UPLC BEH C18 Column(Waters社製、1.7μm、2.1mm×30mm)
移動相:A液:0.1%ギ酸水溶液、B液:0.1%ギ酸アセトニトリル溶液
グラジエント:0分(A液/B液=95/5)、0.1分(A液/B液=95/5)、1.2分(A液/B液=5/95)、1.4分(A液/B液=5/95)、1.5分(A液/B液=95/5)
流速:1mL/min、検出法:254nm、カラム温度:30℃、注入量:2μL
条件2
カラム:ACQUITY UPLC BEH C18 Column(Waters社製、1.7μm、2.1mm×30mm)
移動相:A液:0.1%トリフルオロ酢酸水溶液、B液:0.1%トリフルオロ酢酸アセトニトリル溶液
グラジエント:0分(A液/B液=95/5)、0.1分(A液/B液=95/5)、1.2分(A液/B液=5/95)、1.4分(A液/B液=5/95)、1.5分(A液/B液=95/5)
流速:1mL/min、検出法:254nm、カラム温度:30℃、注入量:2μL
条件3
カラム:YMC Triart C18(YMC社製、1.9μm、2.1mm×30mm)
移動相:A液:0.1%トリフルオロ酢酸水溶液、B液:0.1%トリフルオロ酢酸アセトニトリル溶液
グラジエント:0分(A液/B液=95/5)、0.1分(A液/B液=95/5)、1.2分(A液/B液=5/95)、1.4分(A液/B液=5/95)、1.5分(A液/B液=95/5)
流速:1mL/min、検出法:254nm、カラム温度:30℃、注入量:2μL
1,1,1-トリフルオロ-2-(4-ニトロフェニル)-2-プロパノール
1-(4-ニトロフェニル)エタノン(1.65g)(CAS登録番号:100-19-6)と(トリフルオロメチル)トリメチルシラン(4.26g)のテトラヒドロフラン(16mL)溶液に、氷冷下、テトラブチルアンモニウムフルオリド(1Mテトラヒドロフラン溶液,1mL)を加え、室温で2時間撹拌した。反応混合物に飽和塩化アンモニウム水溶液を加え、酢酸エチルで抽出した。有機層を水、飽和食塩水で順次洗浄し、無水硫酸ナトリウムで乾燥後、減圧濃縮した。得られた残渣をテトラヒドロフラン(16mL)に溶解し、氷冷下、テトラブチルアンモニウムフルオリド(1Mテトラヒドロフラン溶液、12mL)を加えた。反応混合物を氷冷下、10分間撹拌した後、減圧濃縮した。得られた残渣をシリカゲルカラムクロマトグラフィー(ヘキサン:酢酸エチル=85:15→80:20)によって精製することにより、以下の物性値を有する標題化合物(2.28g)を得た。
TLC:Rf 0.47(ヘキサン:酢酸エチル=3:1);
1H-NMR(CDCl3):δ 1.83-1.84, 7.78-7.81, 8.23-8.28。
2-(4-アミノフェニル)-1,1,1-トリフルオロ-2-プロパノール
実施例1で製造した化合物(2.28g)をエタノール(50mL)と水(10mL)に懸濁させ、粉末亜鉛(3.17g)と酢酸(2.82mL)を加えた。反応混合物を50℃で終夜撹拌した。反応混合物を室温まで冷却し、飽和炭酸水素ナトリウム水溶液を加え、30分間撹拌した。反応混合物に酢酸エチルを加え、セライト(商品名)で濾過後、濾液を酢酸エチルで抽出した。有機層を飽和食塩水で洗浄し、無水硫酸マグネシウムで乾燥後、減圧濃縮した。得られた残渣をシリカゲルカラムクロマトグラフィー(ヘキサン:酢酸エチル=80:20→20:80)によって精製することにより、以下の物性値を有する標題化合物(1.20g)を得た。
TLC:Rf 0.37(ヘキサン:酢酸エチル=2:1);
1H-NMR(CDCl3):δ 1.72-1.73, 2.32, 6.65-6.70, 7.33-7.35。
2-(4-アミノ-3,5-ジクロロフェニル)-1,1,1-トリフルオロ-2-プロパノール
実施例2で製造した化合物(1.20g)のN,N-ジメチルホルムアミド(12mL)溶液にN-クロロスクシンイミド(1.56g)加え、室温で15時間撹拌した。反応混合物に水を加えて、酢酸エチルで抽出した。有機層を無水硫酸マグネシウムで乾燥後、減圧濃縮した。得られた残渣をシリカゲルカラムクロマトグラフィー(ヘキサン:酢酸エチル=80:20→40:60)によって精製することにより、以下の物性値を有する標題化合物(867mg)を得た。
TLC:Rf 0.72(ヘキサン:酢酸エチル=2:1);
1H-NMR(CDCl3):δ 1.72-1.73, 2.40, 7.39。
2,6-ジクロロ-4-{1,1,1-トリフルオロ-2-[(トリメチルシリル)オキシ]-2-プロパニル}アニリン
実施例3で製造した化合物(860mg)のテトラヒドロフラン(17mL)溶液にイミダゾール(1.07g)とクロロトリメチルシラン(2mL)を加えた。反応混合物を室温で2.5時間撹拌した後、水を加え、酢酸エチルで抽出した。有機層を水で洗浄し、無水硫酸ナトリウムで乾燥後、減圧濃縮した。得られた残渣をシリカゲルカラムクロマトグラフィー(ヘキサン:酢酸エチル=100:0→60:40)によって精製することにより、以下の物性値を有する標題化合物(1.05g)を得た。
TLC:Rf 0.68(ヘキサン:酢酸エチル=8:1);
1H-NMR(CDCl3):δ 0.15, 1.74-1.75, 4.51, 7.33。
1-[2,6-ジクロロ-4-(1,1,1-トリフルオロ-2-ヒドロキシ-2-プロパニル)フェニル]-3-{[5-(トリフルオロメチル)-2-ピリジニル]メチル}ウレア
TLC:Rf 0.31(ヘキサン:酢酸エチル=1:1);
1H-NMR(DMSO-d6):δ 1.69, 4.47, 6.93, 7.14, 7.58, 7.64, 8.24, 8.43, 8.89。
1-[5-(トリフルオロメチル)-2-ピリジニル]メタンアミン塩酸塩の代わりに、相当するアミンを用い、実施例5と同様の操作を行って、以下の物性値を有する表題化合物を得た。
1-[2,6-ジクロロ-4-(1,1,1-トリフルオロ-2-ヒドロキシ-2-プロパニル)フェニル]-3-(4-フルオロベンジル)ウレア
TLC:Rf 0.54(ヘキサン:酢酸エチル=1:1);
1H-NMR(DMSO-d6):δ 1.69, 4.26, 6.89, 6.92, 7.10-7.19, 7.28-7.37, 7.63, 8.15。
1-[2,6-ジクロロ-4-(1,1,1-トリフルオロ-2-ヒドロキシ-2-プロパニル)フェニル]-3-[(5-フルオロ-2-ピリジニル)メチル]ウレア
TLC:Rf 0.44(ヘキサン:酢酸エチル=1:2);
1H-NMR(DMSO-d6):δ 1.69, 4.37, 6.93, 7.05, 7.41, 7.64, 7.74, 8.36, 8.50。
1-[2,6-ジクロロ-4-(1,1,1-トリフルオロ-2-ヒドロキシ-2-プロパニル)フェニル]-3-{[6-(1-ピペリジニル)-2-ピリジニル]メチル}ウレア
TLC:Rf 0.89(酢酸エチル);
1H-NMR(DMSO-d6):δ 1.50-1.65, 1.69, 3.49-3.52, 4.19, 6.55, 6.65, 6.81, 6.93, 7.46, 7.64, 8.31。
1-[2,6-ジクロロ-4-(1,1,1-トリフルオロ-2-ヒドロキシ-2-プロパニル)フェニル]-3-(3,3-ジメチル-2-ブタニル)ウレア
TLC:Rf 0.38(ヘキサン:酢酸エチル=1:1);
1H-NMR(DMSO-d6):δ 0.87, 0.95, 1.69, 3.44-3.54, 6.24, 6.91, 7.61, 7.83。
1-[2,6-ジクロロ-4-(1,1,1-トリフルオロ-2-ヒドロキシ-2-プロパニル)フェニル]-3-[(2,2-ジメチルテトラヒドロ-2H-ピラン-4-イル)メチル]ウレア
TLC:Rf 0.19(ヘキサン:酢酸エチル=1:1);
1H-NMR(DMSO-d6):δ 0.91-1.05, 1.11, 1.50-1.54, 1.69, 1.75-1.87, 2.98-2.96, 3.46-3.54, 3.58-3.63, 6.43, 6.92, 7.62, 7.94。
1-[2,6-ジクロロ-4-(1,1,1-トリフルオロ-2-ヒドロキシ-2-プロパニル)フェニル]-3-[(4,4-ジフルオロ-1-ヒドロキシシクロヘキシル)メチル]ウレア
TLC:Rf 0.25(ヘキサン:酢酸エチル=1:1);
1H-NMR(DMSO-d6):δ 1.43-1.66, 1.69, 1.76-2.15, 3.10, 4.70, 6.50, 6.92, 7.62, 8.16。
1-[2,6-ジクロロ-4-(1,1,1-トリフルオロ-2-ヒドロキシ-2-プロパニル)フェニル]-3-[(3-メチル-2-ピリジニル)メチル]ウレア
TLC:Rf 0.15(ヘキサン:酢酸エチル=1:1);
1H-NMR(DMSO-d6):δ 1.70, 2.28, 4.40, 6.92, 7.10, 7.25, 7.61, 7.63, 8.39, 8.53。
1-[(5-クロロ-2-チエニル)メチル]-3-[2,6-ジクロロ-4-(1,1,1-トリフルオロ-2-ヒドロキシ-2-プロパニル)フェニル]ウレア
TLC:Rf 0.53(ヘキサン:酢酸エチル=1:1);
1H-NMR(DMSO-d6):δ 1.70, 4.34, 6.82, 6.93-6.94, 7.01, 7.64, 8.21。
1-[2,6-ジクロロ-4-(1,1,1-トリフルオロ-2-ヒドロキシ-2-プロパニル)フェニル]-3-{[3-(トリフルオロメチル)-2-ピリジニル]メチル}ウレア
TLC:Rf 0.35(ヘキサン:酢酸エチル=1:1);
1H-NMR(DMSO-d6):δ 1.69, 4.60, 6.93, 7.11, 7.57, 7.63, 8.19, 8.51, 8.86。
1-(シクロヘキシルメチル)-3-[2,6-ジクロロ-4-(1,1,1-トリフルオロ-2-ヒドロキシ-2-プロパニル)フェニル]ウレア
TLC:Rf 0.59(ヘキサン:酢酸エチル=1:1);
1H-NMR(DMSO-d6):δ 0.80-1.78, 2.91, 6.38, 6.91, 7.61, 7.90。
1-[(5-ブロモ-2-ピリジニル)メチル]-3-[2,6-ジクロロ-4-(1,1,1-トリフルオロ-2-ヒドロキシ-2-プロパニル)フェニル]ウレア
TLC:Rf 0.50(ヘキサン:酢酸エチル=1:2);
1H-NMR(DMSO-d6):δ 1.69, 4.34, 6.93, 7.05, 7.34, 7.64, 8.06, 8.37, 8.63。
1-[(1-ベンジル-1H-イミダゾール-2-イル)メチル]-3-[2,6-ジクロロ-4-(1,1,1-トリフルオロ-2-ヒドロキシ-2-プロパニル)フェニル]ウレア
TLC:Rf 0.64(ヘキサン:酢酸エチル=1:1);
1H-NMR(DMSO-d6):δ 1.69, 4.31, 5.23, 6.87, 6.92, 6.96, 7.16-7.19, 7.28-7.37, 7.62, 8.24。
1-[2,6-ジクロロ-4-(1,1,1-トリフルオロ-2-ヒドロキシ-2-プロパニル)フェニル]-3-[(5-フルオロ-1H-インドール-2-イル)メチル]ウレア
TLC:Rf 0.53(ジクロロメタン:メタノール=9:1);
1H-NMR(DMSO-d6):δ 1.70, 4.39, 6.29, 6.81-6.90, 6.93, 7.19-7.23, 7.28-7.33, 7.64, 8.19, 11.02。
1-[2,6-ジクロロ-4-(1,1,1-トリフルオロ-2-ヒドロキシ-2-プロパニル)フェニル]-3-[(2R)-テトラヒドロ-2-フラニルメチル]ウレア
TLC:Rf 0.43(ヘキサン:酢酸エチル=1:3);
1H-NMR(DMSO-d6):δ 1.47-1.62, 1.69, 1.72-1.95, 3.01-3.12, 3.13-3.28, 3.59-3.66, 3.75-3.86, 6.45, 6.92, 7.62, 8.08。
1-[2,6-ジクロロ-4-(1,1,1-トリフルオロ-2-ヒドロキシ-2-プロパニル)フェニル]-3-[(2S)-テトラヒドロ-2-フラニルメチル]ウレア
TLC:Rf 0.43(ヘキサン:酢酸エチル=1:3);
1H-NMR(DMSO-d6):δ 1.47-1.62, 1.69, 1.72-1.95, 3.01-3.12, 3.13-3.28, 3.59-3.66, 3.75-3.86, 6.45, 6.92, 7.62, 8.08。
1-[2,6-ジクロロ-4-(1,1,1-トリフルオロ-2-ヒドロキシ-2-プロパニル)フェニル]-3-[(5-フェニル-1,2-オキサゾール-3-イル)メチル]ウレア
TLC:Rf 0.37(ヘキサン:酢酸エチル=1:1);
1H-NMR(DMSO-d6):δ 1.70, 4.37, 6.85, 6.93, 7.03, 7.43-7.58, 7.65, 7.82, 8.30。
1-[2,6-ジクロロ-4-(1,1,1-トリフルオロ-2-ヒドロキシ-2-プロパニル)フェニル]-3-{[5-(トリフルオロメチル)-2-フリル]メチル}ウレア
TLC:Rf 0.58(ヘキサン:酢酸エチル=1:1);
1H-NMR(DMSO-d6):δ 1.69, 4.33, 6.44, 6.94, 6.97, 7.16, 7.64, 8.25。
1-[2,6-ジクロロ-4-(1,1,1-トリフルオロ-2-ヒドロキシ-2-プロパニル)フェニル]-3-{[5-(トリフルオロメチル)-1,2,4-オキサジアゾール-3-イル]メチル}ウレア
TLC:Rf 0.65(ヘキサン:酢酸エチル=1:1);
1H-NMR(DMSO-d6):δ 1.69, 4.54, 6.94, 7.14, 7.63, 8.43。
1-[2,6-ジクロロ-4-(1,1,1-トリフルオロ-2-ヒドロキシ-2-プロパニル)フェニル]-3-(3,3,3-トリフルオロプロピル)ウレア
TLC:Rf 0.28(ヘキサン:酢酸エチル=1:1);
1H-NMR(DMSO-d6):δ 1.69, 2.26-2.44, 3.27-3.29, 6.55, 6.93, 7.63, 8.22。
1-[(1R)-1-シクロプロピルエチル]-3-[2,6-ジクロロ-4-(1,1,1-トリフルオロ-2-ヒドロキシ-2-プロパニル)フェニル]ウレア
TLC:Rf 0.30(ヘキサン:酢酸エチル=1:1);
1H-NMR(DMSO-d6):δ 0.15-0.41, 0.82-0.89, 1.12, 1.69, 3.18-3.25, 6.30, 6.91, 7.61, 7.85。
1-[2,6-ジクロロ-4-(1,1,1-トリフルオロ-2-ヒドロキシ-2-プロパニル)フェニル]-3-[(2R)-3-メチル-2-ブタニル]ウレア
TLC:Rf 0.30(ヘキサン:酢酸エチル=1:1);
1H-NMR(DMSO-d6):δ 0.84-0.88, 1.01, 1.61-1.70, 3.46-3.53, 6.24, 6.91, 7.61, 7.82。
1-[(3-シクロプロピル-1,2,4-オキサジアゾール-5-イル)メチル]-3-[2,6-ジクロロ-4-(1,1,1-トリフルオロ-2-ヒドロキシ-2-プロパニル)フェニル]ウレア
TLC:Rf 0.17(ヘキサン:酢酸エチル=1:1);
1H-NMR(DMSO-d6):δ 0.82-0.87, 1.01-1.08, 1.69, 2.05-2.14, 4.47, 6.93, 7.10, 7.63, 8.46。
1-[2,6-ジクロロ-4-(1,1,1-トリフルオロ-2-ヒドロキシ-2-プロパニル)フェニル]-3-{[5-(トリフルオロメチル)-1,2-オキサゾール-3-イル]メチル}ウレア
TLC:Rf 0.45(ヘキサン:酢酸エチル=1:1);
1H-NMR(DMSO-d6):δ 1.69, 4.42, 6.94, 7.08, 7.18, 7.64, 8.41。
1-[(5-クロロ-2-ピリミジニル)メチル]-3-[2,6-ジクロロ-4-(1,1,1-トリフルオロ-2-ヒドロキシ-2-プロパニル)フェニル]ウレア
TLC:Rf 0.60(ヘキサン:酢酸エチル=1:3);
1H-NMR(DMSO-d6):δ 1.69, 4.49, 6.92, 7.01, 7.62, 8.42, 8.92。
1-[2,6-ジクロロ-4-(1,1,1-トリフルオロ-2-ヒドロキシ-2-プロパニル)フェニル]-3-{[5-(トリフルオロメチル)-2-ピラジニル]メチル}ウレア
TLC:Rf 0.38(ヘキサン:酢酸エチル=1:1);
1H-NMR(DMSO-d6):δ 1.69, 4.55, 6.94, 7.21, 7.64, 8.51, 8.78, 9.13。
1-[2,6-ジクロロ-4-(1,1,1-トリフルオロ-2-ヒドロキシ-2-プロパニル)フェニル]-3-{[5-(トリフルオロメチル)-2-チエニル]メチル}ウレア
TLC:Rf 0.54(ヘキサン:酢酸エチル=1:1);
1H-NMR(DMSO-d6):δ 1.70, 4.48, 6.94, 7.05, 7.14, 7.54, 7.64, 8.31。
1-[2,6-ジクロロ-4-(1,1,1-トリフルオロ-2-ヒドロキシ-2-プロパニル)フェニル]-3-{[3-(2-メチル-2-プロパニル)-1,2,4-オキサジアゾール-5-イル]メチル}ウレア
TLC:Rf 0.41(ヘキサン:酢酸エチル=1:1);
1H-NMR(DMSO-d6):δ 1.29, 1.69, 4.52, 6.93, 7.13, 7.63, 8.47。
1-[2,6-ジクロロ-4-(1,1,1-トリフルオロ-2-ヒドロキシ-2-プロパニル)フェニル]-3-{[5-(2-メチル-2-プロパニル)-1,2,4-オキサジアゾール-3-イル]メチル}ウレア
TLC:Rf 0.36(ヘキサン:酢酸エチル=1:1);
1H-NMR(DMSO-d6):δ 1.37, 1.69, 4.37, 6.92, 6.99, 7.63, 8.29。
1-[2,6-ジクロロ-4-(1,1,1-トリフルオロ-2-ヒドロキシ-2-プロパニル)フェニル]-3-[4-(トリフルオロメチル)ベンジル]ウレア
LC保持時間(分)、LC条件2:0.96;
1H-NMR(DMSO-d6):δ 1.68, 4.36, 6.91, 7.00, 7.49-7.51, 7.63, 7.68-7.71, 8.24。
1-(シクロプロピルメチル)-3-[2,6-ジクロロ-4-(1,1,1-トリフルオロ-2-ヒドロキシ-2-プロパニル)フェニル]ウレア
TLC:Rf 0.53(ヘキサン:酢酸エチル=1:1);
1H-NMR(DMSO-d6):δ 0.16-0.21, 0.38-0.44, 0.89-0.97, 1.70, 2.97, 6.45, 6.93, 7.63, 7.99。
1-[2,6-ジクロロ-4-(1,1,1-トリフルオロ-2-ヒドロキシ-2-プロパニル)フェニル]-3-[(2,2-ジフルオロシクロプロピル)メチル]ウレア
TLC:Rf 0.29(ヘキサン:酢酸エチル=1:1);
1H-NMR(DMSO-d6):δ 1.24-1.34, 1.51-1.62, 1.70, 1.86-1.99, 3.08-3.29, 6.63, 6.94, 7.64, 8.13。
1-[2,6-ジクロロ-4-(1,1,1-トリフルオロ-2-ヒドロキシ-2-プロパニル)フェニル]-3-(1,2-オキサゾール-3-イルメチル)ウレア
TLC:Rf 0.34(ヘキサン:酢酸エチル=1:1);
1H-NMR(DMSO-d6):δ 1.70, 4.35, 6.45, 6.94, 6.99, 7.65, 8.29, 8.83。
1-[2,6-ジクロロ-4-(1,1,1-トリフルオロ-2-ヒドロキシ-2-プロパニル)フェニル]-3-(1,3-チアゾール-2-イルメチル)ウレア
TLC:Rf 0.12(ヘキサン:酢酸エチル=1:1);
1H-NMR(DMSO-d6):δ 1.71, 4.56, 6.95, 7.27, 7.61, 7.65, 7.72, 8.40。
1-[2,6-ジクロロ-4-(1,1,1-トリフルオロ-2-ヒドロキシ-2-プロパニル)フェニル]-3-[(3,3-ジフルオロシクロブチル)メチル]ウレア
TLC:Rf 0.42(ヘキサン:酢酸エチル=1:1);
1H-NMR(DMSO-d6):δ 1.70, 2.27-2.65, 3.19, 6.60, 6.93, 7.63, 8.07。
1-[2,6-ジクロロ-4-(1,1,1-トリフルオロ-2-ヒドロキシ-2-プロパニル)フェニル]-3-[4-(トリフルオロメトキシ)ベンジル]ウレア
TLC:Rf 0.55(ヘキサン:酢酸エチル=1:1);
1H-NMR(CD3OD):δ 1.72, 4.42, 7.22-7.25, 7.43-7.46, 7.66。
[2-(2-メチル-2-プロパニル)-1,3-オキサゾール-5-イル]メタノール
[2-(2-メチル-2-プロパニル)-1,3-オキサゾール-5-イル]メチルアセテート(52mg)(Tetrahedron Letters, 2010, vol.51, p.2247-2250)のメタノール(1.3mL)溶液に、氷冷下、炭酸カリウム(54mg)を加えた。反応混合物を室温で30分間撹拌した後、水を加え、酢酸エチルで抽出した。有機層を水、飽和食塩水で順次洗浄し、無水硫酸ナトリウムで乾燥後、減圧濃縮することで、以下の物性値を有する標題化合物(40mg)を得た。
TLC:Rf 0.31(ヘキサン:酢酸エチル=1:1);
1H-NMR(CDCl3):δ 1.39, 1.71, 4.65, 6.88。
2-{[2-(2-メチル-2-プロパニル)-1,3-オキサゾール-5-イル]メチル}-1H-イソインドール-1,3(2H)-ジオン
アルゴン雰囲気下、実施例6で製造した化合物(40mg)のテトラヒドロフラン(1mL)溶液に、トリフェニルホスフィン(135mg)とフタルイミド(75mg)を加えた。反応混合物に氷冷下、ジエチルアゾジカルボキシレート(230μL)を加え、室温で1時間撹拌した。反応混合物を濃縮し、得られた残渣をシリカゲルカラムクロマトグラフィー(ヘキサン:酢酸エチル=80/20→55/45)によって精製することにより、以下の物性値を有する標題化合物(93mg)を得た。
TLC:Rf 0.64(ヘキサン:酢酸エチル=1:1);
1H-NMR(CDCl3):δ 1.34, 4.87, 6.93, 7.73-7.78, 7.86-7.90。
1-[2-(2-メチル-2-プロパニル)-1,3-オキサゾール-5-イル]メタンアミン
アルゴン雰囲気下、実施例7で製造した化合物(73mg)のエタノール(1.7mL)溶液に、ヒドラジン1水和物(129mg)を加えた。反応混合物を80℃で30分間撹拌した後、室温に冷却した。反応混合物に酢酸エチルとエタノールの混合溶媒を加え、濾過した。濾液を減圧濃縮することで、以下の物性値を有する標題化合物(40mg)を得た。
1H-NMR(CDCl3):δ 1.37, 3.85, 6.74。
1-[2,6-ジクロロ-4-(1,1,1-トリフルオロ-2-ヒドロキシ-2-プロパニル)フェニル]-3-{[2-(2-メチル-2-プロパニル)-1,3-オキサゾール-5-イル]メチル}ウレア
TLC:Rf 0.40(ヘキサン:酢酸エチル=1:2);
1H-NMR(DMSO-d6):δ 1.29, 1.69, 4.28, 6.78, 6.84, 6.93, 7.64, 8.17。
1-[2-(トリフルオロメチル)-1,3-チアゾール-5-イル]メタンアミン
実施例6で製造した化合物の代わりに、(2-(トリフルオロメチル)チアゾール-5-イル)メタノール(CAS登録番号:131748-97-5)を用いて、実施例7→実施例8と同様の操作を行って、以下の物性値を有する標題化合物を得た。
1H-NMR(DMSO-d6):δ 2.27, 4.00, 7.91。
1-[2,6-ジクロロ-4-(1,1,1-トリフルオロ-2-ヒドロキシ-2-プロパニル)フェニル]-3-{[2-(トリフルオロメチル)-1,3-チアゾール-5-イル]メチル}ウレア
TLC:Rf 0.26(ヘキサン:酢酸エチル=1:1);
1H-NMR(DMSO-d6):δ 1.70, 4.53, 6.94, 7.19, 7.65, 7.96, 8.40。
1-[5-(2-メチル-2-プロパニル)-1,2-オキサゾール-3-イル]メタンアミン
実施例6で製造した化合物の代わりに、(5-tert-ブチル-1,2-オキサゾール-3-イル)メタノール(CAS登録番号:202817-06-9)を用いて、実施例7→実施例8と同様の操作を行って、以下の物性値を有する標題化合物を得た。
1H-NMR(DMSO-d6):δ 1.27, 3.63, 6.20。
1-[2,6-ジクロロ-4-(1,1,1-トリフルオロ-2-ヒドロキシ-2-プロパニル)フェニル]-3-{[5-(2-メチル-2-プロパニル)-1,2-オキサゾール-3-イル]メチル}ウレア
TLC:Rf 0.53(ヘキサン:酢酸エチル=1:1);
1H-NMR(DMSO-d6):δ 1.27, 1.69, 4.26, 6.10, 6.91-6.99, 7.64, 8.27。
2-(4-ブロモフェニル)-1,1,1-トリフルオロ-2-プロパノール
アルゴン雰囲気下、減圧下で加熱乾燥した塩化セリウム(51g)をテトラヒドロフラン(316mL)に懸濁させ、室温で1時間撹拌した後、-70℃に冷却した。メチルリチウム(3.0Mジエチルエーテル溶液、185mL)を滴下し、-70℃で30分撹拌した後、1-(4-ブロモフェニル)-2,2,2-トリフルオロエタノン(40g)(CAS登録番号:16184-89-7)のテトラヒドロフラン(30mL)溶液を加え、室温で1.5時間撹拌した。反応液を飽和塩化アンモニウム水溶液(500mL)と氷水(500mL)の混合液中へ注いだ後、混合物の色が薄黄色になるまで1N塩酸を加え、酢酸エチルで抽出した。有機層を水、飽和食塩水で順次洗浄し、無水硫酸マグネシウムで乾燥後、減圧濃縮することにより、以下の物性値を有する標題化合物を得た(51g)。
TLC:Rf 0.59(ヘキサン:酢酸エチル=4:1);
1H-NMR(CDCl3):δ 1.77, 2.42, 7.44-7.47, 7.52-7.55。
(2R)-2-(4-ブロモフェニル)-1,1,1-トリフルオロ-2-プロパニル[(1S)-1-(1-ナフチル)エチル]カルバメート(15a)および(2S)-2-(4-ブロモフェニル)-1,1,1-トリフルオロ-2-プロパニル[(1S)-1-(1-ナフチル)エチル]カルバメート(15b)
実施例14で製造した化合物(43g)のジクロロメタン(237mL)溶液に氷冷下でジメチルアミノピリジン(23.2g)と4-ニトロフェニルクロロホルメート(35.1g)を加えた後、室温で1時間撹拌した。反応溶液を再び氷冷し、(1S)-1-(1-ナフチル)エチルアミン(33.2mL)(CAS登録番号:10420-89-0)を加えた後、室温で1時間撹拌した。反応混合物にtert-ブチルメチルエーテル(500mL)を加え、析出物を濾過濾別し、ヘキサン/酢酸エチル(1/1)で洗浄した。濾液と洗浄液を合わせ、約半量まで減圧濃縮した後、1N水酸化ナトリウム水溶液(150mL×4回)、1N塩酸(200mL)、水(150mL)、飽和食塩水で順次洗浄し、無水硫酸マグネシウムで乾燥後、減圧濃縮した。得られた残渣をシリカゲルカラムクロマトグラフィー(ヘキサン:酢酸エチル=90:10→80:20)で精製することにより、標題化合物のジアステレオマー混合物を得た(70g)。ジアステレオマー混合物はシリカゲルカラムクロマトグラフィー(ヘキサン:tert-ブチルメチルエーテル=80:20)で分離精製することにより、以下の物性値を有する標題化合物15a(28g)および15b(33g)を得た。
15a
TLC:Rf 0.39(ヘキサン:ジイソプロピルエーテル=2:1);
1H-NMR(CDCl3):δ 1.63, 2.07, 5.35, 5.50-5.60, 7.32-7.35, 7.42-7.58, 7.78-7.90, 8.02-8.07。
15b
TLC:Rf 0.58(ヘキサン:ジイソプロピルエーテル=2:1);
1H-NMR(CDCl3):δ 1.69, 2.17, 5.25, 5.49-5.58, 7.22-7.25, 7.43-7.58, 7.80-7.95。
(2R)-2-(4-ブロモフェニル)-1,1,1-トリフルオロ-2-プロパノール
実施例15aで製造した化合物(44g)の1,4-ジオキサン(475mL)溶液に水酸化リチウム1水和物(40g)の水(237mL)溶液を加え、55℃で1時間撹拌した。反応混合物を10℃に冷却した後、2N塩酸(520mL)を加えてpH=2とし、酢酸エチルで抽出した。有機層を炭酸水素ナトリウム水溶液、水、塩化アンモニウム水溶液、飽和食塩水で順次洗浄し、無水硫酸マグネシウムで乾燥後、減圧濃縮した。得られた残渣をシリカゲルカラムクロマトグラフィー(ヘキサン:酢酸エチル=90:10→80:20)で精製することにより、以下の物性値を有する標題化合物を得た(27g)。
TLC:Rf 0.59(ヘキサン:酢酸エチル=4:1);
1H-NMR(CDCl3):δ 1.78, 2.42, 7.43-7.56。
2-メチル-2-プロパニル{4-[(2R)-1,1,1-トリフルオロ-2-ヒドロキシ-2-プロパニル]フェニル}カルバメート
実施例16で製造した化合物(27g)、tert-ブチルカルバメート(15g)、酢酸パラジウム(II)(2.2g)、4,5-ビス(ジフェニルホスフィノ)-9,9-ジメチルキサンテン(8.6g)、炭酸セシウム(49g)、1,4-ジオキサン(200mL)の混合物をアルゴン雰囲気下、100℃で2時間撹拌した。反応混合物を室温まで冷却した後、水(250mL)と酢酸エチル(250mL)を加えてセライト(商品名)で濾過した。濾液に水(250mL)を加えて二層を分離した後、水層を酢酸エチルで抽出した。有機層を合わせて、塩化アンモニウム水溶液、飽和食塩水で順次洗浄し、無水硫酸マグネシウムで乾燥後、減圧濃縮した。得られた残渣をシリカゲルカラムクロマトグラフィー(ヘキサン:酢酸エチル=90:10→50:50)で精製することにより、以下の物性値を有する標題化合物を得た(26g)。
TLC:Rf 0.31(ヘキサン:酢酸エチル=4:1);
1H-NMR(CDCl3):δ 1.52, 1.77, 2.56, 6.57, 7.37-7.40, 7.48-7.51。
(2R)-2-(4-アミノフェニル)-1,1,1-トリフルオロ-2-プロパノール
実施例17で製造した化合物(26g)のジクロロメタン(170mL)溶液にトリフルオロ酢酸(85mL)を加えて室温で1.5時間撹拌した。反応混合物にトルエンを加え減圧濃縮した。得られた残渣に飽和炭酸水素ナトリウム水溶液(300mL)を加え、酢酸エチルで抽出した。有機層を塩化アンモニウム水溶液、飽和食塩水で順次洗浄し、無水硫酸マグネシウムで乾燥後、減圧濃縮した。得られた残渣をtert-ブチルメチルエーテル-ヘキサン(1:1、30mL)に60℃で溶解させ、5℃まで冷却し、析出した固体を濾別した。濾液を濃縮することにより、以下の物性値を有する標題化合物を得た(9.8g)。
TLC:Rf 0.34(ヘキサン:酢酸エチル=3:2);
1H-NMR(CDCl3):δ 1.74, 2.38, 3.77, 6.67-6.70, 7.33-7.36。
(2R)-2-(4-アミノフェニル)-1,1,1-トリフルオロ-2-プロパノール塩酸塩
実施例18で製造した化合物(9.8g)のtert-ブチルメチルエーテル(96mL)溶液を氷水浴で冷却した後、4N塩化水素/1,4-ジオキサン溶液(15mL)を加えて撹拌した。生じた析出物を濾取し、tert-ブチルメチルエーテルで洗浄した。得られた固体にアセトニトリル(200mL)を加え、80℃で撹拌し、溶解後、室温まで冷却し終夜撹拌した。析出した結晶を濾取し、アセトニトリル、酢酸エチルで順次洗浄した後、乾燥することにより、以下の物性値を有する標題化合物(7.8g)を得た。
TLC:Rf 0.34(ヘキサン:酢酸エチル=3:2);
1H-NMR(DMSO-d6):δ1.64, 3.57, 6.61, 7.19-7.22, 7.58-7.61。
4-{(2R)-1,1,1-トリフルオロ-2-[(トリメチルシリル)オキシ]-2-プロパニル}アニリン
実施例19で製造した化合物(7.8g)をメタノール(10mL)と酢酸エチル(50mL)に溶解し、撹拌しながら飽和炭酸水素ナトリウム水溶液(150mL)を数回に分けて加えた後、反応混合物を酢酸エチルで抽出した。有機層を飽和食塩水で洗浄し、無水硫酸マグネシウムで乾燥後、減圧濃縮した。得られた残渣にテトラヒドロフラン(130mL)溶液を加え、氷水浴で冷却した後、イミダゾール(11g)とクロロトリメチルシラン(20mL)を加え、30℃で1時間撹拌した。反応混合物を水(300mL)中に注ぎ、水層を分離して飽和炭酸水素ナトリウム水溶液を加えてpHを7以上にした後、酢酸エチルで抽出した。有機層を水と飽和食塩水で順次洗浄し、無水硫酸マグネシウムで乾燥後、減圧濃縮することにより、以下の物性値を有する標題化合物を得た(9.4g)。
TLC:Rf 0.54(ヘキサン:酢酸エチル=2:1);
1H-NMR(CDCl3):δ 0.12, 1.77, 3.69, 6.64-6.67, 7.29-7.32。
2,6-ジクロロ-4-{(2R)-1,1,1-トリフルオロ-2-[(トリメチルシリル)オキシ]-2-プロパニル}アニリン
実施例20で製造した化合物(9.4g)のN,N-ジメチルホルムアミド(100mL)溶液にN-クロロスクシンイミド(9.1g)を加えて室温で15時間撹拌した後、40℃でさらに2時間撹拌した。反応混合物を水(300mL)中に注ぎ、ヘキサン-酢酸エチル(1:1、100mL×3回)で抽出した。有機層を飽和食塩水で洗浄し、無水硫酸マグネシウムで乾燥後、減圧濃縮した。得られた残渣をシリカゲルカラムクロマトグラフィー(ヘキサン:酢酸エチル=90:10→50:50)で精製することにより、以下の物性値を有する標題化合物を得た(9.0g)。
TLC:Rf 0.55(ヘキサン:酢酸エチル=4:1);
1H-NMR(CDCl3):δ 0.15, 1.75, 4.51, 7.33。
1-{2,6-ジクロロ-4-[(2R)-1,1,1-トリフルオロ-2-ヒドロキシ-2-プロパニル]フェニル}-3-[(5-メチル-1,2-オキサゾール-3-イル)メチル]ウレア
TLC:Rf 0.27(ヘキサン:酢酸エチル=1:1);
1H-NMR(DMSO-d6):δ 1.69, 2.37, 4.26, 6.10, 6.90-6.97, 7.64, 8.24。
1-(5-メチル-1,2-オキサゾール-3-イル)メタンアミン塩酸塩の代わりに、実施例10で製造したアミンもしくは相当するアミンを用い、実施例22と同様の操作を行って、以下の物性値を有する表題化合物を得た。
1-{2,6-ジクロロ-4-[(2R)-1,1,1-トリフルオロ-2-ヒドロキシ-2-プロパニル]フェニル}-3-{[5-(トリフルオロメチル)-2-ピリジニル]メチル}ウレア
1H-NMR(CDCl3):δ 1.75, 2.77, 4.65, 5.76, 6.60, 7.49, 7.61, 7.91-7.95, 8.78。
1-{2,6-ジクロロ-4-[(2R)-1,1,1-トリフルオロ-2-ヒドロキシ-2-プロパニル]フェニル}-3-{[5-(トリフルオロメチル)-2-ピリミジニル]メチル}ウレア
1H-NMR(DMSO-d6):δ 1.69, 4.61, 6.92, 7.08, 7.62, 8.46, 9.25。
1-{2,6-ジクロロ-4-[(2R)-1,1,1-トリフルオロ-2-ヒドロキシ-2-プロパニル]フェニル}-3-{[6-(トリフルオロメチル)-3-ピリジニル]メチル}ウレア
1H-NMR(DMSO-d6):δ 1.69, 4.40, 6.93, 7.08, 7.64, 7.87-7.99, 8.35, 8.68。
1-{2,6-ジクロロ-4-[(2R)-1,1,1-トリフルオロ-2-ヒドロキシ-2-プロパニル]フェニル}-3-{[2-(トリフルオロメチル)-5-ピリミジニル]メチル}ウレア
TLC:Rf 0.23(ヘキサン:酢酸エチル=1:1);
1H-NMR(DMSO-d6):δ 1.69, 4.42, 6.94, 7.12, 7.64, 8.46, 8.95。
1-[(5-クロロ-2-ピリジニル)メチル]-3-{2,6-ジクロロ-4-[(2R)-1,1,1-トリフルオロ-2-ヒドロキシ-2-プロパニル]フェニル}ウレア
1H-NMR(DMSO-d6):δ 1.69, 4.36, 6.93, 7.06, 7.39, 7.64, 7.94, 8.37, 8.55。
1-{2,6-ジクロロ-4-[(2R)-1,1,1-トリフルオロ-2-ヒドロキシ-2-プロパニル]フェニル}-3-{[6-(2,2,2-トリフルオロエトキシ)-3-ピリジニル]メチル}ウレア
TLC:Rf 0.38(ヘキサン:酢酸エチル=1:1);
1H-NMR(DMSO-d6):δ 1.70, 4.25, 4.93-5.02, 6.93-6.98, 7.64, 7.74, 8.11, 8.19。
1-{2,6-ジクロロ-4-[(2R)-1,1,1-トリフルオロ-2-ヒドロキシ-2-プロパニル]フェニル}-3-[4-(トリフルオロメチル)ベンジル]ウレア
TLC:Rf 0.60(ヘキサン:酢酸エチル=1:1);
1H-NMR(DMSO-d6):δ 1.70, 4.38, 6.94, 7.02, 7.50-7.53, 7.65, 7.69-7.72, 8.26。
1-ベンジル-3-{2,6-ジクロロ-4-[(2R)-1,1,1-トリフルオロ-2-ヒドロキシ-2-プロパニル]フェニル}ウレア
LC保持時間(分)、LC条件3:0.90;
1H-NMR(DMSO-d6):δ 1.70, 4.29, 6.89, 6.95, 7.20-7.35, 7.64, 8.14。
1-{2,6-ジクロロ-4-[(2R)-1,1,1-トリフルオロ-2-ヒドロキシ-2-プロパニル]フェニル}-3-(4-メトキシベンジル)ウレア
LC保持時間(分)、LC条件3:0.90;
1H-NMR(DMSO-d6):δ 1.69, 3.72, 4.21, 6.79, 6.87-6.92, 7.20-7.23, 7.63, 8.07。
1-{2,6-ジクロロ-4-[(2R)-1,1,1-トリフルオロ-2-ヒドロキシ-2-プロパニル]フェニル}-3-(4-メチルベンジル)ウレア
LC保持時間(分)、LC条件3:0.95;
1H-NMR(DMSO-d6):δ 1.70, 2.27, 4.24, 6.82, 6.94, 7.14-7.20, 7.64, 8.10。
1-{2,6-ジクロロ-4-[(2R)-1,1,1-トリフルオロ-2-ヒドロキシ-2-プロパニル]フェニル}-3-[4-(2-メチル-2-プロパニル)ベンジル]ウレア
LC保持時間(分)、LC条件3:1.05;
1H-NMR(DMSO-d6):δ 1.27, 1.70, 4.25, 6.84, 6.92, 7.21-7.24, 7.34-7.36, 7.64, 8.09。
1-{2,6-ジクロロ-4-[(2R)-1,1,1-トリフルオロ-2-ヒドロキシ-2-プロパニル]フェニル}-3-(4-フェノキシベンジル)ウレア
LC保持時間(分)、LC条件3:1.03;
1H-NMR(DMSO-d6):δ 1.70, 4.28, 6.87-6.91, 6.96-7.00, 7.09-7.15, 7.31-7.41, 7.64, 8.14。
1-{2,6-ジクロロ-4-[(2R)-1,1,1-トリフルオロ-2-ヒドロキシ-2-プロパニル]フェニル}-3-[4-(ジフルオロメトキシ)ベンジル]ウレア
LC保持時間(分)、LC条件3:0.94;
1H-NMR(DMSO-d6):δ 1.70, 4.28, 6.88-6.94, 7.13-7.16, 7.20, 7.33-7.36, 7.64, 8.16。
1-{2,6-ジクロロ-4-[(2R)-1,1,1-トリフルオロ-2-ヒドロキシ-2-プロパニル]フェニル}-3-[4-(4-モルホリニル)ベンジル]ウレア
LC保持時間(分)、LC条件3:0.73;
1H-NMR(DMSO-d6):δ 1.70, 3.07-3.11, 3.72-3.75, 4.19, 6.77, 6.92-6.95, 7.17-7.20, 7.64, 8.07。
1-(4-シアノベンジル)-3-{2,6-ジクロロ-4-[(2R)-1,1,1-トリフルオロ-2-ヒドロキシ-2-プロパニル]フェニル}ウレア
LC保持時間(分)、LC条件3:0.87;
1H-NMR(DMSO-d6):δ 1.70, 4.37, 6.93, 7.02, 7.47-7.50, 7.65, 7.80-7.82, 8.28。
1-{2,6-ジクロロ-4-[(2R)-1,1,1-トリフルオロ-2-ヒドロキシ-2-プロパニル]フェニル}-3-[4-(4-フルオロフェノキシ)ベンジル]ウレア
LC保持時間(分)、LC条件3:1.03;
1H-NMR(DMSO-d6):δ 1.70, 4.27, 6.86-7.05, 7.19-7.23, 7.30-7.33, 7.64, 8.13。
1-{2,6-ジクロロ-4-[(2R)-1,1,1-トリフルオロ-2-ヒドロキシ-2-プロパニル]フェニル}-3-{[2-(トリフルオロメチル)-1,3-チアゾール-5-イル]メチル}ウレア
TLC:Rf 0.50(ヘキサン:酢酸エチル=1:1);
1H-NMR(DMSO-d6):δ 1.71, 4.55, 6.95, 7.20, 7.66, 7.98, 8.41。
1-{2,6-ジクロロ-4-[(2R)-1,1,1-トリフルオロ-2-ヒドロキシ-2-プロパニル]フェニル}-3-{[3-(トリフルオロメチル)-1,2,4-オキサジアゾール-5-イル]メチル}ウレア
TLC:Rf 0.50(ヘキサン:酢酸エチル=1:1);
1H-NMR(DMSO-d6):δ 1.68, 4.68, 6.93, 7.24, 7.63, 8.61。
2,6-ジクロロ-4-{(2S)-1,1,1-トリフルオロ-2-[(トリメチルシリル)オキシ]-2-プロパニル}アニリン
実施例15aで製造した化合物の代わりに実施例15bで製造した化合物を用い、実施例16→実施例17→実施例18→実施例19→実施例20→実施例21と同様の操作を行って、以下の物性値を有する標題化合物を得た。
TLC:Rf 0.56(ヘキサン:酢酸エチル=4:1);
1H-NMR(CDCl3):δ 0.15, 1.75, 4.51, 7.33。
1-{2,6-ジクロロ-4-[(2S)-1,1,1-トリフルオロ-2-ヒドロキシ-2-プロパニル]フェニル}-3-[(5-メチル-1,2-オキサゾール-3-イル)メチル]ウレア
TLC:Rf 0.30(ヘキサン:酢酸エチル=1:1);
1H-NMR(DMSO-d6):δ 1.69, 2.37, 4.25, 6.10, 6.91-7.00, 7.64, 8.24。
実施例21で製造した化合物の代わりに、実施例24で製造した化合物を用い、1-(5-メチル-1,2-オキサゾール-3-イル)メタンアミン塩酸塩の代わりに、実施例10で製造したアミンもしくは相当するアミンを用い、実施例22と同様の操作を行って、以下の物性値を有する表題化合物を得た。
1-{2,6-ジクロロ-4-[(2S)-1,1,1-トリフルオロ-2-ヒドロキシ-2-プロパニル]フェニル}-3-{[5-(トリフルオロメチル)-2-ピリミジニル]メチル}ウレア
1H-NMR(DMSO-d6):δ 1.69, 4.60, 6.92, 7.08, 7.62, 8.46, 9.25。
1-{2,6-ジクロロ-4-[(2S)-1,1,1-トリフルオロ-2-ヒドロキシ-2-プロパニル]フェニル}-3-{[6-(トリフルオロメチル)-3-ピリジニル]メチル}ウレア
1H-NMR(DMSO-d6):δ 1.69, 4.40, 6.93, 7.08, 7.64, 7.89, 7.97, 8.35, 8.67。
1-{2,6-ジクロロ-4-[(2S)-1,1,1-トリフルオロ-2-ヒドロキシ-2-プロパニル]フェニル}-3-{[2-(トリフルオロメチル)-5-ピリミジニル]メチル}ウレア
TLC:Rf 0.21(ヘキサン:酢酸エチル=1:1);
1H-NMR(DMSO-d6):δ 1.69, 4.41, 6.93, 7.12, 7.65, 8.46, 8.95。
1-{2,6-ジクロロ-4-[(2S)-1,1,1-トリフルオロ-2-ヒドロキシ-2-プロパニル]フェニル}-3-{[5-(トリフルオロメチル)-2-ピリジニル]メチル}ウレア
TLC:Rf 0.16(ヘキサン:酢酸エチル=1:1);
1H-NMR(CDCl3):δ 1.76, 2.67, 4.65, 5.73, 6.60, 7.49, 7.61, 7.91-7.95, 8.79。
1-[(5-クロロ-2-ピリジニル)メチル]-3-{2,6-ジクロロ-4-[(2S)-1,1,1-トリフルオロ-2-ヒドロキシ-2-プロパニル]フェニル}ウレア
1H-NMR(DMSO-d6):δ 1.69, 4.36, 6.93, 7.06, 7.38, 7.64, 7.94, 8.37, 8.55。
1-{2,6-ジクロロ-4-[(2S)-1,1,1-トリフルオロ-2-ヒドロキシ-2-プロパニル]フェニル}-3-{[6-(2,2,2-トリフルオロエトキシ)-3-ピリジニル]メチル}ウレア
TLC:Rf 0.37(ヘキサン:酢酸エチル=1:1);
1H-NMR(DMSO-d6)δ 1.70, 4.25, 4.93-5.02, 6.93-6.98, 7.64, 7.74, 8.11, 8.19。
1-{2,6-ジクロロ-4-[(2S)-1,1,1-トリフルオロ-2-ヒドロキシ-2-プロパニル]フェニル}-3-[4-(トリフルオロメチル)ベンジル]ウレア
TLC:Rf 0.60(ヘキサン:酢酸エチル=1:1);
1H-NMR(DMSO-d6):δ 1.70, 4.38, 6.93, 7.02, 7.50-7.53, 7.65, 7.69-7.72, 8.25。
1-{2,6-ジクロロ-4-[(2S)-1,1,1-トリフルオロ-2-ヒドロキシ-2-プロパニル]フェニル}-3-{[2-(トリフルオロメチル)-1,3-チアゾール-5-イル]メチル}ウレア
TLC:Rf 0.50(ヘキサン:酢酸エチル=1:1);
1H-NMR(DMSO-d6):δ 1.71, 4.55, 6.95, 7.19, 7.66, 7.98, 8.40。
1-{2,6-ジクロロ-4-[(2S)-1,1,1-トリフルオロ-2-ヒドロキシ-2-プロパニル]フェニル}-3-{[3-(トリフルオロメチル)-1,2,4-オキサジアゾール-5-イル]メチル}ウレア
TLC:Rf 0.50(ヘキサン:酢酸エチル=1:1);
1H-NMR(DMSO-d6)δ 1.68, 4.68, 6.92, 7.24, 7.63, 8.60。
(1R)-1-(4-ブロモフェニル)-2,2,2-トリフルオロエチル[(1S)-1-(1-ナフチル)エチル]カルバメート(27a)および(1S)-1-(4-ブロモフェニル)-2,2,2-トリフルオロエチル[(1S)-1-(1-ナフチル)エチル]カルバメート(27b)
1-(4-ブロモフェニル)-2,2,2-トリフルオロエタノール(4.0g)(CAS登録番号:76911-73-4)のジクロロメタン(80mL)溶液に、氷冷下、4-ジメチルアミノピリジン(2.3g)と4-ニトロフェニルクロロホルメート(3.3mL)を加えて、室温で1時間撹拌した。反応液を再び氷浴で冷却し、(1S)-1-(1-ナフチル)エタンアミン(4mL)(CAS登録番号:10420-89-0)を加えて室温で30分間撹拌した。反応液を濾過し、濾液を1N水酸化ナトリウム水溶液で二回、1N塩酸で一回、飽和食塩水で一回、順次洗浄した。有機層を無水硫酸マグネシウムで乾燥後、減圧濃縮した。得られた残渣をシリカゲルカラムクロマトグラフィー(ヘキサン:tert-ブチルメチルエーテル=90:10)によって精製することにより、以下の物性値を有する標題化合物27a(1.91g)および27b(2.44g)を得た。
27a
TLC:Rf 0.57(ヘキサン:tert-ブチルメチルエーテル=3:1);
1H-NMR(CDCl3):δ 1.65, 5.30, 5.64, 6.04, 7.34, 7.47-7.57, 7.82, 7.89, 8.07。
27b
TLC:Rf 0.69(ヘキサン:tert-ブチルメチルエーテル=3:1);
1H-NMR(CDCl3):δ 1.72, 5.29, 5.60, 6.03, 7.28, 7.41-7.51, 7.80, 7.86, 7.94。
(1R)-1-(4-ブロモフェニル)-2,2,2-トリフルオロエタノール
実施例27aで製造した化合物(2.37g)の1,4-ジオキサン(40mL)と水(20mL)の混合溶液に、水酸化リチウム1水和物(2.20g)を加え、50℃で1時間撹拌した。反応混合物を氷浴下、2N塩酸(40mL)を加え、酢酸エチルで抽出した。有機層を無水硫酸マグネシウムにて乾燥後、減圧濃縮した。得られた残渣をシリカゲルカラムクロマトグラフィー(ヘキサン:酢酸エチル=90:10)によって精製することにより、以下の物性値を有する標題化合物(1.34g)を得た。
TLC:Rf 0.65(ヘキサン:酢酸エチル=3:1);
1H-NMR(CDCl3):δ 2.57, 4.97-5.05, 7.35-7.38,7.54-7.57。
2-メチル-2-プロパニル{4-[(1R)-2,2,2-トリフルオロ-1-ヒドロキシエチル]フェニル}カルバメート
実施例28で製造した化合物(1.34g)の1,4-ジオキサン(30mL)溶液に、tert-ブチルカルバメート(800mg)、酢酸パラジウム(II)(118mg)、4,5-ビス(ジフェニルホスフィノ)-9,9-ジメチルキサンテン(456mg)、炭酸セシウム(2.57g)を加えて3時間加熱還流した。反応混合物をセライト(商品名)で濾過し、濾液を減圧濃縮した。得られた残渣をシリカゲルカラムクロマトグラフィー(ヘキサン:酢酸エチル=80:20)によって精製することにより、以下の物性値を有する標題化合物(1.32g)を得た。
TLC:Rf 0.48(ヘキサン:酢酸エチル=3:1);
1H-NMR(CDCl3):δ 1.52, 2.58, 4.98, 6.56, 7.40。
(1R)-1-(4-アミノ-3,5-ジクロロフェニル)-2,2,2-トリフルオロエタノール
実施例29で製造した化合物(1.32g)のジクロロメタン(20mL)溶液に、氷浴下、トリフルオロ酢酸(10mL)を加え、室温で1時間撹拌した。反応混合物にトルエン(10mL)を加え、減圧濃縮させた。得られた残渣に飽和炭酸水素ナトリウム水溶液を加え、酢酸エチルで抽出した。有機層を無水硫酸マグネシウムにて乾燥後、減圧濃縮した。得られた残渣をN,N-ジメチルホルムアミド(10mL)に溶解し、N-クロロスクシンイミド(684mg)を加えた。反応混合物を40℃で18時間撹拌した。反応混合物に水を加え、酢酸エチルとヘキサン混合溶媒で抽出した。有機層を無水硫酸マグネシウムにて乾燥後、減圧濃縮した。得られた残渣をシリカゲルカラムクロマトグラフィー(ヘキサン:酢酸エチル=85:15)によって精製することにより、以下の物性値を有する標題化合物(310mg)を得た。
TLC:Rf 0.50(ヘキサン:酢酸エチル=3:1);
1H-NMR(CDCl3):δ 4.58, 4.83-4.91, 7.31。
2,6-ジクロロ-4-{(1R)-2,2,2-トリフルオロ-1-[(トリメチルシリル)オキシ]エチル}アニリン
実施例30で製造した化合物(310mg)のテトラヒドロフラン(10mL)溶液に、クロロトリメチルシラン(583μL)とイミダゾール(405mg)を加え、室温で3時間撹拌した。反応混合物に飽和塩化アンモニウム水溶液を加え、酢酸エチルで抽出した。有機層を無水硫酸マグネシウムで乾燥後、減圧濃縮した。得られた残渣をシリカゲルカラムクロマトグラフィー(ヘキサン:酢酸エチル=95:5)によって精製することにより、以下の物性値を有する標題化合物(396mg)を得た。
TLC:Rf 0.75(ヘキサン:酢酸エチル=5:1);
1H-NMR(CDCl3):δ 0.13, 4.56, 4.75, 7.26。
1-{2,6-ジクロロ-4-[(1R)-2,2,2-トリフルオロ-1-ヒドロキシエチル]フェニル}-3-{[5-(トリフルオロメチル)-2-ピリジニル]メチル}ウレア
TLC:Rf 0.21(ヘキサン:酢酸エチル=1:1);
1H-NMR (CD3OD):δ 4.58, 5.07, 7.57, 7.64, 8.11, 8.80。
1-[5-(トリフルオロメチル)-2-ピリジニル]メタンアミン塩酸塩の代わりに、相当するアミンを用い、実施例32と同様の操作を行って、以下の物性値を有する表題化合物を得た。
1-{2,6-ジクロロ-4-[(1R)-2,2,2-トリフルオロ-1-ヒドロキシエチル]フェニル}-3-{[3-(トリフルオロメチル)-1,2,4-オキサジアゾール-5-イル]メチル}ウレア
1H-NMR(DMSO-d6):δ 4.68, 5.27, 7.13, 7.25, 7.57, 8.62。
1-{2,6-ジクロロ-4-[(1R)-2,2,2-トリフルオロ-1-ヒドロキシエチル]フェニル}-3-[(5-メチル-1,2-オキサゾール-3-イル)メチル]ウレア
TLC:Rf 0.23(ヘキサン:酢酸エチル=1:2);
1H-NMR(DMSO-d6):δ 2.36, 4.24, 5.27, 6.09, 6.95, 7.17, 7.57, 8.27。
1-{2,6-ジクロロ-4-[(1R)-2,2,2-トリフルオロ-1-ヒドロキシエチル]フェニル}-3-{[2-(トリフルオロメチル)-5-ピリミジニル]メチル}ウレア
1H-NMR(DMSO-d6):δ 4.41, 5.27, 7.10-7.14, 7.58, 8.47, 8.94。
1-{2,6-ジクロロ-4-[(1R)-2,2,2-トリフルオロ-1-ヒドロキシエチル]フェニル}-3-{[5-(トリフルオロメチル)-2-ピリミジニル]メチル}ウレア
1H-NMR (CD3OD):δ 4.72, 5.06, 7.55, 9.08。
1-{2,6-ジクロロ-4-[(1R)-2,2,2-トリフルオロ-1-ヒドロキシエチル]フェニル}-3-{[6-(トリフルオロメチル)-3-ピリジニル]メチル}ウレア
TLC:Rf 0.29(ヘキサン:酢酸エチル=1:1);
1H-NMR (CD3OD):δ 4.51, 5.08, 7.57, 7.78, 8.00, 8.69。
1-{2,6-ジクロロ-4-[(1R)-2,2,2-トリフルオロ-1-ヒドロキシエチル]フェニル}-3-{[6-(2,2,2-トリフルオロエトキシ)-3-ピリジニル]メチル}ウレア
TLC:Rf 0.36(ヘキサン:酢酸エチル=1:1);
1H-NMR(DMSO-d6):δ 4.24, 4.92-5.01, 5.27, 6.92-6.97, 7.11, 7.58, 7.73, 8.10, 8.19。
1-{2,6-ジクロロ-4-[(1R)-2,2,2-トリフルオロ-1-ヒドロキシエチル]フェニル}-3-[4-(トリフルオロメチル)ベンジル]ウレア
TLC:Rf 0.55(ヘキサン:酢酸エチル=1:1);
1H-NMR(DMSO-d6):δ 4.38, 5.24-5.33, 7.02, 7.13, 7.50-7.53, 7.59, 7.69-7.72, 8.27。
1-{2,6-ジクロロ-4-[(1R)-2,2,2-トリフルオロ-1-ヒドロキシエチル]フェニル}-3-{[2-(トリフルオロメチル)-1,3-チアゾール-5-イル]メチル}ウレア
TLC:Rf 0.33(ヘキサン:酢酸エチル=1:1);
1H-NMR(DMSO-d6):δ 4.53, 5.27, 7.12, 7.18, 7.58, 7.95, 8.40。
2,6-ジクロロ-4-{(1S)-2,2,2-トリフルオロ-1-[(トリメチルシリル)オキシ]エチル}アニリン
実施例27aで製造した化合物の代わりに、実施例27bで製造した化合物を用い、実施例28→実施例29→実施例30→実施例31と同様の操作を行って、以下の物性値を有する標題化合物を得た。
TLC:Rf 0.75(ヘキサン:酢酸エチル=5:1);
1H-NMR(CDCl3):δ 0.13, 4.56, 4.75, 7.26。
1-{2,6-ジクロロ-4-[(1S)-2,2,2-トリフルオロ-1-ヒドロキシエチル]フェニル}-3-{[5-(トリフルオロメチル)-2-ピリジニル]メチル}ウレア
TLC:Rf 0.31(ヘキサン:酢酸エチル=1:1);
1H-NMR (CD3OD):δ 4.58, 5.08, 7.57, 7.64, 8.11, 8.80。
実施例31で製造した化合物の代わりに、実施例34で製造した化合物を用い、1-[5-(トリフルオロメチル)-2-ピリジニル]メタンアミン塩酸塩の代わりに、相当するアミンを用い、実施例32と同様の操作を行って、以下の物性値を有する表題化合物を得た。
1-{2,6-ジクロロ-4-[(1S)-2,2,2-トリフルオロ-1-ヒドロキシエチル]フェニル}-3-{[3-(トリフルオロメチル)-1,2,4-オキサジアゾール-5-イル]メチル}ウレア
1H-NMR(DMSO-d6):δ 4.68, 5.28, 7.14, 7.26, 7.58, 8.63。
1-{2,6-ジクロロ-4-[(1S)-2,2,2-トリフルオロ-1-ヒドロキシエチル]フェニル}-3-[(5-メチル-1,2-オキサゾール-3-イル)メチル]ウレア
TLC:Rf 0.23(ヘキサン:酢酸エチル=1:2);
1H-NMR(DMSO-d6):δ 2.36, 4.24, 5.27, 6.09, 6.95, 7.17, 7.57, 8.27。
1-{2,6-ジクロロ-4-[(1S)-2,2,2-トリフルオロ-1-ヒドロキシエチル]フェニル}-3-{[2-(トリフルオロメチル)-5-ピリミジニル]メチル}ウレア
1H-NMR(DMSO-d6):δ 4.41, 5.27, 7.10-7.14, 7.58, 8.47, 8.94。
1-{2,6-ジクロロ-4-[(1S)-2,2,2-トリフルオロ-1-ヒドロキシエチル]フェニル}-3-{[5-(トリフルオロメチル)-2-ピリミジニル]メチル}ウレア
TLC:Rf 0.48(ヘキサン:酢酸エチル=3:2);
1H-NMR (CD3OD):δ 4.72, 5.07, 7.56, 9.09。
1-{2,6-ジクロロ-4-[(1S)-2,2,2-トリフルオロ-1-ヒドロキシエチル]フェニル}-3-{[6-(トリフルオロメチル)-3-ピリジニル]メチル}ウレア
TLC:Rf 0.29(ヘキサン:酢酸エチル=1:1);
1H-NMR (CD3OD):δ 4.51, 5.08, 7.57, 7.79, 8.00, 8.69。
1-{2,6-ジクロロ-4-[(1S)-2,2,2-トリフルオロ-1-ヒドロキシエチル]フェニル}-3-{[6-(2,2,2-トリフルオロエトキシ)-3-ピリジニル]メチル}ウレア
TLC:Rf 0.38(ヘキサン:酢酸エチル=1:1);
1H-NMR(DMSO-d6):δ 4.24, 4.92-5.01, 5.27, 6.90-6.97, 7.11, 7.58, 7.73, 8.10, 8.20。
1-{2,6-ジクロロ-4-[(1S)-2,2,2-トリフルオロ-1-ヒドロキシエチル]フェニル}-3-[4-(トリフルオロメチル)ベンジル]ウレア
TLC:Rf 0.55(ヘキサン:酢酸エチル=1:1);
1H-NMR(DMSO-d6):δ 4.38, 5.24-5.31, 7.02, 7.13, 7.50-7.53, 7.59, 7.69-7.72, 8.27。
1-{2,6-ジクロロ-4-[(1S)-2,2,2-トリフルオロ-1-ヒドロキシエチル]フェニル}-3-{[2-(トリフルオロメチル)-1,3-チアゾール-5-イル]メチル}ウレア
TLC:Rf 0.33(ヘキサン:酢酸エチル=1:1);
1H-NMR(DMSO-d6):δ 4.53, 5.27, 7.12, 7.18, 7.58, 7.96, 8.39。
4-アセチル-3-フルオロフェニルトリフルオロメタンスルホナート
1-(2-フルオロ-4-ヒドロキシフェニル)エタノン(2.05g)(CAS登録番号:68301-59-7)をジクロロメタン(20mL)に懸濁させ、氷冷下、トリエチルアミン(2.04mL)とトリフルオロメタンスルホン酸無水物(2.46mL)を加えた。反応混合物を室温で30分間撹拌した後、減圧濃縮した。得られた残渣をシリカゲルカラムクロマトグラフィー(ヘキサン:酢酸エチル=100:0→90/10→70/30)によって精製することにより、以下の物性値を有する標題化合物(3.90g)を得た。
TLC:Rf 0.69(ヘキサン:酢酸エチル=3:1);
1H-NMR(CDCl3):δ 2.67, 7.13-7.21, 8.02。
3-フルオロ-4-(1,1,1-トリフルオロ-2-ヒドロキシ-2-プロパニル)フェニルトリフルオロメタンスルホナート
実施例37で製造した化合物(3.90g)のテトラヒドロフラン(13.6mL)溶液に(トリフルオロメチル)トリメチルシラン(3.88g)とテトラブチルアンモニウムフルオリド(1Mテトラヒドロフラン溶液、40μL)を加えた。反応混合物を室温で14時間撹拌した後、(トリフルオロメチル)トリメチルシラン(2.9g)加え、室温で6時間撹拌した。反応混合物を氷冷後、テトラブチルアンモニウムフルオリド(1Mテトラヒドロフラン溶液、7mL)を加え、室温で5分間撹拌した。反応混合物に1N塩酸を加えて、酢酸エチルで抽出した。有機層を無水硫酸ナトリウムで乾燥後、減圧濃縮した。得られた残渣をシリカゲルカラムクロマトグラフィー(ヘキサン:酢酸エチル=90/10→60/40)によって精製することにより、以下の物性値を有する標題化合物(2.06g)を得た。
TLC:Rf 0.26(ヘキサン:酢酸エチル=6:1);
1H-NMR(CDCl3):δ 1.90-1.92, 2.81, 7.07-7.11, 7.15-7.18, 7.82。
2-メチル-2-プロパニル[3-フルオロ-4-(1,1,1-トリフルオロ-2-ヒドロキシ-2-プロパニル)フェニル]カルバメート
実施例38で製造した化合物(1.49g)の1,4-ジオキサン(22.4mL)溶液にtert-ブチルカルバメート(735mg)、酢酸パラジウム(II)(93mg)、4,5-ビス(ジフェニルホスフィノ)-9,9-ジメチルキサンテン(363mg)、炭酸セシウム(2.04g)を加えた後,アルゴン雰囲気下、110℃で1.5時間撹拌した。反応混合物中の不溶物を濾過濾別し、濾液を濃縮した。得られた残渣をシリカゲルカラムクロマトグラフィー(ヘキサン:酢酸エチル=95/5→75/25)によって精製することにより、以下の物性値を有する標題化合物(1.12g)を得た。
TLC:Rf 0.40(ヘキサン:酢酸エチル=3:1);
1H-NMR(CDCl3):δ 1.52, 1.83, 3.10, 6.57, 6.97-7.00, 7.38-7.47。
2-(4-アミノ-2-フルオロフェニル)-1,1,1-トリフルオロ-2-プロパノール
実施例39で製造した化合物(1.12g)のジクロロメタン(22mL)溶液に、氷冷下、トリフルオロ酢酸(5mL)を加え、室温で14時間撹拌した後、減圧濃縮した。得られた残渣をシリカゲルカラムクロマトグラフィー(ヘキサン:酢酸エチル=80/20→60/40)によって精製することにより、以下の物性値を有する標題化合物(540mg)を得た。
TLC:Rf 0.25(ヘキサン:酢酸エチル=3:1);
1H-NMR(CDCl3):δ 1.79, 3.14, 3.86, 6.35-6.41, 6.44-6.48, 7.23-7.29。
2-(4-アミノ-3,5-ジクロロ-2-フルオロフェニル)-1,1,1-トリフルオロ-2-プロパノール
実施例40で製造した化合物(290mg)のN,N-ジメチルホルムアミド(5mL)溶液に、N-クロロスクシンイミド(347mg)を加えて80℃で17時間撹拌した。反応混合物に水を加え、酢酸エチルとヘキサン混合溶媒(1:1)で抽出した。有機層を無水硫酸マグネシウムで乾燥後、減圧濃縮した。得られた残渣をシリカゲルカラムクロマトグラフィー(ヘキサン:酢酸エチル=90/10)によって精製することにより、以下の物性値を有する標題化合物(219mg)を得た。
TLC:Rf 0.49(ヘキサン:酢酸エチル=5:1);
1H-NMR(CDCl3):δ 1.84, 2.82, 4.67, 7.46。
2,6-ジクロロ-3-フルオロ-4-{1,1,1-トリフルオロ-2-[(トリメチルシリル)オキシ]-2-プロパニル}アニリン
実施例41で製造した化合物(250mg)のテトラヒドロフラン(5mL)溶液に、クロロトリメチルシラン(419μL)とイミダゾール(291mg)を加えて55℃で3時間撹拌した。反応混合物に飽和塩化アンモニウム水溶液を加え、酢酸エチルで抽出した。有機層を無水硫酸マグネシウムで乾燥後、減圧濃縮した。得られた残渣をシリカゲルカラムクロマトグラフィー(ヘキサン:酢酸エチル=95/5)によって精製することにより、以下の物性値を有する標題化合物(310mg)を得た。
TLC:Rf 0.65(ヘキサン:酢酸エチル=5:1);
1H-NMR(CDCl3):δ 0.19, 1.89, 4.63, 7.45。
1-[2,6-ジクロロ-3-フルオロ-4-(1,1,1-トリフルオロ-2-ヒドロキシ-2-プロパニル)フェニル]-3-{[5-(トリフルオロメチル)-2-ピリジニル]メチル}ウレア
TLC:Rf 0.30(ヘキサン:酢酸エチル=1:1);
1H-NMR (CD3OD):δ 1.84, 4.59, 7.64, 7.85, 8.12, 8.81。
実施例4で製造した化合物の代わりに実施例42で製造した化合物を用い、1-[5-(トリフルオロメチル)-2-ピリジニル]メタンアミン塩酸塩の代わりに、相当するアミンを用い、実施例5と同様の操作を行って、以下の物性値を有する表題化合物を得た。
1-[2,6-ジクロロ-3-フルオロ-4-(1,1,1-トリフルオロ-2-ヒドロキシ-2-プロパニル)フェニル]-3-{[5-(トリフルオロメチル)-2-ピリミジニル]メチル}ウレア
TLC:Rf 0.29(ヘキサン:酢酸エチル=1:1);
1H-NMR (CD3OD):δ 1.83, 4.72, 7.83, 9.10。
1-[(5-クロロ-2-ピリジニル)メチル]-3-[2,6-ジクロロ-3-フルオロ-4-(1,1,1-トリフルオロ-2-ヒドロキシ-2-プロパニル)フェニル]ウレア
TLC:Rf 0.35(ヘキサン:酢酸エチル=1:2);
1H-NMR (CD3OD):δ 1.84, 4.49, 7.45, 7.82-7.86, 8.49。
1-[2,6-ジクロロ-3-フルオロ-4-(1,1,1-トリフルオロ-2-ヒドロキシ-2-プロパニル)フェニル]-3-{[5-(トリフルオロメチル)-1,2,4-オキサジアゾール-3-イル]メチル}ウレア
TLC:Rf 0.64(ヘキサン:酢酸エチル=1:2);
1H-NMR (CD3OD):δ 1.83, 4.63, 7.84。
4-アセチル-2-フルオロフェニルトリフルオロメタンスルホナート
1-(3-フルオロ-4-ヒドロキシフェニル)エタノン(1.0g)(CAS登録番号:403-14-5)のジクロロメタン(20mL)溶液に、氷冷下、トリエチルアミン(995μL)とトリフルオロメタンスルホン酸無水物(1.2mL)を加え、室温で1時間撹拌した。反応混合物に飽和炭酸水素ナトリウム水溶液を加え、酢酸エチルで抽出した。有機層を無水硫酸マグネシウムで乾燥後、減圧濃縮した。得られた残渣をシリカゲルカラムクロマトグラフィー(ヘキサン:酢酸エチル=90/10)によって精製することにより、以下の物性値を有する標題化合物(1.8g)を得た。
TLC:Rf 0.57(ヘキサン:酢酸エチル=3:1);
1H-NMR(CDCl3):δ 2.63, 7.46, 7.80-7.88。
2-フルオロ-4-(1,1,1-トリフルオロ-2-ヒドロキシ-2-プロパニル)フェニルトリフルオロメタンスルホナート
実施例44で製造した化合物(1.8g)と(トリフルオロメチル)トリメチルシラン(2.8mL)のテトラヒドロフラン(54mL)溶液に、氷浴下、テトラブチルアンモニウムフルオリド(1Mテトラヒドロフラン溶液、310μL)を加え、室温で2時間撹拌した。反応混合物に、氷冷下、テトラブチルアンモニウムフルオリド(1Mテトラヒドロフラン溶液、7.5mL)を加えて10分間撹拌した。反応混合物に飽和炭酸水素ナトリウム水溶液を加え、酢酸エチルで抽出した。有機層を無水硫酸マグネシウムで乾燥後、減圧濃縮した。得られた残渣をシリカゲルカラムクロマトグラフィー(ヘキサン:酢酸エチル=90/10)によって精製することにより、以下の物性値を有する標題化合物(855mg)を得た。
1H-NMR(CDCl3):δ 1.79, 2.52, 7.35-7.45, 7.56。
2-メチル-2-プロパニル[2-フルオロ-4-(1,1,1-トリフルオロ-2-ヒドロキシ-2-プロパニル)フェニル]カルバメート
実施例45で製造した化合物(855mg)の1,4-ジオキサン(12mL)溶液に、tert-ブチルカルバメート(421mg)、酢酸パラジウム(II)(54mg)、4,5-ビス(ジフェニルホスフィノ)-9,9-ジメチルキサンテン(208mg)、炭酸セシウム(1.17g)を加えてマイクロ波照射下(Biotage社製、Initiator60)、110℃で1時間反応させた。反応混合物をセライト(商品名)で濾過し、濾液を減圧濃縮した。得られた残渣をシリカゲルカラムクロマトグラフィー(ヘキサン:酢酸エチル=80/20)によって精製することにより、以下の物性値を有する標題化合物(160mg)を得た。
TLC:Rf 0.85(ヘキサン:酢酸エチル=2:1);
1H-NMR(CDCl3):δ 1.53, 1.75, 2.36, 6.74, 7.27-7.39, 8.11。
2-(4-アミノ-3-フルオロフェニル)-1,1,1-トリフルオロ-2-プロパノール
実施例46で製造した化合物(160mg)のジクロロメタン(4mL)溶液に、氷浴下、トリフルオロ酢酸(2mL)を加え、室温で1時間撹拌した。反応混合物にトルエン(2mL)を加えて減圧濃縮させた。得られた残渣をシリカゲルカラムクロマトグラフィー(ヘキサン:酢酸エチル=70/30)によって精製することにより、以下の物性値を有する標題化合物(53 mg)を得た。
TLC:Rf 0.65(ヘキサン:酢酸エチル=2:1);
1H-NMR(CD3OD):δ 1.67, 6.95, 7.20, 7.28。
2-クロロ-6-フルオロ-4-{1,1,1-トリフルオロ-2-[(トリメチルシリル)オキシ]-2-プロパニル}アニリン
実施例47で製造した化合物(53mg)のN,N-ジメチルホルムアミド(2mL)溶液に、N-クロロスクシンイミド(32mg)を加え、室温で18時間撹拌した。反応混合物に水を加え、酢酸エチルとヘキサン混合溶媒で抽出した。有機層を無水硫酸マグネシウムで乾燥後、減圧濃縮した。得られた残渣をテトラヒドロフラン(2mL)に溶解し、クロロトリメチルシラン(116μL)とイミダゾール(80mg)を加え、室温で2時間撹拌した。反応混合物に飽和塩化アンモニウム水溶液を加え、酢酸エチルで抽出した。有機層を無水硫酸マグネシウムで乾燥後、減圧濃縮した。得られた残渣をシリカゲルカラムクロマトグラフィー(ヘキサン:酢酸エチル=95/5)によって精製することにより、以下の物性値を有する標題化合物(53mg)を得た。
TLC:Rf 0.84(ヘキサン:酢酸エチル=3:1);
1H-NMR(CDCl3):δ 0.15, 1.75, 4.13, 7.13, 7.20。
1-[2-クロロ-6-フルオロ-4-(1,1,1-トリフルオロ-2-ヒドロキシ-2-プロパニル)フェニル]-3-{[5-(トリフルオロメチル)-2-ピリジニル]メチル}ウレア
TLC:Rf 0.18(ヘキサン:酢酸エチル=1:1);
1H-NMR (CD3OD):δ 1.70, 4.59, 7.38, 7.53, 7.62, 8.12, 8.82。
2-シクロヘキシル-N-[2,6-ジクロロ-4-(1,1,1-トリフルオロ-2-ヒドロキシ-2-プロパニル)フェニル]アセトアミド
TLC:Rf 0.50(ヘキサン:酢酸エチル=3:1);
1H-NMR (CD3OD):δ 1.02-1.40, 1.65-1.91, 2.31, 7.67。
シクロヘキシルアセチルクロリドの代わりに、相当する酸クロリドを用い、実施例50と同様の操作を行って、以下の物性値を有する表題化合物を得た。
N-[2,6-ジクロロ-4-(1,1,1-トリフルオロ-2-ヒドロキシ-2-プロパニル)フェニル]-2-(4-フルオロフェニル)アセトアミド
1H-NMR(DMSO-d6)δ 1.70, 3.68, 6.97, 7.12-7.18, 7.35-7.40, 7.67, 10.11。
N-[2,6-ジクロロ-4-(1,1,1-トリフルオロ-2-ヒドロキシ-2-プロパニル)フェニル]-3-(4-フルオロフェニル)プロパンアミド
LC保持時間(分)、LC条件1:0.97;
1H-NMR(DMSO-d6)δ 1.70, 2.62-2.67, 2.89-2.94, 6.96, 7.07-7.12, 7.27-7.32, 7.66, 9.87。
N-[2,6-ジクロロ-4-(1,1,1-トリフルオロ-2-ヒドロキシ-2-プロパニル)フェニル]-2-[4-(トリフルオロメチル)フェニル]アセトアミド
TLC:Rf 0.70(ヘキサン:酢酸エチル=1:1);
1H-NMR (CD3OD):δ 1.71, 3.86, 7.60-7.67。
N-[2,6-ジクロロ-4-(1,1,1-トリフルオロ-2-ヒドロキシ-2-プロパニル)フェニル]-3,3-ジメチルブタンアミド
TLC:Rf 0.18(ヘキサン:酢酸エチル=4:1);
1H-NMR(DMSO-d6):δ 1.05, 1.70, 2.22, 6.97, 7.67, 9.74。
N-[2,6-ジクロロ-4-(1,1,1-トリフルオロ-2-ヒドロキシ-2-プロパニル)フェニル]-3-[4-(トリフルオロメチル)フェニル]プロパンアミド
TLC:Rf 0.50(ヘキサン:酢酸エチル=1:1);
1H-NMR(DMSO-d6):δ 1.68, 2.70, 3.01, 6.94, 7.48, 7.62-7.65, 9.89。
N-[2,6-ジクロロ-4-(1,1,1-トリフルオロ-2-ヒドロキシ-2-プロパニル)フェニル]-3-[3-(トリフルオロメチル)フェニル]プロパンアミド
LC保持時間(分)、LC条件2: 1.03;
1H-NMR(DMSO-d6):δ 1.69, 2.72, 3.02, 6.94, 7.50-7.65, 9.87。
N-[2,6-ジクロロ-4-(1,1,1-トリフルオロ-2-ヒドロキシ-2-プロパニル)フェニル]-3-[2-(トリフルオロメチル)フェニル]プロパンアミド
LC保持時間(分)、LC条件2:1.03;
1H-NMR(DMSO-d6):δ 1.70, 2.67-2.71, 3.06-3.11, 6.95, 7.42, 7.54-7.70, 9.94。
2-(4-ブロモ-3-メチルフェニル)-1,1,1-トリフルオロ-2-プロパノール
1-(4-ブロモ-3-メチルフェニル)エタノン(4.0g)(CAS登録番号:37074-40-1)のテトラヒドロフラン(40mL)溶液に、氷冷下、(トリフルオロメチル)トリメチルシラン(8.3mL)、テトラブチルアンモニウムフルオリド(1Mテトラヒドロフラン溶液、0.9mL)を加え、室温で1時間撹拌した。反応混合物に、氷冷下、テトラブチルアンモニウムフルオリド(1Mテトラヒドロフラン溶液、22.5mL)を加えた後、飽和塩化アンモニウム水溶液を加え、酢酸エチルで抽出した。有機層を飽和食塩水で洗浄し、硫酸ナトリウムで乾燥後、減圧濃縮した。得られた残渣をシリカゲルカラムクロマトグラフィー(ヘキサン:酢酸エチル=95:5→85:15)によって精製することにより、以下の物性値を有する標題化合物(5.3g)を得た。
TLC:Rf 0.51(ヘキサン:酢酸エチル=5:1);
1H-NMR(CDCl3):δ 1.76, 2.43, 2.48, 7.23-7.26, 7.45, 7.54。
2-メチル-2-プロパニル[2-メチル-4-(1,1,1-トリフルオロ-2-ヒドロキシ-2-プロパニル)フェニル]カルバメート
実施例51で製造した化合物(4.5g)の1,4-ジオキサン(80mL)溶液に、4,5-ビス(ジフェニルホスフィノ)-9,9-ジメチルキサンテン(1.4g)、酢酸パラジウム(II)(360mg)、tert-ブチルカルバメート(2.4g)、炭酸セシウム(7.8g)を加え、1.5時間加熱還流した。反応混合物を酢酸エチルで希釈し、不溶物をセライト(商品名)で濾過濾別後、濾液を減圧濃縮した。得られた残渣をシリカゲルカラムクロマトグラフィー(ヘキサン:酢酸エチル=90:10→80:20→60:40)によって精製することにより、以下の物性値を有する標題化合物(1.7g)を得た。
TLC:Rf 0.49(ヘキサン:酢酸エチル=2:1);
1H-NMR(CDCl3):δ 1.53, 1.75, 2.28, 2.67, 6.32, 7.36-7.39, 7.85-7.89。
2-(4-アミノ-3-メチルフェニル)-1,1,1-トリフルオロ-2-プロパノール
実施例52で製造した化合物(1.7g)のジクロロメタン(20mL)溶液に、氷冷下、トリフルオロ酢酸(12mL)加え、室温で1時間撹拌した。反応混合物にトルエンを加え、減圧濃縮した。得られた残渣に飽和炭酸水素ナトリウム水溶液を加え、酢酸エチルで抽出した。有機層を無水硫酸ナトリウムで乾燥後、減圧濃縮することで、以下の物性値を有する標題化合物(743mg)を得た。
TLC:Rf 0.54(ヘキサン:酢酸エチル=1:1);
1H-NMR(CDCl3):δ 1.73, 2.18, 2.27, 3.66, 6.67, 7.20-7.26。
2-メチル-4-{1,1,1-トリフルオロ-2-[(トリメチルシリル)オキシ]-2-プロパニル}アニリン
実施例53で製造した化合物(743mg)のテトラヒドロフラン(15mL)溶液にイミダゾール(1.15g)とクロロトリメチルシラン(1.93mL)を加え、室温で1時間撹拌した。反応混合物に飽和塩化アンモニウム水溶液を加え、酢酸エチルで抽出した。有機層を無水硫酸ナトリウムで乾燥後、減圧濃縮することで、以下の物性値を有する標題化合物(990mg)を得た。
TLC:Rf 0.55(ヘキサン:酢酸エチル=2:1);
1H-NMR(CDCl3):δ 0.11, 1.76, 2.17, 3.64, 6.62-6.65, 7.18。
2-クロロ―6-メチル-4-{1,1,1-トリフルオロ-2-[(トリメチルシリル)オキシ]-2-プロパニル}アニリン
実施例54で製造した化合物(960mg)のN,N-ジメチルホルムアミド(8mL)溶液に、N-クロロスクシンイミド(439mg)を加え、室温で6時間撹拌した。反応混合物に飽和炭酸水素ナトリウム水溶液を加え、酢酸エチルで抽出した。有機層を飽和食塩水で洗浄し、無水硫酸ナトリウムで乾燥後、減圧濃縮した。得られた残渣をシリカゲルカラムクロマトグラフィー(ヘキサン:酢酸エチル=100:0→98:2)によって精製することにより、以下の物性値を有する標題化合物(619mg)を得た。
TLC:Rf 0.47(ヘキサン:酢酸エチル=8:1);
1H-NMR(CDCl3):δ 0.14, 1.75, 2.22, 4.07, 7.11, 7.30。
1-[2-クロロ-6-メチル-4-(1,1,1-トリフルオロ-2-ヒドロキシ-2-プロパニル)フェニル]-3-{[5-(トリフルオロメチル)-2-ピリミジニル]メチル}ウレア
TLC:Rf 0.47(ヘキサン:酢酸エチル=1:2);
1H-NMR(CDCl3):δ 1.78, 2.43, 2.56, 4.80, 5.57, 6.21, 7.43, 7.57, 8.93。
1-[5-(トリフルオロメチル)-2-ピリジニル]メタンアミン塩酸塩の代わりに、相当するアミンを用い、実施例56と同様の操作を行って、以下の物性値を有する表題化合物を得た。
1-[2-クロロ-6-メチル-4-(1,1,1-トリフルオロ-2-ヒドロキシ-2-プロパニル)フェニル]-3-{[5-(トリフルオロメチル)-2-ピリジニル]メチル}ウレア
TLC:Rf 0.40(ヘキサン:酢酸エチル=1:2);
1H-NMR(CDCl3):δ 1.76, 2.38, 2.59, 4.62, 5.55, 6.20, 7.39, 7.47, 7.55, 7.91, 8.75。
1-[2-クロロ-6-メチル-4-(1,1,1-トリフルオロ-2-ヒドロキシ-2-プロパニル)フェニル]-3-{[6-(トリフルオロメチル)-3-ピリジニル]メチル}ウレア
TLC:Rf 0.36(ヘキサン:酢酸エチル=1:2);
1H-NMR(CDCl3):δ 1.76, 2.37, 2.53, 4.54, 4.89, 5.97, 7.40, 7.56, 7.66, 7.86-7.88, 8.64。
1-[2-クロロ-6-メチル-4-(1,1,1-トリフルオロ-2-ヒドロキシ-2-プロパニル)フェニル]-3-[(5-クロロ-2-ピリジニル)メチル]ウレア
TLC:Rf 0.49(ヘキサン:酢酸エチル=1:2);
1H-NMR(CDCl3):δ 1.76, 2.36, 2.50, 4.52, 5,45, 7.30, 7.38, 7.53, 7.65, 8.45。
2,2,2-トリフルオロ-1-(3-メチル-4-ニトロフェニル)エタノール
3-メチル-4-ニトロベンズアルデヒド(2.5g)(CAS登録番号:18515-67-8)のテトラヒドロフラン(40mL)溶液に、氷冷下、(トリフルオロメチル)トリメチルシラン(6.7mL)とテトラブチルアンモニウムフルオリド(1Mテトラヒドロフラン溶液、0.76mL)を加え、室温で30分間撹拌した。氷冷下、テトラブチルアンモニウムフルオリド(1Mテトラヒドロフラン溶液、18mL)を加え、室温にて30分間撹拌した。反応混合物に飽和塩化アンモニウム水溶液を加え、酢酸エチルで抽出した。有機層を飽和食塩水で洗浄し、無水硫酸ナトリウムで乾燥後、減圧濃縮した。得られた残渣をシリカゲルカラムクロマトグラフィー(ヘキサン:酢酸エチル=90:10→82:18→50:50)によって精製することにより、以下の物性値を有する標題化合物(2.0g)を得た。
TLC:Rf 0.50(ヘキサン:酢酸エチル=2:1);
1H-NMR(CDCl3):δ 2.64, 2.89, 5.06-5.14, 7.46-7.49, 7.99-8.02。
1-(4-アミノ-3-メチルフェニル)-2,2,2-トリフルオロエタノール
実施例57で製造した化合物(1.95g)のエタノール(90mL)溶液に、5%パラジウム/炭素(50%含水品、325mg)を加え、水素雰囲気下1.5時間撹拌した。反応混合物を酢酸エチルで希釈し、セライト(商品名)で濾過後、濾液を減圧濃縮した。得られた残渣をシリカゲルカラムクロマトグラフィー(ヘキサン:酢酸エチル=80:20→67:33→0:100)によって精製することにより、以下の物性値を有する標題化合物(1.50g)を得た。
TLC:Rf 0.34(ヘキサン:酢酸エチル=2:1);
1H-NMR(CDCl3):δ 2.18, 2.37, 3.72, 4.83-4.92, 6.68, 7.11-7.15。
4-(1-{[ジメチル(2-メチル-2-プロパニル)シリル]オキシ}-2,2,2-トリフルオロエチル)-2-メチルアニリン
実施例58で製造した化合物(1.50g)のN,N-ジメチルホルムアミド(30mL)溶液に、イミダゾール(2.50g)とクロロ(ジメチル)(2-メチル-2-プロパニル)シラン(4.94g)を加え、室温で2.5時間撹拌した後、50℃で1時間撹拌した。反応混合物に水を加え、酢酸エチルで抽出した。有機層を飽和食塩水で洗浄し、無水硫酸マグネシウムで乾燥後、減圧濃縮した。得られた残渣をシリカゲルカラムクロマトグラフィー(ヘキサン:酢酸エチル=95:5→90:10)によって精製することにより、以下の物性値を有する標題化合物(507mg)を得た。
TLC:Rf 0.63(ヘキサン:酢酸エチル=2:1);
1H-NMR(CDCl3):δ 0.11, 0.89, 2.17, 3.66, 4.75-4.81, 6.63-6.66, 7.09。
1-[2-メチル-4-(2,2,2-トリフルオロ-1-ヒドロキシエチル)フェニル]-3-{[5-(トリフルオロメチル)-2-ピリジニル]メチル}ウレア
TLC:Rf 0.46(ヘキサン:酢酸エチル=1:2);
1H-NMR(DMSO-d6):δ 2.22, 4.51, 4.95-5.05, 6.66, 7.18, 7.24, 7.30, 7.58, 7.83, 8.02, 8.21, 8.92。
2-クロロ-4-(1-{[ジメチル(2-メチル-2-プロパニル)シリル]オキシ}-2,2,2-トリフルオロエチル)-6-メチルアニリン
実施例59で製造した化合物(470mg)のアセトニトリル(20mL)溶液に、1,3-ジクロロ-5,5-ジメチルヒダントイン(290mg)を加え、室温で40分間撹拌した。反応混合物に飽和塩化アンモニウム水溶液を加え、酢酸エチルで抽出した。有機層を飽和食塩水で洗浄し、無水硫酸マグネシウムで乾燥後、減圧濃縮した。得られた残渣をシリカゲルカラムクロマトグラフィー(ヘキサン:酢酸エチル=95:5→90:10)によって精製することにより、以下の物性値を有する標題化合物(435mg)を得た。
TLC:Rf 0.58(ヘキサン:酢酸エチル=8:1);
1H-NMR(CDCl3):δ 0.12, 0.91, 2.23, 4.11, 4.73-4.80, 7.04, 7.24。
1-[2-クロロ-6-メチル-4-(2,2,2-トリフルオロ-1-ヒドロキシエチル)フェニル]-3-{[5-(トリフルオロメチル)-2-ピリジニル]メチル}ウレア
TLC:Rf 0.44(ヘキサン:酢酸エチル=1:2);
1H-NMR(DMSO-d6):δ 2.23, 4.47, 5.11-5.20, 6.92, 7.03, 7.30, 7.41, 7.57, 8.13, 8.23, 8.89。
実施例59で製造した化合物の代わりに、実施例61で製造した化合物を用い、1-[5-(トリフルオロメチル)-2-ピリジニル]メタンアミン塩酸塩の代わりに、相当するアミンを用い、実施例60と同様の操作を行うことで、以下の物性値を有する表題化合物を得た。
1-[2-クロロ-6-メチル-4-(2,2,2-トリフルオロ-1-ヒドロキシエチル)フェニル]-3-{[5-(トリフルオロメチル)-2-ピリミジニル]メチル}ウレア
TLC:Rf 0.48(ヘキサン:酢酸エチル=1:2);
1H-NMR(DMSO-d6):δ 2.22, 4.59, 5.10-5.19, 6.90-6.97, 7.29, 7.40, 8.18, 9.24。
1-[2-クロロ-6-メチル-4-(2,2,2-トリフルオロ-1-ヒドロキシエチル)フェニル]-3-{[6-(トリフルオロメチル)-3-ピリジニル]メチル}ウレア
TLC:Rf 0.56(ヘキサン:酢酸エチル=1:2);
1H-NMR(DMSO-d6):δ 2.21, 4.40, 5.11-5.20, 6.92, 6.98, 7.30, 7.41, 7.87-7.97, 8.04, 8.67。
1-[2-クロロ-6-メチル-4-(2,2,2-トリフルオロ-1-ヒドロキシエチル)フェニル]-3-[(5-クロロ-2-ピリジニル)メチル]ウレア
TLC:Rf 0.33(ヘキサン:酢酸エチル=1:2);
1H-NMR(DMSO-d6):δ 2.22, 4.36, 5.11-5.19, 6.90-6.97, 7.30-7.40, 7.93, 8.07, 8.55。
2-[4-(ジベンジルアミノ)フェニル]-4,4,4-トリフルオロ-2-ブタノール
N,N-ジベンジル-4-ブロモアニリン(300mg)(CAS登録番号:65145-14-4)のテトラヒドロフラン(4mL)溶液に、-78℃でn-ブチルリチウム(1.64Mヘキサン溶液、0.78mL)を滴下した。反応混合物を-78℃で10分間撹拌した後、4,4,4-トリフルオロ-2-ブタノン(214mg)を加え、室温で1時間撹拌した。反応混合物に飽和塩化アンモニウム水溶液を加え、酢酸エチルで抽出した。有機層を無水硫酸マグネシウムで乾燥後、減圧濃縮した。得られた残渣をシリカゲルカラムクロマトグラフィー(ヘキサン:酢酸エチル=85:15)によって精製することにより、以下の物性値を有する標題化合物(100mg)を得た。
TLC:Rf 0.50(ヘキサン:酢酸エチル=5:1);
1H-NMR(CDCl3):δ 1.67, 2.51-2.67, 4.65,6.68-6.73, 7.22-7.38。
2-(4-アミノフェニル)-4,4,4-トリフルオロ-2-ブタノール
実施例63で製造した化合物(100mg)のメタノール(2mL)と酢酸エチル(2mL)の混合溶媒に5%パラジウム/炭素(50%含水品、10mg)を加えた。反応混合物を水素雰囲気下、室温で2時間撹拌した。反応混合物をセライト(商品名)で濾過し、濾液を濃縮することで標題化合物を得た。
TLC:Rf 0.15(ヘキサン:酢酸エチル=3:1);
1H-NMR (CD3OD):δ 1.60, 2.56-2.70, 6.83-6.86, 7.31-7.34。
4-{4,4,4-トリフルオロ-2-[(トリメチルシリル)オキシ]-2-ブタニル}アニリン
実施例64で製造した化合物(54mg)のテトラヒドロフラン(5mL)溶液に、クロロトリメチルシラン(120μL)とイミダゾール(83mg)を加え、室温で17時間撹拌した。反応混合物に飽和塩化アンモニウム水溶液を加え、酢酸エチルで抽出した。有機層を無水硫酸マグネシウムで乾燥後、減圧濃縮した。得られた残渣をシリカゲルカラムクロマトグラフィー(ヘキサン:酢酸エチル=85:15)によって精製することにより、以下の物性値を有する標題化合物(31mg)を得た。
TLC:Rf 0.61(ヘキサン:酢酸エチル=2:1);
1H-NMR(CDCl3):δ 0.04, 1.74, 2.38-2.60, 3.65, 6.63-6.66,7.18-7.21。
2,6-ジクロロ-4-{4,4,4-トリフルオロ-2-[(トリメチルシリル)オキシ]-2-ブタニル}アニリン
実施例65で製造した化合物(31mg)のN,N-ジメチルホルムアミド(2mL)溶液に、N-クロロスクシンイミド(31mg)を加え、40℃で20時間撹拌した。反応混合物に水を加え、酢酸エチルで抽出した。有機層を無水硫酸マグネシウムで乾燥後、減圧濃縮した。得られた残渣をシリカゲルカラムクロマトグラフィー(ヘキサン:酢酸エチル=95:5)によって精製することにより、以下の物性値を有する標題化合物(21mg)を得た。
TLC:Rf 0.80(ヘキサン:酢酸エチル=5:1);
1H-NMR(CDCl3):0.09, 1.71, 2.37-2.56, 4.42, 7.22。
1-[2,6-ジクロロ-4-(4,4,4-トリフルオロ-2-ヒドロキシ-2-ブタニル)フェニル]-3-{[5-(トリフルオロメチル)-2-ピリジニル]メチル}ウレア
TLC:Rf 0.35(ヘキサン:酢酸エチル=1:2);
1H-NMR(CDCl3):δ 1.69, 2.42, 2.56-2.68, 4.62, 5.81, 6.62, 7.47, 7.49, 7.91, 8.76。
1-ニトロ-4-(1,1,1-トリフルオロ-2-メトキシ-2-プロパニル)ベンゼン
実施例1で製造した化合物(1.49g)のN,N-ジメチルホルムアミド(13mL)溶液に氷冷下、水素化ナトリウム(60%in oil、278mg)を加え、室温で15分間撹拌した。反応混合物に氷冷下、ヨウ化メチル(987mg)を加えて、室温で1時間撹拌した。反応混合物に氷冷下、飽和塩化アンモニウム水溶液と水を加えて、酢酸エチルで抽出した。有機層を水、飽和食塩水で順次洗浄し、無水硫酸マグネシウムで乾燥後、減圧濃縮した。得られた残渣をシリカゲルカラムクロマトグラフィー(ヘキサン:酢酸エチル=100:0→80:20)によって精製することにより、以下の物性を有する標題化合物(1.55g)を得た。
TLC:Rf 0.69(ヘキサン:酢酸エチル=4:1);
1H-NMR(CDCl3):δ 1.83, 3.29, 7.70-7.73,8.25-8.28。
4-(1,1,1-トリフルオロ-2-メトキシ-2-プロパニル)アニリン
実施例68で製造した化合物(1.55g)のメタノール(21mL)溶液に5%パラジウム/炭素(50%含水品,155mg)を加え、水素雰囲気下、室温で2時間撹拌した。反応混合物をセライト(商品名)で濾過後、濾液を濃縮することにより、以下の物性値を有する標題化合物(1.35g)を得た。
TLC:Rf 0.33(ヘキサン:酢酸エチル=4:1);
1H-NMR(CDCl3):δ 1.72, 3.19, 3.75, 6.67-6.70,7.27-7.29。
2,6-ジクロロ-4-(1,1,1-トリフルオロ-2-メトキシ-2-プロパニル)アニリン
実施例69で製造した化合物(1.35g)のアセトニトリル(25mL)溶液に、氷冷下、1,3-ジクロロ-5,5-ジメチルヒダントイン(1.21g)を加え、室温で1時間撹拌後、45℃で3時間撹拌した。反応混合物に氷冷下、亜硫酸ナトリウム水溶液を加えた。反応混合物を室温で30分間撹拌後、酢酸エチルで抽出した。有機層を亜硫酸ナトリウム水溶液、水、飽和食塩水で順次洗浄し、無水硫酸マグネシウムで乾燥後、減圧濃縮した。得られた残渣をシリカゲルカラムクロマトグラフィー(ヘキサン:酢酸エチル=100:0→80:20)によって精製することにより、以下の物性を有する標題化合物(1.74g)を得た。
TLC:Rf 0.62(ヘキサン:酢酸エチル=4:1);
1H-NMR(CDCl3):δ 1.70, 3.22, 4.56, 7.31。
1-[2,6-ジクロロ-4-(1,1,1-トリフルオロ-2-メトキシ-2-プロパニル)フェニル]-3-{[5-(トリフルオロメチル)-2-ピリジニル]メチル}ウレア
TLC:Rf 0.32(ヘキサン:酢酸エチル=1:1);
1H-NMR(DMSO-d6):δ 1.78, 3.19, 4.46, 7.15, 7.54-7.62, 8.23, 8.48, 8.88。
{[1,1-ジフルオロ-2-(4-ニトロフェニル)-2-プロパニル]オキシ}(トリメチル)シラン
1-(4-ニトロフェニル)エタノン(CAS登録番号:100-19-6)(1.00g)のN,N-ジメチルホルムアミド(15mL)溶液にフッ化セシウム(183mg)を加えた後、氷冷下、(ジフルオロメチル)(トリメチル)シラン(CAS登録番号:65864-64-4)(2.26g)を加えた。反応混合物を、氷冷下、1時間撹拌後、室温で2時間撹拌後、45℃で2時間撹拌した。反応混合物に水を加え、酢酸エチルとヘキサンの混合溶媒で抽出した。有機層を水、飽和食塩水で順次洗浄し、無水硫酸ナトリウムで乾燥後、減圧濃縮した。得られた残渣をシリカゲルカラムクロマトグラフィー(ヘキサン:酢酸エチル=100/0→95/5→65/35→40/60)によって精製することにより、以下の物性値を有する標題化合物(454mg)を得た。
1H-NMR(CDCl3):δ 0.17, 1.76, 5.58, 7.66-7.69, 8.21-8.26。
4-{1,1-ジフルオロ-2-[(トリメチルシリル)オキシ]-2-プロパニル}アニリン
実施例72で製造した化合物(237mg)のメタノール(4.1mL)溶液に、5%パラジウム/炭素(エヌイーケムキャット社製,含水品,KERタイプ)(20mg)を加え、水素雰囲気下、室温で2時間撹拌した。反応混合物をセライト(商品名)で濾過し、濾液を減圧濃縮することにより、以下の物性値を有する標題化合物(203mg)を得た。
TLC:Rf 0.26(ヘキサン:酢酸エチル=4:1);
1H-NMR(CDCl3):δ 0.08, 1.65, 3.68, 5.51, 6.64-6.69, 7.22-7.25。
2,6-ジクロロ-4-{1,1-ジフルオロ-2-[(トリメチルシリル)オキシ]-2-プロパニル}アニリン
実施例73で得られた化合物(203mg)のN,N-ジメチルホルムアミド(5.2mL)溶液に、N-クロロスクシンイミド(209mg)を加え、35℃で1時間撹拌後、45℃で終夜撹拌した。反応混合物を酢酸エチルとヘキサンの混合溶媒で希釈した後、水、飽和食塩水で順次洗浄し、無水硫酸ナトリウムで乾燥後、減圧濃縮した。得られた残渣のテトラヒドロフラン(5.2mL)溶液に、イミダゾール(106mg)、クロロトリメチルシラン(0.20mL)を加え、室温で2時間撹拌した。反応混合物に水を加え、酢酸エチルで抽出した。有機層を水、飽和食塩水で順次洗浄し、無水硫酸ナトリウムで乾燥後、減圧濃縮した。得られた残渣をシリカゲルカラムクロマトグラフィー(ヘキサン:酢酸エチル=100/0→95/5→90/10)によって精製することにより、以下の物性値を有する標題化合物(238mg)を得た。
TLC:Rf 0.76(ヘキサン:酢酸エチル=4:1);
1H-NMR(CDCl3):δ 0.13, 1.63, 4.47, 5.47, 7.26。
1-[2,6-ジクロロ-4-(1,1-ジフルオロ-2-ヒドロキシ-2-プロパニル)フェニル]-3-{[5-(トリフルオロメチル)-2-ピリジニル]メチル}ウレア
実施例4で製造した化合物の代わりに、実施例74で製造した化合物を用い、実施例5と同様の操作を行って、以下の物性値を有する表題化合物を得た。
TLC:Rf 0.35(ヘキサン:酢酸エチル=1:2);
1H-NMR(DMSO-d6):δ 1.50, 4.47, 6.02, 7.10, 7.57-7.59, 8.22-8.26, 8.39, 8.89。
1-(4-アミノ-3,5-ジクロロフェニル)-2,2,2-トリフルオロエタノン
1-(4-アミノフェニル)-2,2,2-トリフルオロエタノン(CAS登録番号:23516-79-2)(2.60g)のN,N-ジメチルホルムアミド(30mL)溶液に、N-クロロスクシンイミド(3.70g)を加え、40℃で18時間撹拌した。反応混合物に飽和炭酸水素ナトリウム水溶液を加え、酢酸エチルで抽出した。有機層を飽和食塩水で洗浄し、無水硫酸マグネシウムで乾燥後、減圧濃縮した。得られた残渣をシリカゲルカラムクロマトグラフィー(ヘキサン:酢酸エチル=95/5)によって精製することにより、以下の物性値を有する標題化合物(3.20g)を得た。
TLC:Rf 0.55(ヘキサン:酢酸エチル=5:1);
1H-NMR(CDCl3):δ 5.26, 7.94。
1-(4-アミノ-3,5-ジクロロフェニル)-2,2,2-トリフルオロエタノール
実施例76で製造した化合物(1.00g)のメタノール(10mL)溶液に、氷冷下、水素化ホウ素ナトリウム(146mg)を加え、室温で1時間撹拌した。反応混合物に飽和塩化アンモニウム水溶液を加え、酢酸エチルで抽出した。有機層を飽和食塩水で洗浄し、無水硫酸マグネシウムで乾燥後、減圧濃縮することにより、以下の物性値を有する標題化合物(975mg)を得た。
1H-NMR(CDCl3):δ 4.58, 4.83-4.91, 7.31。
4-(1-アジド-2,2,2-トリフルオロエチル)-2,6-ジクロロアニリン
実施例77で製造した化合物(314mg)のトルエン(10mL)溶液に、2,3,4,6,7,8,9,10-オクタヒドロピリミド[1,2-a]アゼピン(CAS登録番号:41015-70-7)(0.22mL)とジフェニルホスホラジダート(CAS登録番号 26386-88-9)(0.33mL)を加え、45℃で3時間撹拌した。反応混合物に飽和炭酸水素ナトリウム水溶液を加え、酢酸エチルで抽出した。有機層を飽和食塩水で洗浄し、無水硫酸マグネシウムで乾燥後、減圧濃縮した。得られた残渣をシリカゲルカラムクロマトグラフィー(ヘキサン:酢酸エチル=95/5)によって精製することにより、以下の物性値を有する標題化合物(314mg)を得た。
TLC:Rf 0.70(ヘキサン:酢酸エチル=5:1);
1H-NMR(CDCl3):δ 4.65, 4.75, 7.26。
1-[4-(1-アミノ-2,2,2-トリフルオロエチル)-2,6-ジクロロフェニル]-3-{[6-(トリフルオロメチル)-3-ピリジニル]メチル}ウレア
LC保持時間(分)、LC条件3:0.72;
1H-NMR(DMSO-d6):δ 4.41, 5.34-5.46, 7.18, 7.75, 7.88-7.97, 8.52, 8.68。
1-[6-(トリフルオロメチル)-3-ピリジニル]メタンアミンの代わりに、実施例10で製造したアミンもしくは相当するアミンを用い、実施例79と同様の操作を行って、以下の物性値を示す本発明品を得た。
1-[4-(1-アミノ-2,2,2-トリフルオロエチル)-2,6-ジクロロフェニル]-3-{[5-(トリフルオロメチル)-2-ピリジニル]メチル}ウレア
TLC:Rf 0.50(ヘキサン:酢酸エチル=1:2);
1H-NMR(CD3OD):δ 4.61, 5.37-5.45, 7.63-7.66, 7.69, 8.11-8.14, 8.83。
1-[4-(1-アミノ-2,2,2-トリフルオロエチル)-2,6-ジクロロフェニル]-3-[(5-クロロ-2-ピリジニル)メチル]ウレア
LC保持時間(分)、LC条件3:0.66;
1H-NMR(DMSO-d6):δ 4.38, 5.42-5.50, 7.14, 7.39, 7.75, 7.94, 8.54-8.56。
1-[4-(1-アミノ-2,2,2-トリフルオロエチル)-2,6-ジクロロフェニル]-3-(4-フルオロベンジル)ウレア
LC保持時間(分)、LC条件3:0.74;
1H-NMR(DMSO-d6):δ 4.26, 5.30-5.40, 6.98, 7.12-7.18, 7.30-7.35, 7.73, 8.29。
1-[4-(1-アミノ-2,2,2-トリフルオロエチル)-2,6-ジクロロフェニル]-3-{[2-(トリフルオロメチル)-1,3-チアゾール-5-イル]メチル}ウレア
LC保持時間(分)、LC条件3:0.74;
1H-NMR(DMSO-d6):δ 4.54, 5.28-5.40, 7.28, 7.74, 7.97, 8.55。
1-[4-(1,1,1-トリフルオロ-2-ヒドロキシ-2-プロパニル)フェニル]-3-{[5-(トリフルオロメチル)-2-ピリジニル]メチル}ウレア
TLC:Rf 0.25(ヘキサン:酢酸エチル=1:1);
1H-NMR(DMSO-d6):δ 1.63, 4.49, 6.42, 6.86, 7.41, 7.57, 8.18, 8.90。
N-(2-ブロモ-4,6-ジクロロフェニル)-2-(4-フルオロフェニル)アセタミド(特許文献1 実施例1g)
TLC:Rf 0.43(ヘキサン:酢酸エチル=1:1);
1H-NMR(CD3OD):δ 3.72, 7.02-7.08, 7.38-7.43, 7.58, 7.69。
ヒトKCNQ2/3の発現細胞(CHO-DHFR-細胞)を384穴プレート(コラーゲンコート、黒、クリアボトム)1穴あたり0.5×104個/50μLずつ播種し、MEM ALPHA培地(10vol%非働化(56℃、30min)済みFetal Bovine Serum及び100IU/mL Penicillin-100μg/mL Streptomycin-2mM L-Glutamine含有)を用いて、37℃にて5%CO2下で18~24時間培養した。プレート内の培地を除去した後、ローディングバッファー(FluxOR Thallium Detection Kit(invitrogen、F10016、F10017)のマニュアルに記載された方法で調製)中でインキュベーション(室温、60分、遮光)した。FLIPR TETRA(Molecular Devices)で脱分極刺激(5mMカリウム及び0.5mMタリウム)によるKCNQ2/3チャネル開口作用(細胞内タリウム流入)を測定した。本発明化合物は脱分極刺激5分前に処置し、脱分極刺激で誘発される反応を180秒間経時的に測定した。本発明化合物のチャネル開口作用は、脱分極刺激前から180秒後までの蛍光強度変化量で評価し、本実験条件下におけるレチガビンの最大反応(10μM処置時)の蛍光強度変化の50%を満たす濃度(ECrtg50)を算出した。
また、上記方法においてヒトKCNQ2/3の発現細胞の代わりに、ヒトKCNQ4またはヒトKCNQ5の発現細胞を使用し、当業者の通常の知識に基づいて上記条件を適宜変更することで、ヒトKCNQ4チャネルまたはヒトKCNQ5チャネルに対する開口作用を測定することができる。
ペントバルビタール(ソムノペンチル,シェーリング・プラウ アニマルヘルス社)を雌性Jcl:Wistarラット(日本クレア、使用時体重:170~200g)に約40mg/kgを腹腔内投与することで麻酔を施し、放血致死させた。腹部を切開して膀胱を摘出し、直ちに混合ガス(95%O2,5%CO2)で飽和させた氷冷Krebs buffer(炭酸水素ナトリウム(終濃度:15mM)及び塩化カルシウム(終濃度:2.5mM)を添加したKrebs Ringer bicarbonate buffer(Sigma-Aldlich Co.))に浸した。
検量線溶液は、被験物質(10mM DMSO溶液)をアセトニトリルで希釈し、内標準物質(カンデサルタン)を含むアセトニトリルを添加して0.1、0.4及び2μMに調製した。
被験化合物(10mmol/L DMSO溶液、5μL)を50%アセトニトリル水溶液(195μL)で希釈し、0.25mmol/L溶液を作製した。
ヒト ether-a-go-go-related gene(hERG)を過剰発現したHEK293細胞を用いて、脱分極パルスに続く再分極パルスによって誘導されるhERG IKr電流の最大テール電流をパッチクランプ法で測定し、被験物質適用前の最大テール電流に対する被験物質適用10分後の変化率(抑制率)を算出した(バイオフィジカル・ジャーナル、74巻、230-241頁(1998年)参照)。その結果を表5に示す。表5から明らかであるように、表5に例示された化合物に代表される本発明化合物は、hERGチャネルの50%阻害活性が>10μMであり、薬物によるQT延長を誘発する可能性が低い、安全性に優れた化合物であることが分かった。
本発明に用いられる代表的な製剤例を以下に示す。
以下の各成分を常法により混合した後打錠して、一錠中に10mgの活性成分を含有する錠剤1万錠を得た。
・1-{2,6-ジクロロ-4-[(2R)-1,1,1-トリフルオロ-2-ヒドロキシ-2-プロパニル]フェニル}-3-{[5-(トリフルオロメチル)-2-ピリジニル]メチル}ウレア(100g);
・カルボキシメチルセルロースカルシウム(崩壊剤)(20g);
・ステアリン酸マグネシウム(潤滑剤)(10g);
・微結晶セルロース(870g)。
以下の各成分を常法により混合した後、除塵フィルターでろ過し、5mlずつアンプルに充填し、オートクレーブで加熱滅菌して、1アンプル中20mgの活性成分を含有するアンプル1万本を得た。
・1-{2,6-ジクロロ-4-[(2R)-1,1,1-トリフルオロ-2-ヒドロキシ-2-プロパニル]フェニル}-3-{[5-(トリフルオロメチル)-2-ピリジニル]メチル}ウレア(200g);
・マンニトール(2kg);
・蒸留水(50L)。
Claims (19)
- 一般式(I)
- Yが-NH-または結合手である、請求項1に記載の化合物、その塩、その溶媒和物またはその共結晶。
- X1がC-R6であり、X2がC-R7である、請求項1または請求項2に記載の化合物、その塩、その溶媒和物またはその共結晶。
- R1が水素原子である、請求項1~4いずれか1項に記載の化合物、その塩、その溶媒和物またはその共結晶。
- R2およびR3の一方がハロゲンで置換されていてもよいメチル基であり、他方が水素原子またはハロゲンで置換されていてもよいメチル基である、請求項1~5いずれか1項に記載の化合物、その塩、その溶媒和物またはその共結晶。
- R6が水素原子またはハロゲンであり、R7が水素原子である、請求項1~6いずれか1項に記載の化合物、その塩、その溶媒和物またはその共結晶。
- R4およびR5がそれぞれ独立してハロゲンまたはメチル基である、請求項1~9いずれか1項に記載の化合物、その塩、その溶媒和物またはその共結晶。
- R8が水素原子またはメチル基である、請求項1~10いずれか1項に記載の化合物、その塩、その溶媒和物またはその共結晶。
- 化合物が、(1)1-{2,6-ジクロロ-4-[(2R)-1,1,1-トリフルオロ-2-ヒドロキシ-2-プロパニル]フェニル}-3-{[5-(トリフルオロメチル)-2-ピリジニル]メチル}ウレア、
(2)1-{2,6-ジクロロ-4-[(2R)-1,1,1-トリフルオロ-2-ヒドロキシ-2-プロパニル]フェニル}-3-{[5-(トリフルオロメチル)-2-ピリミジニル]メチル}ウレア、
(3)1-{2,6-ジクロロ-4-[(2R)-1,1,1-トリフルオロ-2-ヒドロキシ-2-プロパニル]フェニル}-3-{[6-(トリフルオロメチル)-3-ピリジニル]メチル}ウレア、
(4)1-[(5-クロロ-2-ピリジニル)メチル]-3-{2,6-ジクロロ-4-[(2R)-1,1,1-トリフルオロ-2-ヒドロキシ-2-プロパニル]フェニル}ウレア、
(5)1-{2,6-ジクロロ-4-[(2R)-1,1,1-トリフルオロ-2-ヒドロキシ-2-プロパニル]フェニル}-3-{[3-(トリフルオロメチル)-1,2,4-オキサジアゾール-5-イル]メチル}ウレア、
(6)1-{2,6-ジクロロ-4-[(2S)-1,1,1-トリフルオロ-2-ヒドロキシ-2-プロパニル]フェニル}-3-{[5-(トリフルオロメチル)-2-ピリミジニル]メチル}ウレア、
(7)1-{2,6-ジクロロ-4-[(2S)-1,1,1-トリフルオロ-2-ヒドロキシ-2-プロパニル]フェニル}-3-{[6-(トリフルオロメチル)-3-ピリジニル]メチル}ウレア、
(8)1-[(5-クロロ-2-ピリジニル)メチル]-3-{2,6-ジクロロ-4-[(2S)-1,1,1-トリフルオロ-2-ヒドロキシ-2-プロパニル]フェニル}ウレア、
(9)1-{2,6-ジクロロ-4-[(2S)-1,1,1-トリフルオロ-2-ヒドロキシ-2-プロパニル]フェニル}-3-{[3-(トリフルオロメチル)-1,2,4-オキサジアゾール-5-イル]メチル}ウレア、
(10)1-{2,6-ジクロロ-4-[(1R)-2,2,2-トリフルオロ-1-ヒドロキシエチル]フェニル}-3-{[3-(トリフルオロメチル)-1,2,4-オキサジアゾール-5-イル]メチル}ウレア、
(11)1-{2,6-ジクロロ-4-[(1R)-2,2,2-トリフルオロ-1-ヒドロキシエチル]フェニル}-3-{[2-(トリフルオロメチル)-5-ピリミジニル]メチル}ウレア、
(12)1-{2,6-ジクロロ-4-[(1R)-2,2,2-トリフルオロ-1-ヒドロキシエチル]フェニル}-3-{[5-(トリフルオロメチル)-2-ピリミジニル]メチル}ウレア、
(13)1-{2,6-ジクロロ-4-[(1R)-2,2,2-トリフルオロ-1-ヒドロキシエチル]フェニル}-3-{[2-(トリフルオロメチル)-1,3-チアゾール-5-イル]メチル}ウレア、
(14)1-{2,6-ジクロロ-4-[(1S)-2,2,2-トリフルオロ-1-ヒドロキシエチル]フェニル}-3-{[3-(トリフルオロメチル)-1,2,4-オキサジアゾール-5-イル]メチル}ウレア、
(15)1-{2,6-ジクロロ-4-[(1S)-2,2,2-トリフルオロ-1-ヒドロキシエチル]フェニル}-3-{[2-(トリフルオロメチル)-5-ピリミジニル]メチル}ウレア、
(16)1-{2,6-ジクロロ-4-[(1S)-2,2,2-トリフルオロ-1-ヒドロキシエチル]フェニル}-3-{[2-(トリフルオロメチル)-1,3-チアゾール-5-イル]メチル}ウレア、
(17)1-{2,6-ジクロロ-4-[(2S)-1,1,1-トリフルオロ-2-ヒドロキシ-2-プロパニル]フェニル}-3-{[5-(トリフルオロメチル)-2-ピリジニル]メチル}ウレア、または
(18)1-{2,6-ジクロロ-4-[(1S)-2,2,2-トリフルオロ-1-ヒドロキシエチル]フェニル}-3-{[5-(トリフルオロメチル)-2-ピリミジニル]メチル}ウレアである請求項1記載の化合物、その塩、その溶媒和物またはその共結晶。 - 一般式(I)で示される化合物、その塩、その溶媒和物またはその共結晶と薬学的に許容される担体とを含有してなる医薬組成物。
- KCNQ2~5チャネル関連疾患の予防および/または治療剤である、請求項13記載の医薬組成物。
- KCNQ2~5チャネル関連疾患が排尿障害である、請求項14記載の医薬組成物。
- 排尿障害が過活動膀胱である、請求項15記載の医薬組成物。
- 一般式(I)で示される化合物、その塩、その溶媒和物またはその共結晶の有効量を哺乳動物に投与することを特徴とするKCNQ2~5チャネル関連疾患の予防および/または治療方法。
- KCNQ2~5チャネル関連疾患の予防および/または治療のための一般式(I)で示される化合物、その塩、その溶媒和物またはその共結晶。
- KCNQ2~5チャネル関連疾患の予防および/または治療剤の製造のための一般式(I)で示される化合物、その塩、その溶媒和物またはその共結晶の使用。
Priority Applications (18)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BR112017008178A BR112017008178A2 (pt) | 2014-10-24 | 2015-10-23 | ativador do canal de kcnq2-5 |
KR1020177010846A KR20170076673A (ko) | 2014-10-24 | 2015-10-23 | Kcnq2∼5 채널 활성화제 |
JP2016555419A JP6217866B2 (ja) | 2014-10-24 | 2015-10-23 | Kcnq2〜5チャネル活性化剤 |
EP15852712.7A EP3210969B1 (en) | 2014-10-24 | 2015-10-23 | Kcnq2-5 channel activator |
ES15852712T ES2871673T3 (es) | 2014-10-24 | 2015-10-23 | Activador de los canales KCNQ2-5 |
RU2017117566A RU2712163C2 (ru) | 2014-10-24 | 2015-10-23 | Активатор kcnq2-5 каналов |
SG11201703284XA SG11201703284XA (en) | 2014-10-24 | 2015-10-23 | Kcnq2-5 channel activator |
US15/515,243 US9809544B2 (en) | 2014-10-24 | 2015-10-23 | KCNQ2-5 channel activator |
AU2015336458A AU2015336458B2 (en) | 2014-10-24 | 2015-10-23 | KCNQ2-5 channel activator |
CN201580057252.0A CN107108485B (zh) | 2014-10-24 | 2015-10-23 | Kcnq2~5通道活化剂 |
CA2965467A CA2965467A1 (en) | 2014-10-24 | 2015-10-23 | Kcnq2-5 channel activator |
MX2017005044A MX2017005044A (es) | 2014-10-24 | 2015-10-23 | Activador de canales de kcnq2-5. |
IL251827A IL251827B (en) | 2014-10-24 | 2017-04-20 | kcnq2-5 channel activators, preparations containing them and their uses |
PH12017500737A PH12017500737A1 (en) | 2014-10-24 | 2017-04-21 | Kcnq2-5 channel activator |
ZA2017/03498A ZA201703498B (en) | 2014-10-24 | 2017-05-22 | Kcnq2-5 channel activator |
US15/671,428 US10196358B2 (en) | 2014-10-24 | 2017-08-08 | KCNQ2-5 channel activator |
US16/059,270 US10676438B2 (en) | 2014-10-24 | 2018-08-09 | KCNQ2-5 channel activator |
US16/752,076 US20200157050A1 (en) | 2014-10-24 | 2020-01-24 | Kcnq2-5 channel activator |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014217540 | 2014-10-24 | ||
JP2014-217540 | 2014-10-24 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/515,243 A-371-Of-International US9809544B2 (en) | 2014-10-24 | 2015-10-23 | KCNQ2-5 channel activator |
US15/671,428 Continuation US10196358B2 (en) | 2014-10-24 | 2017-08-08 | KCNQ2-5 channel activator |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2016063990A1 true WO2016063990A1 (ja) | 2016-04-28 |
Family
ID=55761020
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2015/080034 WO2016063990A1 (ja) | 2014-10-24 | 2015-10-23 | Kcnq2~5チャネル活性化剤 |
Country Status (17)
Country | Link |
---|---|
US (4) | US9809544B2 (ja) |
EP (1) | EP3210969B1 (ja) |
JP (2) | JP6217866B2 (ja) |
KR (1) | KR20170076673A (ja) |
CN (1) | CN107108485B (ja) |
AU (1) | AU2015336458B2 (ja) |
BR (1) | BR112017008178A2 (ja) |
CA (1) | CA2965467A1 (ja) |
ES (1) | ES2871673T3 (ja) |
IL (1) | IL251827B (ja) |
MX (1) | MX2017005044A (ja) |
PH (1) | PH12017500737A1 (ja) |
RU (1) | RU2712163C2 (ja) |
SG (1) | SG11201703284XA (ja) |
TW (1) | TWI664166B (ja) |
WO (1) | WO2016063990A1 (ja) |
ZA (1) | ZA201703498B (ja) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017183723A1 (ja) * | 2016-04-22 | 2017-10-26 | 小野薬品工業株式会社 | Kcnq2~5チャネル活性化剤 |
WO2017183725A1 (ja) * | 2016-04-22 | 2017-10-26 | 小野薬品工業株式会社 | Kcnq2~5チャネル活性化剤の結晶多形 |
JP2017197534A (ja) * | 2016-04-22 | 2017-11-02 | 小野薬品工業株式会社 | Kcnq2〜5チャネル関連疾患の予防および/または治療剤 |
US11840516B2 (en) | 2019-02-06 | 2023-12-12 | Eli Lilly And Company | KCNQ potentiators |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2965467A1 (en) | 2014-10-24 | 2016-04-28 | Ono Pharmaceutical Co., Ltd. | Kcnq2-5 channel activator |
EP3730141A4 (en) * | 2017-12-21 | 2021-10-13 | Kyorin Pharmaceutical Co., Ltd. | THERAPEUTIC FOR NIGHTLY POLLAKISURIA |
CN109232380B (zh) * | 2018-10-22 | 2021-08-10 | 新乡市润宇新材料科技有限公司 | 一种4-溴咔唑的合成方法 |
CN109232383B (zh) * | 2018-12-04 | 2022-02-01 | 河南省科学院高新技术研究中心 | 一种合成4-溴咔唑的方法 |
US20230303486A1 (en) * | 2020-06-25 | 2023-09-28 | Idorsia Pharmaceuticals Ltd | Cyclobutyl-urea derivatives |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5182239A (ja) * | 1974-12-02 | 1976-07-19 | Scherico Ltd | |
JP2003192660A (ja) * | 2001-12-26 | 2003-07-09 | Bayer Ag | 尿素誘導体 |
JP2008512402A (ja) * | 2004-09-13 | 2008-04-24 | ハー・ルンドベック・アクチエゼルスカベット | 置換されたアニリン誘導体 |
WO2011085351A2 (en) * | 2010-01-11 | 2011-07-14 | The Johns Hopkins University | Method of treating kcnq related disorders |
JP2014521616A (ja) * | 2011-07-26 | 2014-08-28 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | バニロイド受容体リガンドとしての置換ヘテロ芳香族ピラゾール含有カルボキサミドおよび尿素誘導体 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES442992A1 (es) * | 1974-12-02 | 1977-08-01 | Scherico Ltd | Un procedimiento para preparar 2-anilino-oxazolinas. |
US4058612A (en) * | 1974-12-02 | 1977-11-15 | Schering Corporation | 6-(Polyhaloisopropyl)quinazoline-2,4-diones |
US7524969B2 (en) * | 2001-01-26 | 2009-04-28 | Chugai Seiyaku Kabushiki Kaisha | Malonyl-CoA decarboxylase inhibitors useful as metabolic modulators |
DE60219595T2 (de) * | 2001-01-26 | 2008-01-10 | Chugai Seiyaku K.K. | Verfahren zur behandlung von erkrankungen mit malonyl coa-decarboxylase-inhibitoren |
CA2469967A1 (en) * | 2001-12-26 | 2003-07-10 | Bayer Healthcare Ag | Urea derivatives as vr1- antagonists |
US7399866B2 (en) | 2003-01-14 | 2008-07-15 | Cytokinetics, Inc. | Compounds, compositions, and methods |
UA93387C2 (ru) * | 2005-09-09 | 2011-02-10 | X. Луннбэк A/C | Производные пиримидина и их применение b качестве открывателей калиевых каналов kcnq |
WO2009015667A1 (en) | 2007-08-01 | 2009-02-05 | H. Lundbeck A/S | Use of kncq potassium channel openers for reducing symptoms of or treating disorders or conditions wherein the dopaminergic system is disrupted |
JP2010037311A (ja) | 2008-08-08 | 2010-02-18 | Bayer Cropscience Ag | 新規殺虫性アシルアミノベンズアミド誘導体 |
WO2010065333A1 (en) | 2008-12-01 | 2010-06-10 | Lexicon Pharmaceuticals, Inc. | 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds for the treatment of osteoporosis |
TWI475020B (zh) | 2009-03-12 | 2015-03-01 | The substituted nicotine amide as a KCNQ2 / 3 modifier | |
AU2011203897B2 (en) | 2010-01-11 | 2016-11-17 | Inotek Pharmaceuticals Corporation | Combination, kit and method of reducing intraocular pressure |
CA2854217C (en) * | 2011-11-02 | 2019-12-31 | Boehringer Ingelheim International Gmbh | Substituted pyrazinoylguanidine compounds and their use as epithelial sodium channel blockers, medicaments containing said compounds and processes for the preparation thereof |
CA2965467A1 (en) * | 2014-10-24 | 2016-04-28 | Ono Pharmaceutical Co., Ltd. | Kcnq2-5 channel activator |
-
2015
- 2015-10-23 CA CA2965467A patent/CA2965467A1/en not_active Abandoned
- 2015-10-23 US US15/515,243 patent/US9809544B2/en active Active
- 2015-10-23 EP EP15852712.7A patent/EP3210969B1/en active Active
- 2015-10-23 BR BR112017008178A patent/BR112017008178A2/pt not_active Application Discontinuation
- 2015-10-23 KR KR1020177010846A patent/KR20170076673A/ko unknown
- 2015-10-23 JP JP2016555419A patent/JP6217866B2/ja active Active
- 2015-10-23 MX MX2017005044A patent/MX2017005044A/es active IP Right Grant
- 2015-10-23 WO PCT/JP2015/080034 patent/WO2016063990A1/ja active Application Filing
- 2015-10-23 ES ES15852712T patent/ES2871673T3/es active Active
- 2015-10-23 RU RU2017117566A patent/RU2712163C2/ru active
- 2015-10-23 CN CN201580057252.0A patent/CN107108485B/zh not_active Expired - Fee Related
- 2015-10-23 SG SG11201703284XA patent/SG11201703284XA/en unknown
- 2015-10-23 AU AU2015336458A patent/AU2015336458B2/en not_active Ceased
- 2015-10-23 TW TW104134839A patent/TWI664166B/zh not_active IP Right Cessation
-
2017
- 2017-04-20 IL IL251827A patent/IL251827B/en active IP Right Grant
- 2017-04-21 PH PH12017500737A patent/PH12017500737A1/en unknown
- 2017-05-22 ZA ZA2017/03498A patent/ZA201703498B/en unknown
- 2017-08-08 US US15/671,428 patent/US10196358B2/en not_active Expired - Fee Related
- 2017-09-25 JP JP2017183651A patent/JP6627835B2/ja not_active Expired - Fee Related
-
2018
- 2018-08-09 US US16/059,270 patent/US10676438B2/en active Active
-
2020
- 2020-01-24 US US16/752,076 patent/US20200157050A1/en not_active Abandoned
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5182239A (ja) * | 1974-12-02 | 1976-07-19 | Scherico Ltd | |
JP2003192660A (ja) * | 2001-12-26 | 2003-07-09 | Bayer Ag | 尿素誘導体 |
JP2008512402A (ja) * | 2004-09-13 | 2008-04-24 | ハー・ルンドベック・アクチエゼルスカベット | 置換されたアニリン誘導体 |
WO2011085351A2 (en) * | 2010-01-11 | 2011-07-14 | The Johns Hopkins University | Method of treating kcnq related disorders |
JP2014521616A (ja) * | 2011-07-26 | 2014-08-28 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | バニロイド受容体リガンドとしての置換ヘテロ芳香族ピラゾール含有カルボキサミドおよび尿素誘導体 |
Non-Patent Citations (2)
Title |
---|
See also references of EP3210969A4 * |
YU ,H. ET AL.: "Discovery, Synthesis, and Structure-Activity Relationship of a Series of N-Aryl-bicyclo[2.2.1]heptane-2-carboxamides: Characterization of ML213 as a Novel KCNQ2 and KCNQ4 Potassium Channel Opener", ACS CHEMICAL NEUROSCIENCE, vol. 2, no. 10, 2011, pages 572 - 577, XP055275425, ISSN: 1948-7193 * |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017183723A1 (ja) * | 2016-04-22 | 2017-10-26 | 小野薬品工業株式会社 | Kcnq2~5チャネル活性化剤 |
WO2017183725A1 (ja) * | 2016-04-22 | 2017-10-26 | 小野薬品工業株式会社 | Kcnq2~5チャネル活性化剤の結晶多形 |
JP2017197534A (ja) * | 2016-04-22 | 2017-11-02 | 小野薬品工業株式会社 | Kcnq2〜5チャネル関連疾患の予防および/または治療剤 |
US20190135755A1 (en) * | 2016-04-22 | 2019-05-09 | Ono Pharmaceutical Co., Ltd. | Crystal polymorphism of kcnq2-5 channel activator |
US10519105B2 (en) | 2016-04-22 | 2019-12-31 | Ono Pharmaceutical Co., Ltd. | KCNQ2-5 channel activator |
US11840516B2 (en) | 2019-02-06 | 2023-12-12 | Eli Lilly And Company | KCNQ potentiators |
JP7451543B2 (ja) | 2019-02-06 | 2024-03-18 | イーライ リリー アンド カンパニー | Kcnq増強剤としての1-((2-(2,2,2-トリフルオロエトキシ)ピリジン-4-イル)メチル)尿素誘導体 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6627835B2 (ja) | Kcnq2〜5チャネル活性化剤 | |
JP4671123B2 (ja) | 新規三環性複素環化合物 | |
JPWO2005040135A1 (ja) | 抗ストレス薬およびその医薬用途 | |
JPWO2004007472A1 (ja) | Ccr4アンタゴニストおよびその医薬用途 | |
JPWO2005047286A1 (ja) | スピロ複素環化合物 | |
JP2013129632A (ja) | Enpp2阻害化合物 | |
WO2017131149A1 (ja) | テトラヒドロナフタレン誘導体 | |
JPWO2004080943A1 (ja) | シンナミルアルコール誘導体化合物およびその化合物を有効成分として含有する薬剤 | |
KR20210065944A (ko) | Dp 길항제 | |
JP6197971B1 (ja) | Kcnq2〜5チャネル関連疾患の予防および/または治療剤 | |
JPWO2016088834A1 (ja) | ジヒドロナフタレン誘導体 | |
WO2006095822A1 (ja) | スルホンアミド化合物およびその医薬 | |
US10519105B2 (en) | KCNQ2-5 channel activator | |
WO2006090850A1 (ja) | ベンズアミド化合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15852712 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2016555419 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 15515243 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2017/005044 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 251827 Country of ref document: IL |
|
ENP | Entry into the national phase |
Ref document number: 2965467 Country of ref document: CA Ref document number: 20177010846 Country of ref document: KR Kind code of ref document: A |
|
REEP | Request for entry into the european phase |
Ref document number: 2015852712 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11201703284X Country of ref document: SG |
|
ENP | Entry into the national phase |
Ref document number: 2017117566 Country of ref document: RU Kind code of ref document: A |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112017008178 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 2015336458 Country of ref document: AU Date of ref document: 20151023 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 112017008178 Country of ref document: BR Kind code of ref document: A2 Effective date: 20170420 |